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1.1 Introduction 
 
Since the proposal on the circulation of blood in man by the English physician 
William Harvey1 in 1628 and the first published report on human-to-human blood 
transfusion by James Blundell2, an obstetrician at the United hospitals of Guy’s 
and St. Thomas’, in 1818, blood transfusion has nowadays become a relatively 
simple and live-saving part of daily medical practice.   
The discovery of the AB0 blood group system, by the Austrian pathologist Karl 
Landsteiner3 together with his colleques von Decastello and Sturli4, and the 
introduction of the AB0 blood grouping test for selected donors by Reuben 
Ottenberg5 in 1911, greatly reduced the fatalities associated with blood 
transfusion in the early days of transfusion therapy. In 1921, Unger6 reported 
intra-AB0-group transfusion reactions and recommended additional tests to 
exclude the possibility of a recipient’s serum agglutinating the donor’s red cells, 
now known as irregular alloantibodies. 
After the introduction of the indirect antiglobulin test by Coombs7 in 1945, which 
added a new dimension to the safety of blood transfusion, there was a rapid 
increase in the identification of alloantibodies that caused transfusion reactions or 
hemolytic disease of the newborn. This has led to the discovery of 245 blood 
group antigens classified in 29 blood group systems and 38 high or low frequency 
antigens not yet fulfilling the requirements for classification into a system8.  
Alloimmunization occurs when an incompatible antigen introduced in an 
immuno-competent host evokes an immune response. The way the immune 
system reacts depends on several factors. The immune response to carbohydrate 
antigens, is usually thymus independent. Multivalent antigens directly stimulate B 
cells to synthesize antibodies without the aid of helper T cells resulting in the 
majority of cases in the production of IgM antibodies. Individuals lacking a 
particular carbohydrate blood group antigen on their red cells can have ‘naturally 
occurring’ IgM antibodies, which are most probably stimulated by cross-reacting 
antigens present in the environment, such as on gut bacteria. The most important 
carbohydrate antigens for blood transfusion practice are the A- and B-antigens. 
Normal individuals who lack either the A or B antigen make IgM B- or A-
antibodies, respectively. Since IgM antibodies are complement-binding, these 
antibodies can cause immediate and severe intravascular hemolysis after 
transfusion of incompatible red cells, which can lead to serious or fatal 
complications. 
Numerous other blood group antigens reside on membrane proteins and comprise 
polymorphic determinants dependent primarily on amino acid sequence. These 
protein antigens can stimulate a thymus-dependent immune response, and the 
resulting IgG antibodies can cause extravascular clearance of antigen-positive 
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cells. These IgG antibodies may also cross the placenta, resulting in hemolytic 
disease of the newborn.  
The most important irregular red blood cell alloantibodies in daily transfusion 
practice, in terms of frequency of occurrence, are directed towards the RH (anti-
D, -C, -E, -c and -e), KEL (anti-K), FY (anti-Fya and -Fyb), JK (anti-Jka and -Jkb) 
and the MNS (anti-M, -S and -s) blood group systems. Of these, the D-antigen is 
the most immunogenic, resulting in more than 80% of immunocompetent D-
negative persons becoming alloimmunized after a transfusion of D-positive 
erytrocytes9,10. This has resulted in prophylactic matching of red cell transfusions 
for the D-status. Such routine is not common to prevent other RBC antibodies, for 
which we rely on serologic screening before transfusion.  
Retrospective studies in the general population reported antibody frequencies 
after transfusion of less than 1 to 3 percent. However, in multitransfused patients 
alloimmunizaton occurs in up to 70% of patients. Whether the recipient’s immune 
system will react depends on genetic and acquired patient related factors, dose 
and route of administration and the immunogenicity of the foreign antigen. 
Studies on the alloimmunization frequency in several patient cohorts and factors 
influencing these results are subject of this thesis. 
 
1.2 Outline of the thesis 
 
Since the discovery of the indirect antiglobulin test, several techniques have been 
applied in the transfusion laboratories to detect irregular RBC antibodies. In the 
Netherlands, up till the 1990’s, it was common policy, in pre-transfusion testing, 
to detect all blood group antibodies present in patients, irrespective of their 
clinical importance. When it came clear that antibodies reacting at lower 
temperatures but not at 37 ºC are of no clinical significance and only generate 
useless extra investigations, routine pre-transfusion testing at low temperature 
was abbreviated. Furthermore, it has been shown that the antiglobulin phase 
crossmatch as part of compatibility testing in patients without RBC alloantibodies 
is of limited value.  
Nowadays, before a transfusion event, patients are routinely tested for their AB0 
and D blood groups and for the presence of irregular IgG alloantibodies using 
panels of red cells with homozygous expression of the most relevant blood group 
antigens. In case of an alloantibody, red blood cells lacking the corresponding 
antigen, are transfused after an antiglobulin crossmatch. When the patient has no 
irregular alloantibodies, the type and screen strategy together with an immediate-
spin or computer crossmatch, is being applied in an increasing number of 
transfusion laboratories in the Netherlands.   
However, despite the understanding of red cell antigens and their clinical 
significance in transfusion medicine, fatalities due to alloimmunization still 
occur. 
General introduction 
 13 
The characterization of genes and the molecular basis of antigens and phenotypes 
has introduced DNA-based molecular methods for the detection of blood group 
antigens. The development of microassay technology will soon make it possible 
to analyze many blood group alleles on a single synthetic chip. Application of 
molecular genotyping to transfusion medicine practice will enable selection of 
donor units that are antigen matched for recipients at multiple blood group loci, 
potentially diminishing alloimmunization. The introduction of such a policy 
should be based on information regarding patient groups to whom it should be 
applied, for which RBC antigens it should be applied and the costs compared to 
the current policy. 
The aim of this thesis was primarily to investigate whether we should change the 
current policy to improve transfusion safety. For this purpose the risk of red cell 
alloimmunization and identification of (patient related) factors associated with 
alloimmunization were investigated. 
 
The aim of the studies, described in detail in the following chapters, is 
summarized in short. 
 
Chapter 2 
Review of the literature regarding blood groups and red cell alloimmunization 
 
Chapter 3 
Multicenter retrospective study on the influence of prestorage filter 
leucodepletion on the development of clinically significant red blood cell 
alloimmunization against antigens in the RH, KEL, FY, JK and MNS blood 
group systems. Comparisons were made between the transfused patient cohorts 
during two periods, two years before and two years after universal 
leucodepletion. To control for changes not related to leucoreduction, antibody 
incidence was compared to antibody prevalence. 
 
Chapter 4 
A 23-year retrospective study on the safety of the type and screen policy with 
regard to the presence of unexpected antibodies directed against low incidence 
antigens.   
Chapter 1 
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Chapter 5 
A 10-year retrospective study on RBC alloimmunization in patients with 
oncohematologic diseases. Comparisons for myeloproliferative and lympho-
proliferative diseases were made. The main goal of this study was to investigate, 
whether these patients should receive RBC transfusions matched for other 
antigens than ABO and D. 
 
Chapter 6 
The development of additional antibodies in non-multitransfused alloimmunized 
patients was the subject of this 20-year retrospective multicenter study. The aim 
of the study was to investigate to which extend these patients are prone to form 
additional antibodies after repeat transfusion and if extended matching should be 
applied in these patients. 
 
Chapter 7 
An 11-year retrospective single center national study on additional RBC 
alloimmunization in women, whose fetusses were treated with intra-uterine 
transfusion for hemolytic disease. In addition, a number of risk factors for the 
occurrence of additional antibodies were defined. 
    
Chapter 8 
The aim of this 20-year retrospective study was to achieve information on the 
risks of current pre-transfusion testing, with regard to the persistence of clinically 
significant RBC alloantibodies. 
 
Chapter 9 
A 5-year retrospective multicenter study analyzing factors influencing the rate 
and specificity of RBC alloimmunization. Special emphasis was taken on the time 
interval between transfusion event and antibody detection.  
 
Chapter 10 
General discussion concerning studies of the thesis and proposals for further 
studies. 
General introduction 
 15 
References 
 
1. Harvey W. Exercitatio Anatomica de Motu Cordis et Sanquinis in Animalibus = An 
Anatomical Exercise on the Motion of the Heart and Blood in Animals 
2. Blundell J. Experiments on the transfusion of blood by a syringe, Med. Chir. Trans. 
1818;9:56-92 
3. Landsteiner K. Ueber Agglutinationserscheinungen normalen menschlichen Blutes. 
Wien. Klin. Wochenschr. 1901;14:1132-1134 
4. von Castello A. and Sturli A. Ueber di iso-agglutinine im serum gesunder und kranker 
menschen. Munch. Med. Wochenschr. 1902;49:1090-1095 
5. Ottenberg R. Studies on isoagglutination. Transfusion and the question of intra-
vascular agglutination. J. Exp. Med. 1911;13:425-438 
6. Unger L.J. Precautions necessary in the selection of a donor for blood transfusion. 
JAMA. 1921;76:9-11 
7. Coombs R.R.A., Mourant A.E. and Race R.R. A new test for the detection of weak 
and incomplete Rh agglutinins. Br. J. Exp. Pathol. 1945;26:255-266 
8. Daniels, G. L., Fletcher, A., Garratty, G., Henry, S., Jørgensen, J., Judd, W. J., 
Levene, C., Lomas-Francis, C., Moulds, J. J., Moulds, J. M., Moulds, M., Overbeeke, 
M., Reid, M. E., Rouger, P., Scott, M., Sistonen, P., Smart, E., Tani, Y., Wendel, S. & 
Zelinski, T. Blood group terminology 2004: from the International Society of Blood 
Transfusion committee on terminology for red cell surface antigens. Vox 
Sang. 2004;87:304-316. 
9. Pollack W, Ascari WQ, CrispenJF, O’Connor RR, Ho TY. Studies on Rh prophylaxis 
II. Rh immune prophylaxis after transfusion wth Rh-positive blood. Transfusion 
1971;11:340-344  
10. Urbaniak SJ, Robertson AE. A successful program of immunizing Rh-negative 
volunteers for anti-D production using frozen/thawed blood. Transfusion 
1981;21:64-69. 
 
  16 
 
  
2 
 
 
 
 
REVIEW OF THE LITERATURE  
ON RED CELL ALLOIMMUNIZATION 
Chapter 2  
 
 
18 
 
Contents 
 
2.1 History of red cell alloimmunization 
2.2 Red cell compatibility testing 
2.3 Blood group diversity and function 
2.4 Immunogenicity 
2.5 Alloimmune response to red blood cell antigens 
2.6 Red blood cell antibodies in disease 
Review of the literature on red cell alloimmunization.  
 
 19 
2.1 History of red cell alloimmunization 
 
Red blood cell alloimmunization results from the genetic red blood cell antigen 
disparity between donor and recipient or from mother and fetus.  
The first reports on alloimmunization date from the 17th century describing 
hydropic stillborns. This disease, today known as hemolytic disease of the fetus 
or newborn (HDFN), is caused by immune IgG antibodies from the mother 
directed against the red blood cells of the fetus. These antibodies are transferred 
into the fetal circulation where they coat the fetal red blood cells causing 
extravascular hemolysis. In 1939, Levine and Stetson published a case report of 
HDFN and reported that the mother’s serum agglutinated the red blood cells of 
her husband and also 80 percent of group O-donors1. The name for the antibody 
involved, anti-Rhesus, came from work of Landsteiner and Wiener who 
immunized rabbits and guinea pigs with blood from Macacus Rhesus monkeys2. 
In 1940, Wiener and Peters reported on the first hemolytic transfusion reactions 
due to anti-Rhesus3. Years later, this antibody turned out to be different from the 
human anti-Rh and it was renamed anti-LW, after Landsteiner and Wiener.  
Antibodies with different RH specificities (e.g. C, c, E and e)4-7 were discovered 
soon after and already in 1944 Sir Ronald Fisher proposed the current RH blood 
group system nomenclature8. 
After the development of the antiglobulin test by Coombs9 in 1945, many other 
blood group antigens were recognized in the next years. Antibodies to the S and 
s-antigens, belonging to the MNS blood group system, of which the M and N 
antigens had already been discovered in 1927 by Landsteiner and Levine10,11, 
were first reported in respectively 1947 and 195112,13. 
Often the name of a blood group system was derived from the first patient 
described. Coombs identified the K-antigen in a patient (Mrs Kell) whose child 
had HDFN14 and anti-k was found in 1949 by Levine and coworkers15. The FY 
system was named after Joseph Duffy, a hemophilac, who had become 
alloimmunized after several blood transfusions, and the JK system taking the 
initials of a baby named John Kidd, who suffered from HDFN16-19.  
Untill today, the aforementioned blood group systems, together with the 
ABO-system, are still the most important in transfusion medicine and pre-
transfusion antibody screening is primarily focussed on detecting antibodies 
against these blood group antigens. 
 
 
2.2 Red cell compatibility testing 
The basis for a succesfull blood transfusion is the simple recognition of red cell 
clumping as a result of antigen-antibody reactions. The description of red cell 
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agglutination and its development as a tool in elucidating blood groups took place 
in the last 30 years of the 19th century. In 1869, Adolf Creite, was the first who 
reported that, after mixing serum from one species with red blood cells from 
another species, serum proteins had the property of both dissolving (lysis) and 
bringing about clustering (agglutination) of red cells20. Landois who extended 
Creite’s in vitro experiments described agglutination as ‘cells develop the ability 
to stick to neighboring cells and form larger or smaller clumps’21.  
In 1901, Landsteiner made a great breakthrough by elucidating the mechanism 
underlying intraspecies agglutination, through his discovery of the ABO-blood 
group system, clarifying the frequently observed hemolytic reactions after 
transfusion22.  
Minot advocated pretransfusion ABO determination of the patient and blood 
donors, to select compatible donors in advance, rather than performing 
crossmatches between the patient and random donors. This led to the first 
‘walking’ blood bank23. Although Ottenberg24,25 is credited for being the first to 
advocate and practice cross-matching besides ABO blood grouping as routine 
pretransfusion testing, Hektoen had proposed an early form of cross-match a year 
before26. These first cross-match procedures required 10-15 ml blood and at least 
a 2 hour incubation. Rous and colleques and Lee improved the technique by 
reducing the amount of blood needed and shortening the incubation time to less 
than 15 minutes27,28.  
The first recognition of non-ABO antibodies (probably against RH system 
antigens) was made by Unger in 1921, who stated that ‘preliminary to 
transfusion, the blood of every patient should be grouped and then tested directly 
against that of the prospective donor’29. This statement was further strenghtened 
by reports on hemolytic transfusion reactions, especially in previously transfused 
patients30-32. 
Levine observed that these irregular antibodies were detected better after a 30 
minutes incubation at 37 ºC and Diamond and coworkers enhanced agglutination 
reactions further by the addition of bovine albumin to the testsuspension33,34. 
A milestone in transfusion medicine and compatibility testing was the re-
discovery of the antiglobulin test by Coombs, Mourant and Race in 19459,35-37. 
After the ‘Coombs’ test became routine in compatibility testing38 thousands of 
antibodies were detected.  
To further increase transfusion safety, sensitive cross-matching protocols were 
developed, including direct antiglobulin tests, autocontrols and minor 
crossmatches (i.e. donor serum and recipient cells). Enzyme treated red blood 
cells39 and additives such as bovine albumin34, low ionic strenght media40, 
polybrene41, and polyethylene-glycol (PEG)42 were used to enhance agglutination 
and to further shorten incubation times. By these sensitive techniques many new 
bloodgroups were discovered. Yearly, new blood group antigens are identified by 
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unusual serologic findings43-49. Subsequently a number of pretransfusion tests that 
did not add to transfusion safety were abandonded50,51. 
Currently, routine pretransfusion tests focus primarily on potential clinical 
significant antibodies that only react in the indirect antiglobulin phase after 
incubation at 37 °C.  
 
 
2.3   Blood group diversity and function 
Antigens are defined by antibodies, which can be immune or ‘naturally’ occuring 
human antibodies, as well as deliberately stimulated antibodies in animals. Blood 
group antigens are cell surface molecules and reside on a variety of structures e.g. 
proteins, polysaccharides, glycoproteins, glycolipids and lipoproteins. The 
membrane proteins are subdivided into structural (integral membrane or 
transmembrane proteins) or functional structures (structural integrity, transporter, 
enzymes, receptors). 
Blood groups antigens are the product of genes. Evolutionary pressure from 
various environmental pathogens is thought to be responsible for the generation 
of genetic variants, resulting in survival advantage. A wellknown example are 
individuals whose phenotype is Fy(a-b-) and lack gp-Fy on their erythrocytes, 
preventing the invasion of malaria Plasmodium vivax parasite52.  
The genes encoding the blood group proteins have been mapped to different 
chromosomes throughout the genome. Many antigens are related by arising from 
mutations of the same ‘parent’ molecule and together form blood groups systems. 
Within these systems, antigens excist either as different epitopes on the same 
molecule or as the products of allelic genes. In case of polysaccharide blood 
group antigens, genes code for enzymes that cause the production of specific red 
cell membrane carbohydrates53-55.  
The development of DNA sequenching and amplification techniques (polymerase 
chain reaction) has created the possibility for molecular characterization of the 
genes encoding blood group antigens56,57. The most common mechanism 
responsible for diversity in blood groups arises from single nucleotide 
polymorphisms (SNPs). These SNPs can be silent or affect the translated gene 
product (missense or non-sence mutations). It is estimated that two thirds of all 
blood group antigens are defined by missense SNPs in blood group genes58. The 
SNPs cannot only alter the antigen expressed by a certain blood group molecule 
but also modify the number of copies expressed on the red cell membrane, e.g. 
weakened expression of the D-antigen.  
There is increasing knowledge of the functional aspects of the molecules that 
express RBC antigens and the potential pathophysiological significance of these 
structures59-61. Because there are important interactions between proteins at the 
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cell surface and the cytoskeleton, gene mutations resulting in complete lack of 
antigen-bearing molecules result in red cell abnormalities as well as in other 
organ dysfuctions (e.g. RH-null, Leach, McCloed), but in general the antigenic 
composition does not affect intrinsic red cell function.  
In the clinical transfusion practise, applications of genomic typing assays include 
donor typing for RBC, HLA and platelet antigens, fetal RBC phenotype 
prediction to determine the risk of hemolytic disease, genotyping of multiple 
transfused patients and in situations where the RBC phenotype cannot be 
accurately determined by serological techniques62-66. 
Today, almost all of the genes underlying expression of the human blood group 
systems have been cloned and the polymorphisms responsible for the phenotypes 
encountered in different individuals and populations are increasingly being 
clarified.  
 
 
2.4 Immunogenicity 
The nature of the immune response to blood group antigens depends on several 
factors, including the dose and route of administration, genetic host factors and 
the immunogenicity of the antigen. Immunogenicity is the ability to stimulate a 
specific immune response, estimated as effector cells or antibody production. 
Compared to the immune response against micro-organisms blood group antigens 
are generally poor immunogens. After exposure by transfusion only 1-3 percent 
of recipients respond with antibodies against a red cell antigen. Antigen factors 
such as chemical and physical form, number of antigen sides, degradability and 
whether a response is T-cell dependent influence the host’s immune response67. 
The most immunogenic blood group antigens are A and B, because the natural 
antibodies to these antigens occur in virtually all individuals lacking the 
corresponding antigen. With regard to immune alloantibodies, the D-antigen 
appears to be the most immunogenic of all blood group antigens. Studies 
deliberately exposing healthy D-negative volunteers to D-positive blood, to 
obtain IgG anti-D for immunoprophylaxis purposis, showed that appoximately 
eighty percent of D-negative individuals will produce serological detectable anti-
D68-71. Studies on D-immunization after D-positive RBC transfusions in D-
negative patients reported comparable72 or lower immunization rates73-79. In a 
number of these studies the low rate of D immunization is associated with a 
depressed immune system73-76.    
It is presumed that the explanation for the strong immunogenicity of the D-
antigen is related to the genetic basis and organization of the RH system. DNA 
analysis revealed that the corresponding RHD gene is deleted in D-negative 
individuals and that no alternative allelic form exists at the same locus in 
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Caucasians. Therefore, a D-negative recipient of D-positive cells will recognize 
an entirely foreign antigen, with several distinct epitopes, whereas in case of most 
other blood group disparities a single or a few amino acid differences are seen as 
foreign. Even the weak D type red blood cells with very low antigen density have 
been reported to be capable of anti-D immunization80-82.  
The exact immunogenicity of other antigens is unknown, as few studies exist 
deliberately exposing antigen-negative persons to antigen-positive RBC83. With 
regard to K-immunogenicity, Schabel et al found anti-K immunization 3-months 
after K-incompatible transfusions in 11 out of 116 K-negative patients (9.5%)84.  
Giblett85 estimated the relative immunogenicity for a number of RBC antigens 
compared to K-immunization by relating the observed frequency with which a 
specific antibody is found in the population to the estimated frequency of an 
immunizing event by transfusion, using the formula: 
 
Number of antibodies of interest x Probability of exposure to K antigen 
 
Number of K antibodies x Probability of exposure to antigen of interest 
 
Based on her calculations, the K-antigen was 2.5 times more potent than c-
antigen, 3 times more potent than E-antigen, 21 times more potent than Fya-
antigen and 71 times more potent than Jka-antigen in inducing antibody 
formation. Combined data from 3 studies performed between 1974 and 1995 
show comparable relative immunogenicity results for E-antigen, but c-antigen 
was 3 times (range, 1.2-4.2) less immunogenic, while Fya- and Jka-antigens were 
respectively 3 (range, 2.3-3.5) and 8 times (range, 5.7-12.7) more immunogenic 
than reported by Giblett86-88. 
Factors such as the sensitivity of antibody detection techniques, which has 
improved considerably over these study years, and the (patient) population under 
study may have had great impact on the occurrence of certain antibody 
specificities and therefore on its calculated immunogenicity.  
Genetic recipient factors may determine as to whether a person will response to a 
foreign RBC antigen or not. The adaptive immune system reacts only to foreign 
antigens if CD4 T-lymphocytes are activated upon interaction with peptide 
fragments presented by class II major histocompatibility complex (MHC) 
molecules on antigen presenting cells. The binding groove formed by the various 
MHC class II genes has a variable affinity for different peptides, with 
consequences for peptide presentation to T-cells. Recent studies showed that, 
within a particular ethnic group, the intrinsic immunogenicity of a given red cell 
antigen is, amongst other factors, related to the presence of particular HLA-
DRB1* molecules, capable of effective binding and presentation of blood group 
derived peptides to CD4 T lymphocytes89-92.  
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2.5 Alloimmune response to Red Blood Cell antigens 
The immune system consists of two closely connected defense layers, the innate 
and the adaptive or specific immune system. The first is evolutionary older and 
consists of barriers such as skin and mucosal surfaces and soluble factors in 
which broad pattern recognition leads to phagocytosis, complement activation 
and extracellular killing.  
The adaptive immune system is responsible for specific antibodies to red blood 
cell antigens. The first step in this response requires the recognition of foreign 
antigen. The production of naturally occuring IgM antibodies, such as anti-A, 
anti-B and anti-M, is primarily a T-cell independent response. Antibody 
production to these antigens is stimulated by B-cell receptor (sIg) binding to 
bacterial polysaccharide molecules, which are cross-reactive with the repetitive 
carbohydrate structures of human red blood cell antigens93-95. B-cells are 
activated, by cross-linking of their antigen receptors, to differentiate into IgM 
antibody secreting cells. A T-cell independent response usually does not induce a 
reponse maturation leading to immunoglobulin class switching from IgM to IgG, 
a process typical for T-cell dependent responses96.  
The main mechanism for alloimmunization involves the presentation of the donor 
antigen peptides by APCs to the T-cell receptor (TCR) on recipient CD4 T cells 
(a T-cell dependent response). Presentation of alloantigens may involve two 
distinct routes, the direct and indirect pathway of allorecognition. In direct 
recognition, the foreign (donor) HLA class II antigens expressed on donor APCs 
are directly recognized by recipient CD4 T-cells97,98. This occurs mainly for 
foreign HLA antigens99,100. Leucoreduction of blood products, removing donor 
APCs, has greatly reduced the occurrence of HLA immunization, particular in 
case of platelet transfusions, where fresh viable APCs enhance 
immunogenicity101,102. Because mature RBC lack HLA class II antigens, direct 
antigen presentation will not occur.  
Red blood cells have an approximate lifespan of 120 days103, after which the 
senescent red blood cells and during aging formed microvesicles are 
phagocytized by splenic and hepatic macrophages. This process takes place either 
through the phosphatidylserine receptor binding to externalized 
phosphatidylserine on apoptotic cells or by FcγR recognition of IgG 
(auto)antibodies bound on senescent cells104,105. We assume that when no 
alloantibodies are present allogeneic RBC are removed by similar mechanisms. 
After phagocytosis, the RBC antigens are proteolysed into small peptide 
fragments in lysosomes and short linear segments of 12-28 amino acids are 
associated with newly formed HLA class II molecules in postlysosomal vesicles. 
Genetic HLA class II restriction determines which peptides are tightly bound in 
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the HLA class II groove90,92,106-108. The peptide/HLA complex is transported to 
the plasma membrane of the macrophage where they are presented to TCR and 
immunoglobulin receptors on B-cells109,110. B cells by themselves can also take up 
native antigen through their membrane immunoglobulin, process this and present 
the peptides to activated antigen specific CD4 T-cells. Antigen specificity of T 
and B cell receptors is obtained by recombination of variable (V), diversity (D) 
and joining (J) gene segments, N-region nucleotide addition and somatic 
hypermutation, thereby creating the possibility to recognize an almost unlimited 
array of different aminoacid sequences96,111,112.  
The TCR variable antigen recognition unit of CD4 T-cells recognizes specific 
foreign amino acid sequences from processed exogenous antigens presented in 
the context of the self HLA class-II molecules.  
Whether T-cell recognition of foreign peptides leads to an effective immune 
response depends on additional signals, generated by co-stimulatory cell surface 
structures.  
The first step after engagement of the TCR/MHC class-II/foreign peptide 
complex is the activation of CD28 on the CD4 T-cell and CD80 or CD86 on the 
APC113. If these costimulatory signals are not activated during initial antigen 
exposure, the T cell cascade is down regulated, eventually leading to functional 
inactivation (anergy)114. 
When, in case of non-self peptides, the CD4 accessory molecules on the T-cells 
bind to their ligands on the APC, the strenght and specificity of the interaction is 
increased and additional signals (IL-2) for T-cell activation are provided. 
Activated T-cells rapidly expand resulting in a 100-fold increase. This activation 
also induces the expression of the inhibitory cytotoxic T-lymphocyte antigen 
(CTLA)-4 on the expanding T-cell clone, which competes with CD28 for binding 
with CD80 and CD86, balancing the expansion of the antigen-specific T-cell 
clone by limiting IL-2 production115,116. A second mechanism controlling 
homeostasis of immune response involves direct cell-cell contact. Activated 
T-cells express cell-surface Fas (CD95) and engagement of Fas by Fas-ligand 
bearing cells triggers apoptosis in the Fas-expressing cells by activated enzymes 
from the caspase cascade which degradates DNA117,118. Finally, if antibodies are 
produced the immune response is cooled down by immunecomplexes activating 
inhibitory signals. 
Activated T-cells produce IL-2 (T-cell growth factor) leading to proliferation and 
differentiation into effector Th cells, memory Th cells, and suppressor Th cells. 
Effector Th cells can differentiate into two major subtypes of effector cells, Th1 
and Th2 cells, defined by the specific cytokines they produce. The original black 
and white concept of the Th1/Th2 paradigma is later reconsidered as a model in 
which there are no discrete subsets but rather a continuum of different 
combinations of cytokine secretion reinforcing each other’s actions119-121. 
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Activated Th cells express CD154 (CD40L) which interacts with CD40 on B cells 
and this CD40/CD154 interaction drives the B-cells into cell cycle122. Besides, 
Th2 cytokines also induce B-cell activation and division (IL-4) and promote the 
differentiation into antibody-forming plasmacells (IL-6, IL-10). Upon activation, 
B cells undergo repeated cell divisions and differentiation to form a clone of 
short-lived antibody secreting plasma cells. These plasma cells initially secrete 
low-affinity IgM antibodies, but in the course of the response, switch to the 
production of high affinity IgG antibodies by means of gene-segment 
rearrangement of the constant part of the Ig molecule and somatic mutation of the 
rearranged variable gene.  
The primary antibody response is generally relatively slow, it may take several 
weeks to months before antibody reaches a detectable level and will therefore, in 
most cases, not affect the RBC survival of the immunizing transfusion.  
Despite the antigenic differences between donor and recipient RBC, the 
likelihood of alloimmunization is, depending on the antigen, in the order of 1-8 
percent in the general recipient population. Besides genetic factors, several 
unknown or ill defined factors may influence the immune response. It is observed 
that intravenous injection of high concentrations of antigens that are close to self-
antigens and persist for a long period of time may delete T-cell responses and 
more recent studies showed that phagocytosis of apoptotic cells inhibits the 
production of pro-inflammatory cytokines (the ‘danger’ signal) and thereby T-cell 
activation123-125. In this respect it is interesting whether longer stored RBC, with a 
higher number of apoptotic cells, elicit different immune reponses than fresh 
RBC. It may be clear that more studies are needed to elucidate all factors 
involved in the immune response towards red blood cell transfusions.  
When the antigen has disappeared activated cells are eliminated through apoptotic 
death, but a small fraction of cells differentiate into memory B and T cells, which 
are long-lived and provide long-term protection against the antigen concerned. 
Compared to naïve cells, these memory cells, with an increased antigen 
sensitivity, require far less antigen and stringent activation requirements, resulting 
in a more rapid, greater and effective formation of high affinity IgG antibodies 
upon antigen rechallenge.  
 
Antibody mediated red blood cell destruction 
There are tree main pathways of RBC destruction by antibodies. In most cases, an 
ABO incompatible transfusion elicits a complement mediated acute intravascular 
hemolytic transfusion reaction (AHTR). The CH2 domain of IgM antibodies 
complexed with the RBC antigens binds to C1q (complement recognition unit) 
triggering the complement cascade through the classical pathway. After 
subsequent activation of the complement activation unit (C2-C4-C3) the 
membrane attack complex (C5-C9) is formed. This complex penetrates the lipid 
bilayer of the red blood cell membrane making the cell permeable resulting in 
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osmotic cell lysis. An AHTR is characterized by the release of vasoactive amines 
(e.g. histamine) and other mediators/cytokines, (e.g. IL-1, TNF-alpha and IL-6 
and IL-8) which cause vasodilation, hypotension, and contraction of bronchial 
and intestinal smooth muscle. The clinical symptoms, although variable in 
individual patients, are sudden onset of fever, chills, facial flushing, chest or low 
back pain, hypotension, dyspnea, hemoglobinuria, renal damage, disseminated 
intravascular coagulation, shock and even death126. 
In case of an incompatible RBC transfusion in an immunized patient, immediate 
destruction may occur if antibodies are still present but have not been detected 
during antibody tests, or a delayed transfusion reaction, typically after 5-14 days, 
which occurs after a secondary immune response.  
The IgG antibodies, bind specifically to the foreign RBC antigens and target them 
for extravascular phagocytosis and lysis predominantly via the interaction of the 
IgG constant domain with Fcγ receptors on splenic macrophages. Most IgG RBC 
antibodies do not activate complement efficiently enough to activate the MAC 
causing RBC lysis. However, some (e.g. Kidd-antibodies, although in part 
IgM127) can, completely activate the complement cascade, and may cause 
intravascular hemolysis, while others, such as some K and Duffy antibodies, can 
activate complement only to the C3b stage. The latter are predominantly 
destroyed in the liver after binding with the CR1 receptor on Kupffer cells.  
Although hemolysis by IgG antibodies may occur and be accompanied by the 
complete array of symptoms described for acute hemolytic transfusion reactions 
and even involve destruction of the patients’ own RBCs128-132, referred to 
hyperhemolysis, but in many cases there are no clinical symptoms. Factors such 
as antigen density, number of bound antibodies, antibody IgG subclasses and the 
RES capacity affect the rate of destruction133-135. Ness and colleques introduced 
the term ‘serologic transfusion reaction’ for post-transfusion cases of a positive 
direct antiglobulin test without signs of hemolysis, which were found about 2-5 
times more often than hemolytic transfusion reactions136-138.  
 
 
2.6 Red blood cell antibodies in disease  
Observational studies in random patients, who most often receive incidental 
transfusions, and pregnant women, estimated the antibody prevalence between 
less than 1 to 3 percent86-88,139-147, but prospective systematic studies and studies 
in multitransfused patients reported on an up to over 70 percent alloimmunization 
incidence148. 
Three large retrospective studies on alloimmunization in random hospital 
transfusion recipients, covering the period 1975-1995 and a total of 10,226 
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antibodies, showed that antibodies to RH and K blood group antigens comprise 
almost 80 percent of clinically significant non-D antibodies (fig 1)87,88,147.  
Transfusion dependent diseases are characterized by a high alloimmunization 
frequency and is highest in sickle cell patients. Combined data from 18 studies on 
4005 sickle cell patients148-165 and 11 studies regarding 3394 thalassemia 
patients128,130,166-174 showed an overall alloimmunization risk of 22 (range 3-76) 
respectively 13 (range 5-28) percent. A total of 1606 RBC antibodies were 
reported in 675 sickle cell patients148,150-156,162-165 and 834 antibodies in 446 
thalassemia patients128,130,150,167-173. Multiple antibody specificities were present in 
46 respectively 35 percent of patients. The immunization rate, expressed as the 
number of antibodies per 100 transfusions, varied between 1.7 and 4.0. 
 
Fig. 1.  Clinical significant non-D antibody specificities1 in random patients and in 
patients with sickle cell disease (SCD) and thalassemia patients (Thal). 
 
1 For comparison only clinically significant non-D antibodies that are routinely screened upon are 
taken into account. These antibodies comprise 55% of antibodies in random patients and 78% of 
antibodies in hemoglobinopathy patients. 
 
Most other diseases requiring transfusions exhibit lower immunization risks 
(table 1). Differences in immunization risk and antibody specificity for various 
diseases are dependent on a number of factors. The genetic disparity between 
patient and donor RBC phenotypes is considered to be the main reason for the 
high immunization risk in patients with sickle cell disease. Especially C, Fya, Fyb, 
Jkb and S RBC antigens are significantly less frequent (p<0.001) in the 
predominantly black sickle cell patients than in the predominantly white 
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donors128,154,162,175 and antibodies against these antigens are more frequently found 
than in most other patients (fig 1). Studies in sickle cell patients performed in 
Jamaica148 and Brasil156,162, with a closer racial matching of donor and recipients, 
showed a three times lower immunization risk compared to European and 
American studies (9% versus 27%). This led to the policy to prophylactically 
match donor RBCs for RH and K antigens in patients with hemoglobinopathies. 
Studies, although not in a randomized controlled design, evaluating this policy 
found a reduction in the number of immunized patients and lower immunization 
rates128,154,160,168,169,176.  
A dysfunctioning immune system, either hyper- or hyposensitive can result in an 
enhanced respectively a reduced antibody production. Patients with 
myelodysplastic syndromes are fully immunecompetent, associated with a high 
incidence of autoimmune phenomena177, and also in a high immune response 
against allogeneic RBC antigens178-182. On the other hand, patients with lymphoid 
leukemia178,179, AIDS183,184 and hematopoietic stem cell transplantation185-189 show 
a highly reduced RBC alloimmune response probably related to the disease’s 
pathophysiology or the intensive immuno-suppressive therapy. However, the 
immuno-suppressive therapy in myeloid leukemia178,179 and organ transplant76,190-
193 and the impaired immune response in end-stage renal disease143,178,180,183,194-198 
does not prevent alloimmunization against allogeneic RBC antigens and is 
comparable to surgical patients199-201. 
 
Table 1. Alloimmunization risk in various diseases 
Disease References 
Number of patients 
per study  
(range; total) 
Immunization 
risk  
(median; range) 
SCD1 148-162 34-1044; 3409 30.0; 9.9-46.8 
Children 161-165 42-245; 596 18.5; 7.8-29.5 
Thalassemia 128,130,150,166-173 39-1434; 3424 9.7; 5.0-28.4 
Hematologic    
MDS2 and CMPD3 178-182 16-112; 231 23.2; 12.5-58.6 
Myeloid leukemia 178,179 35-209; 244 7.5; 5.7-8.6 
Lymphoid leukemia 178,179 13-193; 206 0.3; 0.0-0.5 
Renal failure 143,178,180,183,194-198 81-405; 1296 5.9; 1.1-14.0 
Transplantation    
Organ 76,190-193 35-1132; 3007 6.2; 2.7-9.0 
HSC4 185-189 117-217; 885 2.3; 1.3-9.1 
AIDS 183,184 72-81; 153 2.6; 1.4-3.7 
Surgery 199-201 374-530; 1356 5.3; 2.1-8.0 
1 Sickle cell disease; 2 Myelodysplastic syndrome; 3 Chronic myeloproliferative disease 
4 Hematopoietic Stem Cell 
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The formation of red cell antibodies may be influenced by the patients’ age at 
which the transfusions are given or when chronic transfusion therapy is started. 
Four studies on RBC alloimmunization performed in (pre-term) neonates who 
received multiple transfusions during the first 3-4 months of life did not 
encounter any RBC antibodies202-205. Also, in hemoglobinopathy patients it has 
been shown that alloimmunization risk was significantly lower in patients who 
started transfusion therapy at a very young age (<3 years) compared to those who 
started later in life153,168,169, although Ameen et al130 reported an immunization 
frequency of 30% in 190 thalassemia patients who all started transfusion therapy 
before the age of 1 year. An immature immune system and some form of acquired 
immune tolerance to allogeneic RBC antigens is held responsible for the reduced 
alloimmunization risk. 
A number of studies reported on an increasing number of alloimmunized patients 
dependent on the number of RBC units transfused143,148,153,156,158,164,176, although 
others do not confirm this association148,152,165,171,196,198,201. The conflicting results 
are explained by the number of transfusions, the interval between transfusions-
events, the frequency of antibody testing (single versus serial) and the specificity 
of the antibodies (e.g. common clinically significant versus non-significant and 
low-incidence) in the different studies. Besides, for most studies all transfusions 
administered to the patients were considered untill antibody detection. After 
transfusion with an incompatible antigen, a primary immune response needs time 
to result in a serological detectable antibody and additional transfusions can be 
given during this period. As a consequence the number of transfusions needed to 
elicit an antibody response can be overestimated. Based on the frequency of 
common RBC antigens in the caucasian population, most patients will 
theoretically encounter alloantigens during the first 3-4 transfusions. Blumberg et 
al showed that the rate of antibody formation per transfusion actually decreases 
with increasing numbers of transfusions (e.g. 7.9 per 1000 transfusions when less 
than 15 units were transfused compared to 2.5 when more than 44 units were 
transfused)178. This is in agreement with others who reported that the majority of 
alloimmunized patients have made the antibodies early during the transfusion 
course and probably after the first few encounters with the foreign 
antigen147,150,160,162,163,166,195. 
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SUMMARY 
Leucodepletion has shown to reduce human leucocyte antigen immunization, but 
studies on the effect of leucodepletion on red cell alloimmunization reported 
discordant results. We conducted a retrospective multicentre study to determine 
whether prestorage filter leucodepletion alters the development of clinically 
significant red blood cell alloimmunization against the RH, KEL, FY, JK and 
MNS blood group systems. Two periods were investigated, 2 years before and 2 
years after universal leucodepletion. Comparisons were made between the 
transfused patient cohorts. To control for changes not related to leucoreduction, 
we compared antibody incidence with antibody prevalence in the two study 
periods. Newly detected antibodies (n = 4770) were found in 4115 patients from 
19 participating hospitals. Of these, 857 antibodies in 659 patients were because 
of transfusions given in the study periods. The immunization risk was 0.13% for 
both periods. No differences were found regarding incidence of new antibodies, 
nor for patients regarding age, sex, previous antibodies, multiple antibodies, 
additional antibodies, number of transfusions, transfusions episodes, and days 
from transfusion to date of immunization. 
In conclusion, compared to buffy-coat leucoreduction, universal prestorage filter 
leucodepletion did not alter the development of clinically significant red blood 
cell alloimmunization.  
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INTRODUCTION 
Contaminating leucocytes in allogeneic blood transfusion are presumed to play an 
important role in immunomodulatory effects in the recipient. One hypothesis is 
that these contaminating leucocytes in the blood products downregulate a 
T-helper cell type 1 (Th1) immune response and drive the recipient toward a 
T-helper cell type 2 (Th2) response. Such skewing towards type 2 immunity may 
enhance alloantibody formation (Blumberg & Heal, 2000).  
Leucodepletion has been shown to reduce human leucocyte antigen (HLA) 
alloimmunization (Vamvakas, 1998). Leucodepletion also removes the donor 
antigen presenting cells (APCs) abrogating the direct pathway of 
alloimmunization by donor-recipient T cell interaction. Besides, donor leucocytes 
readily express activation and costimulatory molecules upon recognition of 
recipient antigens (Fast, 2000). Whether the removal of leucocytes from cellular 
blood products ameliorates the antibody response by the indirect classical 
pathway is unknown. 
Red blood cell (RBC) alloimmunization, a result of indirect immunization, is a 
common unwanted transfusion effect that occurs in up to 40% of patients 
depending on patient related factors, number of transfusion events and the type 
and timing of studies performed (Shirey & King, 2000).  
In the Netherlands, standard RBC products have been leucoreduced [white blood 
cells (WBC) <1 x 109] by buffy-coat removal since many years. The indication 
for filter-method leucodepletion (WBC <1 x 106) was originally restricted to 
special patient-groups, primarily to prevent HLA-immunization to minimize 
refractoriness to platelet transfusions.  
In November 2001, universal leucodepletion, by means of pre-storage filtration, 
of all RBC and platelet products, was implemented in the Netherlands as a 
precautionary measure to reduce the possible transmission of variant Creutzfeld 
Jacob disease. All transfusions have been leucodepleted since January 2002.  
Recently, the effect of leucodepletion on RBC alloimmunization was addressed in 
a number of studies (Strauss et al, 1999; Singer et al, 2000; Blumburg et al, 2003; 
van de Watering et al, 2003), with discordant conclusions. We investigated the 
effect of leucodepletion on RBC alloimmunization in a large non-selected patient 
cohort in a region covering 25% (≈4.2 x 106 inhabitants) of the Netherlands.  
We conducted a 4-year retrospective regional multicentre study to investigate the 
incidence of newly developed RBC antibodies upon transfusion before and after 
the implementation of universal leucoreduction. To control for possible changes 
not related to leucoreduction, we compared the antibody incidence with the 
antibody prevalence in patients admitted to these hospitals in the same interval, 
but who did not receive transfusions in the two study periods. 
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METHODS 
Hospitals 
Hospital transfusion laboratories (n = 27) in the Dutch Sanquin Bloodbank 
Southwest region were asked to participate in this retrospective study regarding 
RBC alloimmunization before and after universal leucodepletion. The study 
periods were from January 1999 to December 2000 and from January 2002 to 
December 2003. Hospitals were asked to provide details of their transfusion 
policy and the antibody detection test methods employed over the years. Yearly, 
total numbers of antibody screens and RBC transfusions were used to normalize 
the number of antibodies found for the periods under study. However, data on the 
total number of patients with antibody screens and complete data on the number 
of transfused patients were not available. 
 
Antibodies 
We retrospectively analyzed the records of all patients with newly detected RBC 
antibodies, during the 4-year period, by searching the participating hospital 
computer databases. Data collected included sex, age and the transfusion history. 
No detailed information on pregnancies, transfusions and antibodies detected in 
other hospitals was available.  
Only the clinically significant RBC alloantibodies of the RH, KEL, FY, JK and 
MNS blood group systems were included. Autoantibodies and antibodies to low 
and high frequency antigens were excluded. Anti-D was excluded because 
D-immunization is not related to RBC transfusions in the majority of cases. 
Comparisons were made between two periods of two years each, 1999-2000 vs. 
2002-2003, 2 years before and 2 years after the implementation of universal 
leucodepletion. We compared new antibodies that were detected in patients 
transfused during the study intervals (antibody incidence) with antibodies in 
patients admitted to these hospitals in the same period but who had not received 
transfusions during the study periods (antibody prevalence) (Fig. 1). This control 
group consisted of all patients for whom a blood type and screen was performed. 
New antibodies were defined as antibodies detected for the first time in a patient, 
additional antibodies were defined as new antibody specificities, in a patient with 
(historical) antibodies. 
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Fig. 1 Study flow diagram of alloimmunized patients 
 
Total study population* 
4148 patients with RBC antibodies 
  
   
Period January 1999 - December 2000 
Buffycoat leucoreduction 
2124 patients 
 Period January 2002 - December 2003 
Pre-storage filter leucodepletion 
2053 patients 
     
       
Cohort I 
346 transfused      
patients 
 Cohort III 
1778 control 
   patients 
Cohort II 
309 transfused 
patients 
Cohort IV† 
1744 control 
patients 
* The total study population, i.e. all patients with antibodies, was divided into four cohorts:   
Cohort I, patients who formed antibodies upon transfusions in the period 1999-2000 (antibody 
incidence) 
Cohort II, patients who formed antibodies upon transfusions in the period 2002-2003 (antibody 
incidence) 
Cohort III, patients presenting with antibodies without transfusions in the period 1999-2000 (antibody 
prevalence)  
Cohort IV, patients presenting with antibodies without transfusions in the period 2002-2003 (antibody 
prevalence)  
† Including 29 patients who formed antibodies in the period 1999-2001 and who presented with 
additional antibody specificity in the period 2002-2003 
 
Statistics 
The statistical software packages, EXCEL 5.0 (Microsoft, Redmond, CA, USA); 
and Statistical Package for the Social Sciences (SPSS) 11.0, (SPSS Inc. Chicago, 
IL, USA) were used for data management and analysis respectively. The chi-
square or Fisher exact test were used for comparisons of proportions in the two 
periods. Medians were compared by the Mann-Whitney test. Groups were 
assumed to differ significantly when the probability level was less than 0.05.   
 
 
RESULTS 
Nineteen of 27 hospitals in this Southwest region participated in the study, which 
enclosed 9909 (70%) of the regional hospital beds and 80% of transfusions 
(n=494,505) in the 4-year period. Antibody detection methods did not change 
during the study years and either a polyethylene glycol (PEG) enhancement tube 
test or a low ionic strength solution (LISS) enhancement column technique was 
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used, both tests of comparable sensitivity to detect RBC antibodies. Transfusion 
policy, especially regarding the prevention of alloantibodies (e.g. c, E and K 
matching) did not change but antibody screens increased by almost 4% during the 
periods, while RBC transfusions decreased by 11%, indicating a more widely 
applied type and screen policy, associated with a restrictive transfusion policy 
(Table I). 
 
Table I. Hospital production data in the study periods. 
 Study period 
 1999-2000 2002-2003 
Number of antibody screens 332,210 344,503 
Number of units transfused 261,879 232,626 
Ratio screens/transfusion 1.3 1.5 
 
 
Table II. Antibody frequency and specificity for transfused and control patients 
 Transfused cohort I and II 
n = 655 
Control cohort III and IV 
n = 3522 
 
Antibody 
specificity 
1999-
2000 
2002-
2003 
% of all 
antibodies 
1999-
2000 
2002-
2003 
% of all 
antibodies 
P-value* 
 
E† 168 133 35.1 504 519 26.1 <0.0001 
K 99 92 22.3 556 473 26.3 0.017 
C‡ 29 27 6.5 204 189 10.0 0.0018 
Fya 16 21 4.3 198 214 10.5 <0.0001 
M 11 6 2.0 187 215 10.3 <0.0001 
c 32 46 9.1 151 125 7.1 0.046 
Jka 55 47 11.9 84 72 4.0 <0.0001 
S 8 8 1.9 63 60 3.1 0.057 
Jkb 11 19 3.5 10 20 0.8 <0.0001 
e 6 10 1.9 11 16 0.7 0.0019 
Fyb 3 6 1.1 15 16 0.8 0.59 
s 2 1 0.4 5 5 0.3 0.91 
k 1 0 0.1 1 0 <0.1 0.80 
All 441 416  1989 1924  0.77§ 
* Antibody specificity cohort I + II versus cohort III + IV  
† Including anti-D+E (n=44), ‡ Including anti-D+C (n=275)  
§ P-value cohort I/I+III versus cohort II/II+IV   
 
In the four study years, antibodies (n = 4770, Table II) were detected in 4148 
patients (female to male ratio 3.1, mean age 59, range 1-105 years). Of these, 124 
patients already possessed historical (non-D) antibodies before entering the study 
period (Tables III and IV). This included 29 cases that had made antibodies upon 
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transfusion in the period 1999-2001 (cohort I) and who were identified with 
additional antibodies in the period 2002-2003 (Fig. 1, cohort IV).  
Of the total 4148 patients with antibodies, 399 (9.6%) patients had multiple 
antibody specificities at the initial antibody screening test. This distribution was 
similar for the two study periods without differences between the four cohorts 
(p=0.41). A total of 224 patients (5.4%, including the 124 patients with historical 
antibodies) made 239 additional antibodies during subsequent antibody screening 
tests.  
 
Table III. Demographics, transfusion and alloimmunization data for transfused patients 
                  (cohorts I and II) 
 Cohort I 
1999-2000 
Cohort II 
2002-2003 
p-
value 
Number of immunized patients 346 309 n.a. 
Female-male ratio 2.0 1.7 0.25 
Mean age at immunization 66 65 0.27 
Transfusion history:    
Median number of units transfused 4 4 0.79 
Median number of transfusion events 1 1 0.47 
Alloimmunization:    
New antibodies 441 416 n.a. 
Patients with historical antibodies 7 7 1.0 
Patients who presented with multiple 
antibodies 
48 50 0.38 
Patients who formed additional antibodies 19 24 0.35 
Median interval after transfusion to 
immunization (days) 
43 38 0.36 
Patients with antibodies within 14 days after 
transfusion 
84 74 1.0 
New alloimmunization rate (%)*:    
Patients immunized/antibody screens  0.10 0.09 0.061 
Patients immunized/ units transfused 0.13 0.13 0.98 
Antibodies/antibody screens 0.13 0.12 0.18 
Antibodies/units transfused 0.17 0.18 0.40 
* Number of antibody screens and transfusions, see table 1 
n.a.: not applicable 
 
 
The antibody specificity distribution between the transfused patients (cohorts I 
and II) and control patients, that presented with antibodies, but were not 
transfused during the study periods (cohorts III and IV) differed significantly for 
both study periods (Table II, p<0.0001). The incidence of the antibody 
specificities E, e, Jka and Jkb was significantly higher in the transfused group 
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compared to the frequency in the control group, whereas  anti-C, -c, -K, -Fya and 
-M were increased in the control group. 
No differences in antibody incidence or prevalence between the two study periods 
were observed. Similarly, patients age, sex, multiple antibodies, historical 
antibodies and additional antibodies were comparable (Tables III and IV). 
Regarding the transfused cohorts, number of units transfused, transfusions events 
and interval from transfusion to immunization were comparable.  
Alloimmunization within 14 days after transfusion, presumably reflecting a 
secondary immune response, was similar for both study periods (Table III).  
The alloimmunization rate for transfused patients normalized to the number of 
antibody screens or to the number of transfusions showed no significant 
difference between the periods 1999-2000 and 2002-2003 (Table III). In cohorts 
III and IV the alloimmunization rate, expressed as antibodies identified per 
antibody screen, showed a significant decrease (Table IV).  
 
Table IV. Demographics and alloimmunization data for control patients  
                 (cohorts III and IV) 
 Cohort III 
1999-2000
Cohort IV 
2002-2003
p-value 
Number of immunized patients 1778 1744 n.a. 
Female-male ratio 3.4 3.4 0.98 
Mean age at immunization 60 59 0.25 
Alloimmunization:    
New antibodies 1989 1924 n.a. 
Patients with historical antibodies 49 61 0.24 
Patients who presented with multiple antibodies 173 182 0.43 
Patients who formed additional antibodies 84 97 0.25 
New alloimmunization rate (%)*:    
Patients immunized/antibody screens  0.54 0.51 0.10 
Antibodies/antibody screens 0.60 0.56 0.029 
* Number of antibody screens, see table 1 
n.a.: not applicable 
 
 
DISCUSSION 
In a 4 year retrospective multicentre ‘before-and-after’ study we investigated the 
incidence of clinically significant antibodies that developed against RH, KEL, 
FY, JK and MNS antigens and found that the immunization rate, expressed as 
immunized patients and antibodies per transfusion event (0.13% and 0.17%, 
respectively), was not favourably affected by universal leucodepletion. Our study 
concerned non-selected random transfused patients with RBC antibodies. The 
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effect of universal leucodepletion in different patients groups (i.e. chronically 
multi-transfused patients) was not studied.  
We conducted our study the last 2 years before and the first two years following 
the implementation of universal leucodepletion. We excluded changes in 
laboratory and transfusion practices that could affect the results, except for an 
increase in blood typing and screening and a 11% reduction in the use of RBCs. 
However, in terms of preventing alloimmunization, we would have expected a 
decreased number of immunized patients as a result from this transfusion policy. 
Other causes of bias or uncontrolled confounders that could have affected the 
results can never be excluded entirely but are unlikely given our closely related 
study periods.  
In a recent study by Blumberg et al (2003), RBC alloimmunization was found to 
be reduced in relation to an increased use of leucodepleted red blood cell products 
in a group of 410 AML patients and in 217 random transfusion recipients. This 
effect was only significant in the AML patients (8.2% vs 2.8%, p=0.016). In the 
random patient group, antibodies known to be not necessarily induced by blood 
transfusion (e.g. Lewis, P1, Lutheran, HTLA, and Bg) were decreased, while 
alloimmunization to RH, KEL, FY and JK antigens only showed a non significant 
decrease over the years. Singer et al (2000) studied alloimmunization in 64 multi-
transfused thalassemia patients and reported a non-significant RBC 
alloimmunization decrease that could be related to the parallel change to the use 
of leucodepleted RBC blood products. It was, however, more likely that a change 
in transfusion policy, in terms of preventive of RH and K antigen matching, 
contributed to the decreased immunization. Strauss et al (1999) compared 
alloimmunization in 47 preterm infants after transfusion of fresh unmodified 
versus leucodepleted RBC in a randomized controlled blinded trial and found no 
RBC antibodies in either study arm. van de Watering et al (2003) did not find a 
reduction of RBC alloimmunization by leucodepletion in a randomized controlled 
trial study in 374 cardiac surgery patients.  
The number of transfusion events could have played a role in the differences 
found regarding the effect of leucodepletion on RBC alloimmunization. In the 
study by Blumberg et al (2003) patients were transfused by a mean of 17 RBC 
units, probably administered during several events, while patients in the study of 
van de Watering et al (2003) and in our study received a median of only 4 units 
(mean seven units), often as a single transfusion event. RBC alloimmunization is 
more likely after multiple transfusion events than after a single transfusion event 
(Issitt & Anstee, 1998).  
Another aspect that could influence the differences in study outcomes is the time 
interval between transfusion and the antibody screening. Recent studies (Ramsey 
& Larson, 1988; Schonewille et al, 2000), observed that antibodies could become 
undetectable over time. The mean number of weeks between the transfusion date 
and new alloimmunization varied, between 260 (non-WBC reduced) and 340 
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weeks (100% WBC reduction), in the groups studied by Blumberg et al (2003). 
Theoretically, this could have resulted in 7% decline in detectable antibodies 
(calculated from Schonewille et al, 2000). In our study, the median interval 
between transfusion and antibody detection in the two study periods in the 
transfused groups (cohort I and II) differed by only 5 days, and therefore unlikely 
that the antibodies had become undetectable.  
From prospective studies on alloimmunization in recently transfused patients 
(Redman et al, 1996), the antibody specificity distributions were in agreement 
with our transfused patients. The different antibody specificity distribution in 
recently transfused patients (cohorts I and II) compared with the control patients 
who had received transfusions in the past (cohorts III and IV) (Table 2) is 
probably dependent on two factors: the time needed for an antibody to develop to 
detectable levels and the period the antibody level remains high enough to be 
detectable. For instance, Kidd antibodies are frequently seen soon after 
transfusion but are often only detectable for a short period of time (Heddle et al, 
1995, Schonewille et al 2000). In terms of a role of leucocytes in RBC products 
creating more cytokine activation and a Th2 skewing of the immune response, 
one would have expected rather a difference in immediate antibody response, 
such as antibodies against JK antigens, which was not the case. 
In conclusion, this pre- and post intervention, retrospective multicentre study in a 
large non-selected patient cohort, found no differences in the development of 
clinically significant red blood cell alloimmunization by prestorage filter 
leucodepletion compared with buffy-coat leucoreduced RBC transfusions.  
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ABSTRACT  
BACKGROUND: It is common practice to perform an antiglobulin cross-match 
only when unexpected RBC alloantibodies are present, to detect antibodies 
against additional RBC antigens. In this study, the incidence of unexpected 
antibodies to low-incidence antigens (Ab-LIA) over a period of 23 years was 
investigated. 
STUDY DESIGN AND METHODS: Records of RBC antibodies and the 
accompanying transfusion history from 1978 through 2000 was retrospectively 
examined. Complete cross-matches were performed for all RBC transfusions 
before 1991. As of 1991, the type-and-screen policy was applied. To study the 
incidence of anti-Wra, a prospective study was conducted on sera from 462 
patients sent to the transfusion laboratory and 486 blood donors. 
RESULTS: The records of 1795 patients containing 2257 RBC antibodies were 
examined. In 89 patients, a total of 94 Ab-LIAs was found. Anti-Wra was the 
most frequently encountered Ab-LIA. Thirty-nine patients had Ab-LIA in 
combination with other antibodies, 20 of which were autoantibodies. Eighty 
percent of these Ab-LIA were found at the first positive antibody screening test. 
Fifty-one solitary Ab-LIA were found in 50 patients, 37 during antibody 
screening tests, and 14 after positive complete cross-matches conducted before 
1991. After an RBC antibody was detected, 664 patients received a total of 7792 
RBC transfusions. Since the introduction of the type-and-screen policy, only one 
anti-Wra has been discovered during complete cross-matching. No transfusion 
reactions due to Ab-LIA were reported during the study period. In the prospective 
study, 12.3 percent of patients and 4.3 percent of blood donors had anti-Wra. 
CONCLUSIONS: Although Ab-LIAs are found coincidentally in the sera of 
only 2 to 3 percent of patients with other RBC antibodies, they are formed often. 
Because we found no difference in serologic incompatibility, due to Ab-LIAs, 
between patients with and without other blood group antibodies, we conclude that 
blood can be transfused safely to patients without performing a complete cross-
match. 
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INTRODUCTION 
Antibodies to low-incidence antigens (Ab-LIAs) are discovered coincidentally 
during routine RBC antibody (screening and/or identification) investigations, 
after unexpected positive cross-matches or after an incompatible transfusion 
resulting in a hemolytic transfusion reaction. A number of studies1-14 mention the 
presence of Ab-LIAs. The incidence of Ab-LIAs in these studies varied between 
0.3 and 10 percent. 
It has become common practice to perform an antiglobulin cross-match only 
when the transfusion recipient has unexpected alloantibodies (UA), to detect 
additional RBC incompatibility.15 The chance of an incompatible blood 
transfusion due to Ab-LIA, based on the incidence of some LIAs, has been 
estimated to be 1 in 1600 to 1 in 10,000 transfusions.16 In studies11,14,17,18 on the 
risk of incompatible transfusions after immediate spin cross-match, the incidence 
of serologic or delayed hemolytic transfusion reactions was found to be more than 
1 in 1800 or 1 in 100,000 transfusions, respectively. 
Many sera contain Ab-LIAs from the IgM or IgG immunoglobulin class, which 
can be naturally occurring or immune antibodies.16,19-21 In autoimmune hemolytic 
anemia, Ab-LIAs are found in up to 30 percent of the patients.16 
Although Contreras et al.19 studied Ab-LIAs in hyperimmunized donors, we 
know of no systemic investigation of Ab-LIAs in patients with unexpected RBC 
alloantibodies. 
We retrospectively investigated the incidence of coincidentally discovered Ab-
LIAs in a patient population with unexpected alloantibodies over a period of 23 
years. In addition, we also prospectively studied the presence of anti-Wra in 
hospital patients, pregnant women, and blood donors to estimate the incidence of 
the most frequently encountered Ab-LIAs when tested. 
 
 
MATERIALS AND METHODS 
We examined retrospectively all the records on RBC antibodies in the transfusion 
laboratory computer database of Leyenburg Hospital (a 600-bed, 
multidisciplinary teaching hospital) during a 23-year period (i.e., 1978–2000). 
The study includes all RBC antibodies found. Antigens with a frequency of less 
than 10 percent of the population and routinely not present on antibody screening-
test cells were considered to be low-incidence antigens (LIAs). Information 
collected included patient's age and sex, dates and results of tests for RBC 
antibodies, and transfusion history, but no detailed information on pregnancies, 
transfusions, and antibodies detected in other hospitals was available. 
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Blood samples from successive patients submitted to the blood transfusion 
laboratory between January 1978 and December 2000 were screened for RBC 
antibodies as previously described.22 In short, a two- (1978–1986) or three-cell 
set (1987–2000) of reagent RBCs for antibody detection was used. The antibody-
detection RBCs were not selected to have LIAs. The technique for antibody 
detection consisted of a saline, albumin, and antiglobulin tube test (1978–1990); 
later a LISS gel test (DiaMed AG, Murten, Switzerland) (1991–2000) was used. 
Antibody identification was accomplished with commercial panels of cells 
obtained by means of similar methods or additional techniques (e.g., PEG, 
enzyme) whenever needed. If the specificity could not be determined, the blood 
sample was sent to a reference laboratory for further analysis. 
Cross-matching, including an IAT, was performed routinely from 1978 through 
1990; as of 1991, the "type and screen" policy (immediate centrifugation using 
saline-suspended donor RBCs without antiglobulin test) was adopted for all 
patients, including hematologic patients, until antibody formation was detected. 
When an antibody was identified, RBC components that were negative for the 
corresponding antigen were transfused after complete cross-matching, including 
an indirect antiglobulin phase. 
We also conducted a prospective study on successive hospital patients (n=108), 
pregnant women (n=193), and blood donors (n=486) to investigate the incidence 
of anti-Wra in a population without unexpected alloantibodies. In addition, we 
also tested frozen serum samples from 161 patients with UA for the presence of 
anti-Wra. 
 
Statistics 
Statistical software packages (Excel 5.0, Microsoft, Redmond, CA; NCSS 6.0, 
Jerry L. Hintze PhD, Kaysville, Utah) were used for data management and 
analysis, respectively. The Chi-square test was used to compare the incidence of 
Ab-LIAs between groups. Groups were assumed to differ significantly when the 
probability level was less than 0.05. 
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RESULTS 
Fig. 1. Flow sheet of the patients with antibodies. 
P=patients 
 
Figure 1 presents a flow sheet of the patients with antibodies. The records of 1795 
patients contained RBC antibodies (female-to-male ratio 3.2). Median patient age 
at the time of first antibody detection was 63 years (mean, 60; range, 15–97).  
A total of 3418 antibody specificity tests was performed (median, 1; mean 1.9; 
range, 1–42). For 1202 patients (67%) one antibody specificity test and for 593 
patients (33%) more than one antibody specificity test were performed. We 
identified 2257 RBC allo- and/or autoantibodies; the blood group system 
specificities are listed in Table 1.  
 
Table 1. Antibody blood group specificity and frequeny for 1795 patients  
with 2257 antibodies 
Blood group 
system 
Number 
Percentage of 
total 
Blood group 
system 
Number 
Percentage 
of total 
RH 955 42.3 LIA 94 4.2 
KEL 443 19.6 JK 64 2.8 
FY 165 7.3 HTLA/HLA 48 2.1 
MNS 121 5.4 Other sytems 30 1.3 
LE 110 4.9 Unidentified 27 1.2 
   Autoantibodies 200 8.9 
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In total, 1428 patients had one antibody, 303 had two, 41 had three, and 23 
patients had more than three antibodies. 
Fifty-one solitary Ab-LIAs were found in 50 patients, 14 were discovered by 
positive complete cross-matches conducted before 1991, and 37 were discovered 
during antibody screening tests. Five patients had two Ab-LIAs. 
The characteristics of the Ab-LIAs are listed in Tables 2 and 3. Thirty-nine 
patients had 43 Ab-LIAs in combination with other antibodies. The incidence of 
patients with Ab-LIAs in combination with other RBC antibodies is 2.2 percent. 
In 38 patients, these antibodies were found coincidentally during antibody 
specificity tests. In 20 (53%) cases, autoantibodies accompanied the antibodies. 
 
Table 2. Type and frequency of antibodies against LIAs 
Antibody type Frequency (N) 
First + additional* 
Solitary 
In combination with 
other antibodies 
Wra 24 + 2 8 18 
Lua 23 + 1 16 8 
Cw 18 + 3 11 10 
Unidentified 12 + 0 11 1 
Kpa 7 + 0  3 4 
V 2 + 0 2 NA 
Cob 0 + 1 NA 1 
Vr 0 + 1 NA 1 
Total 86 + 8 51 43 
* First, the AB-LIA is found (together with the UA) during the first antibody detection test; 
additionaly, the Ab-LIA is found after subsequent testing in patients with known UA. 
 
After initial antibody demonstration, 94 patients formed 121 antibodies in 106 
additional antibody-forming episodes. There were no differences (p>0.05) in the 
number of patients who formed additional antibodies between patients with one 
(n=79/482) and those with more than one antibody (n=11/111) at initial 
screening. In seven patients, these additional antibodies were Ab-LIAs. 
Thirty-five (81%) Ab-LIAs were found during the first antibody identification 
test, and eight were found after subsequent testing. In a patient with anti-c, -E, -K, 
and -Lua, an additional anti-Cw was found. A 75-year-old transfusion-dependent 
(80 U in 30 months) female patient with a chronic myelomonocytic leukemia and 
anti-K made anti-Lua and anti-Wra, as well as anti-c and -E, autoantibodies and 
HLA antibodies. 
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Table 3. Characteristics of Ab-LIAs 
Ab-LIA Accompanying antibodies 
Number of 
patients 
Test-type at 
first discovery* 
Wra None 7 CCM 
Wra E 2 AI 
Wra K 1 CCM 
Wra AA 6 DAT+/AI 
Wra K + AA 1 DAT+/AI 
Wra Auto-e + AA 1 DAT+/AI 
Wra Auto-D + AA 1 DAT+/AI 
Wra E + c + AA 1 DAT+/AI 
Wra E + auto-C + AA 1 DAT+/AI 
Wra E + auto-e + auto-C + AA 1 DAT+/AI 
Lua None 15 AS 
Lua E, K 1, 2 AI 
Lua E + c 1 AI 
Lua C + e + Fya 1 AA 
Lua C + Lea + AA 1 DAT+/AI 
Cw None 11 AS 
Cw E, c, K, S 3, 1, 1, 1 AI 
Cw E + K + AA 1 DAT+/AI 
Cw Auto-e + auto-c + AA 1 DAT+/AI/Eluate 
Kpa None 2 CCM 
Kpa None 1 AS 
Kpa Lea, K + E 1, 1 AI 
Kpa K + AA 1 DAT+/AI 
V None 2 CCM 
Cob E + c 1 AI 
Vr E + K + S + Jkb + AA 1 DAT+/AI 
Wra + Lua None 1 CCM 
Wra + Cw C + AA 1 AI 
Lua + Cw C + e + K 1 AI 
Wra + Lua E + c + K + AA + HLA 1 DAT+/AI 
Wra + Kpa K + S + Jkb + auto-e + AA 1 DAT+/AI 
Unidentified None 10 AS 
Unidentified None 1 CCM 
Unidentified Fya 1 AI 
* CCM = complete cross-match; AA = autoantibody; AI = antibody identification; AS=antibody 
screen. 
Chapter 4 
 
 
62 
An anti-Cw was found in the eluate of the RBCs of a patient with auto-e, auto-c, 
and unidentified autoantibodies after receiving 28 e- and c-matched transfusions 
in 11 transfusion episodes. This patient did not suffer from a hemolytic 
transfusion reaction at the clinical level. 
The specificity of the Ab-LIAs could not be identified in 12 cases. 
After an RBC antibody was detected, 664 patients received a total of 7792 RBC 
transfusions (median, 5; mean, 11.7, range, 1–326) in 2803 transfusion episodes 
(median, 2; mean, 4.2; range, 1–101). The number of complete cross-matches for 
all transfused hospital patients during the study period was estimated to be 
117,000 (1978–1990, 110,800; 1991–2000, 6200) and the number of transfusions 
204,000. During the whole study period, no transfusion reactions were reported to 
have been caused by Ab-LIAs. 
 
Ab-LIAs detected by "complete cross-match" versus "abbreviated cross-
match" 
From 1978 to 1990, 22 Ab-LIAs were found - nine Ab-LIAs during 1896 
antibody identification tests and 13 during 110,800 complete cross-matches. After 
the type-and-screen policy was applied (from 1991), only one Ab-LIA was found 
during 6200 cross-matches in patients with unexpected alloantibodies, and 70 Ab-
LIAs were found during 1522 antibody identification tests. 
 
Table 4. Type of investigation during which Wra antibodies were found 
 Antibody identification 
 Anti-Wra in patients 
without UA 
Anti-Wra in patients 
with UA 
Anti-Wra found during 
complete cross-match 
1978-1990 NA 3/902 8/110.800* 
1991-2000 NA 14/893 1/6200† 
Prospective 46/787 32/161 NA 
* Number of complete cross-matches for all patients 
† Number of complete cross-matches only for patient with UA 
NA, not applicable 
 
Wra antibodies 
Wra antibodies were the most frequently encountered Ab-LIA (Table 4). Out of 
19 nonsolitary Wra antibodies, 15 were discovered together with unidentified 
autoantibodies. One anti-Wra was discovered after a positive cross-match in a 
patient with anti-K. 
The prospective study on the presence of anti-Wra revealed the presence of this 
antibody in 46 of 787 persons (5.8%) without RBC antibodies (21/486 [4.3%] 
blood donors, 14/193 [7.3%] pregnant women, 11/108 [10.2%] hospital patients) 
and 32 of 161 (19.9%) patients with alloantibodies. 
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DISCUSSION  
In this study we found that in the total cohort of patients with RBC antibodies, 5.0 
percent had Ab-LIAs detected by screening with RBCs not selected to have Ab-
LIAs or by cross-matching, and 2.2 percent of these Ab-LIAs were accompanied 
by other RBC antibodies. 
Twelve Ab-LIAs were of unknown specificity. Further investigations of the 
specificity of an Ab-LIA are often not undertaken because of the high costs 
involved and the limited clinical relevance. 
We found no Ab-LIAs together with D-antibodies (n=334) retrospectively, but 
prospectively four anti-Wra were discovered in 25 patients with anti-D 
(p<0.00001). Cleghorn,23 who compared recently delivered women without anti-
D to those who made anti-D during pregnancy, found that the presence of anti-
Wra increased from 1 in 50 to 1 in 14 women. Based on these findings and the 
fact that anti-D is one of the most frequently encountered antibodies in our study, 
we should have encountered combinations of anti-D with Ab-LIAs in seven (95% 
CI, 2–12) patients. 
We found five patients with multiple Ab-LIAs, and anti-Wra was present in four 
cases. Anti-Wra was also identified prospectively in 19.9 percent of patients with 
allo-UA. This value is in agreement with Contreras et al.,19 who found that 12 
percent of plasmas from donors hyperimmunized against Rh antibodies contained 
antibodies to Wra antigens (p=0.2). Because they also found that 57 percent of 
hyperimmunized donors had multiple Ab-LIAs, they postulated that the 
production of antibodies to RBCs in general stimulates the production of Ab-
LIAs. Because we only tested for the presence of anti-Wra and found our results 
are comparable to those of Contreras et al.,19 it is conceivable that many more 
different Ab-LIAs are actually present in our population of patients as well as 
healthy individuals. 
In our prospective study, we found anti-Wra in 7.3 percent of pregnant women 
and 10.2 percent of hospital patients without other RBC antibodies. These 
incidences are in agreement with those of Wallis et al.24 who found anti-Wra in 
7.9 percent of their hospital patients. They noted that the anti-Wra incidence 
among patients decreased with age, but they could not find an association with 
sex, AB0-D blood group, type of illness, or medical or surgical speciality. Issitt 
and Anstee16 state that probably as the result of an unbalanced immune system 
together with RBC destruction, Wra antibodies are frequently formed in patients 
with autoimmune hemolytic anemia and in pregnant and recently delivered 
women. On the other hand, one could hypothesize that hospitalization in itself or 
other stress situations could alter the immune system and therefore enhance anti-
Wra production. Cleghorn,23 in this regard, suggested that most human sera 
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contain many Ab-LIAs and that some nonspecific boost is needed to "activate" 
them. The mechanisms of the antigen presentation involved are still unclear, but 
RBC transfusions with the corresponding antigen are not always involved. 
Another explanation could be that during activation of the immune system, 
certain proteins are formed that cross-react with the Wra-antigen on RBCs. 
As far as blood donors are concerned, we found a much higher incidence of anti-
Wra than reported in a number of other studies23-25 (4.3 vs. 0.4–1.3%, p<0.00001). 
In accordance with our results, Contreras et al.19 found anti-Wra in 1 of 50 donors 
hyperimmunized with microbial antigens (Herpes-Zoster, HBsAg, or Tetanus 
Toxoid) and no other RBC antigens. Further investigations are needed to explain 
these discrepancies. 
Forty-eight percent of Ab-LIAs are found simultaneously the first time that other 
RBC antibodies are detected. Only for 7 out of 593 (1.2%) patients who 
underwent multiple antibody-specificity investigations were Ab-LIAs found after 
the initial testing. In view of the facts that once a patient has made an RBC 
antibody the chance of additional antibodies is three to four times6,13 greater and 
sera from patients with RBC antibodies are tested against a variety of test RBCs 
during repeated antibody investigations and cross-matches and therefore there is a 
greater chance of encountering LIAs, we should even coincidentally have 
encountered more Ab-LIAs. It could mean that the risk of additional Ab-LIA 
formation in patients with RBC antibodies is low. This is in contrast with our 
prospective findings concerning anti-Wra in patients with UA. Also, Dunsford26 
found that 14 of 48 sera with anti-E also contained anti-Wra, in agreement with 
our results, where 8 of 36 anti-E sera and 3 of 8 sera containing multiple 
antibodies including anti-E also contained anti-Wra. It is not known if the above 
findings are specific for the combination of an UA and anti-Wra. Anti-Cw, 
however, was only present in 10 patients with other UA, despite the fact that most 
RBC identification panels comprise Cw-positive cells. 
In view of the fact that 14 Ab-LIAs were found after a positive indirect 
antiglobulin phase cross-match, the risk of serologic incompatibility in this study 
is 1 in 8300 transfusions. Before 1991, 13 serologic Ab-LIA incompatibilities 
were found in 110,800 complete cross-matches in all patients versus 1 in 6200 
complete cross-matches in patients with UA from 1991 through 2000 (p>0.10). 
This means that the risk of an serologic incompatible transfusion due to an Ab-
LIA is comparable in patients with and without UA. The low incidence of 
positive complete cross-matches and incompatible transfusions (1 in 204,000) due 
to Ab-LIA is in agreement with others.14,17,18,27,28 Because up to 30 percent of 
RBC antibodies can become undetectable over time,22,29,30 patients are likely to 
receive RBC transfusions on a type-and-screen basis when transfused in another 
Antibodies to low frequency antigens 
 
 65 
hospital, where the antibody history is unknown. This is also the case for patients 
with Ab-LIAs. 
Taken together, it is likely that many units carrying a LIA have been transfused to 
patients with the corresponding antibody. No transfusion reactions due to Ab-
LIAs have been reported to our laboratory. Because many transfusion reactions 
probably have gone unrecognized and therefore only severe reactions are 
routinely reported to the laboratory, this could reflect the mildness of the possible 
transfusion reactions in most cases of Ab-LIA incompatibility. The consequences 
of incompatibility based on Ab-LIAs in terms of in vivo RBC survival are 
unknown. For patients with normal hematopoiesis who receive a single 
transfusion for surgical reasons, this incompatibility probably has no serious 
harmful effects, but in patients with a dysfunctioning marrow who are transfusion 
dependent, the maximum efficiency per transfusion must be obtained. Serologic 
incompatibility can be an indicator of shortened in vivo RBC survival, resulting 
in additional transfusions. 
In conclusion, some Ab-LIAs (e.g., anti-Wra) are often formed but are seldom 
detected because LIA is missing from detection RBCs and/or cross-matched 
RBCs. Prospective studies can give insight into the incidence and consequences 
of the most common Ab-LIAs in different populations. The results of such studies 
can have an impact on the transfusion policy applied for selected groups of 
patients. Because the risk of a transfusion reaction due to an Ab-LIA is very low, 
transfusion without complete cross-matching can be considered safe. 
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ABSTRACT 
BACKGROUND: Because of intensive marrow depression and improved 
survival, patients with hematologic and oncologic malignancies are dependent on 
transfusion for a longer period. It has been advocated that these patients should 
receive blood that is matched for blood group antigens other than ABO and D. A 
retrospective study was performed on the rate of alloimmunization against red 
cell antigens in 564 patients with malignant hematologic diseases over a period of 
10 years. 
STUDY DESIGN AND METHODS: Records of transfusion and immuno-
hematologic studies of all patients (n =1066) with malignant myeloproliferative 
and lymphoproliferative diseases diagnosed between 1987 and 1996 at one 
hospital were collected from the hospital computer blood bank files. Transfusions 
were correlatedwith antibody formation. Factors affecting this correlation were 
analyzed. 
RESULTS: Seventy-one antibodies were found in 51 patients. The overall 
immunization rate was 9.0 percent. Fifty percent of antibodies were formed after 
13 units had been transfused. Once a patient had formed an antibody, the 
probability of additional antibodies increased 3.3-fold. Anti-c, anti-E, and anti-K 
composed the majority of antibodies found. Four patients formed RH system 
antibodies after incompatible platelet transfusions. Patients who underwent 
intensive chemotherapy formed antibodies at a much lower rate than other 
patients. More than40 percent of antibodies became undetectable after the first 
detection. No difficulty was encountered in finding compatible blood for these 
patients. 
CONCLUSIONS: Antibody formation in hematologic malignancies is 
comparable to that in other diseases requiring multiple blood transfusions. 
Extensive antigen matching before transfusion of patients with hematologic and 
oncologic malignancies is not necessary and leads to increased costs. 
Alloimmunization in hemato-oncology 
 71 
INTRODUCTION 
Transfusion support is vital to the management of patients with hematologic 
disorders and malignancies. Many such patients require blood transfusion during 
the course of their illness, and almost all patients who undergo chemotherapy or 
radiotherapy become anemic. It is well known that alloimmunization to red cell 
(RBC) antigens resulting from the genetic disparities between donor and recipient 
is one of the risks of blood transfusion. The risk depends on the recipient’s 
exposure to the foreign antigen and its immunogenicity. Immunization may also 
be influenced by the number and frequency of the transfusions as well as the 
recipient’s sex, age, and underlying disease1-19. Clinically significant RBC 
alloantibodies develop in more than 30 percent of patients receiving multiple 
transfusions and can pose major problems in the case of long-term transfusion 
therapy. Several authors found that RBC alloimmunization mainly occurs after 
the first few transfusions 11,12. RBC antibodies, which can become undetectable 
over time 20,21, can cause delayed transfusion reactions after incompatible blood 
transfusions. Several authors6,10-14,22 advocated that transfusions given to patients 
who are likely to become transfusion-dependent over a longer period of time 
should be matched for antigens other than ABO and D (e.g., C, E, c, and K) in an 
attempt to prevent alloimmunization. However, cost-effective considerations as 
well as the question of whether this would truly add to the patient’s safety make 
this policy a matter of debate1,4,17,23. 
Patients undergoing chemotherapy, especially those with leukemia, exhibit a 
lesser antibody response than do other patients. Impairment of the immune status 
as a result of the malignant process4,12,24,25 or transient immunosuppression due to 
intensive chemotherapy could enable patients to develop a tolerance for or 
unresponsiveness to incompatible transfusions2,24-30. 
We retrospectively analyzed RBC alloantibodies detected and identified in serum 
from patients with hematologic and oncologic malignancies submitted to our 
laboratory. 
 
 
MATERIALS AND METHODS 
Laboratory testing 
Blood samples from hematologic and oncologic patients submitted to the blood 
transfusion laboratory of the Leyenburg Hospital (The Hague, the Netherlands) 
between January 1987 and December 1996 were screened for RBC alloantibodies 
by use of a selected three-cell set of reagent RBCs for antibody detection. The 
technique for antibody detection involved the use of 100 μL of serum and 50 μL 
of 5-percent RBCs (serum-to-cell ratio, 40:1), a saline, albumin, and antiglobulin 
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tube test (1987 through 1990); later (1991 through 1996), 25 μL of serum and 50 
μL of 0.8-percent RBCs (serum-to-cell ratio, 63:1) were used in a low ionic-
strength solution gel test (DiaMed AG, Cressier Switzerland). 
Antibody identification was accomplished with commercial panels of cells tested 
by similar methods or additional techniques (e.g., polyethylene glycol, enzyme) 
whenever needed. If the specificity could not be determined clearly, the blood 
sample was sent to a reference laboratory for further analysis. 
The results of both antibody screening and antibody identification were valid for 
72 hours (a transfusion episode); then, in case of transfusion, a fresh blood 
sample was tested. 
Crossmatching, including an indirect antiglobulin test, was performed routinely 
from 1987 to 1990; as of 1991, the type and screen policy was used for all 
patients until antibody formation. Subsequently, complete crossmatching 
including an indirect antiglobulin phase was performed. 
 
Patients 
The identification of all patients (n=1066) with a malignant myeloproliferative 
(n=399) and lymphoproliferative (n=667) disease diagnosed between 1987 and 
1996 at the Leyenburg Hospital was obtained by searching the computer 
database. Patients who never received a transfusion (n=369) and those who did 
not undergo at least one antibody screening after the first blood transfusion 
(n=133) were excluded. This left 564 evaluable patients. 
Myeloproliferative diseases consisted of acute myeloid leukemia (AML, French-
American-British [FAB] classifications M0-M7)31, myelodysplastic syndromes 
(FAB: RA [refractory anemia], RARS [RA with sideroblasts], RAEB [RA with 
excess blasts], chronic myelomonocytic leukemia, and RAEB-T [RA with excess 
blasts in transformation])32, and myeloproliferative syndromes (MYPRO) 
(chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, 
and myelofribrosis). Lymphoproliferative diseases consisted of Hodgkin’s 
lymphoma and non-Hodgkin’s lymphoma (NHL), myeloma, and acute 
lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). 
 
Methods 
Records of transfusions and immunohematologic studies on the patients were 
collected from the hospital’s computer blood bank files. The data included all 
transfusions and tests performed for each patient during all previous admissions 
to this hospital. Information collected included age, sex, transfusion history (date, 
quantity, and type of blood component), and results of tests for RBC antibodies. 
No detailed information on pregnancies and transfusions in other hospitals was 
collected. We excluded 1) antibodies that were present before the study began, 2) 
antibodies against low frequency antigens that were coincidentally found, 3) non-
RBC-stimulated antibodies, and 4) autoantibodies. Only results obtained from 
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antibody screening after transfusion were considered. When an antibody had been 
detected, we recorded its specificity, the number of previous RBC transfusions, 
and the number of transfusion episodes since the first transfusion. 
Patients received RBC-containing transfusions compatible with their ABO and D 
phenotype. These included packed RBCs, white cell-reduced RBCs, washed 
RBCs, and whole blood. Patients who received packed RBCs and had a febrile 
nonhemolytic transfusion reactions twice, subsequently received white cell-
reduced blood components. 
Platelet components were prepared by combining the platelets from the buffy 
coats of five to eight donors in one platelet pack. The transfused platelet 
components were ABO and D compatible whenever possible. After an antibody 
had been identified, RBC components that were negative for the corresponding 
antigen were transfused. 
 
Statistics 
Statistical software packages (Excel 5.0, Microsoft, Redmond, CA; NCSS 6.0, 
Jerry L. Hintle, Kaysville, UT) were used for data management and analysis, 
respectively. The Kaplan-Meier product limit estimator was used to calculate the 
rate of antibody formation. Product-limit antibody formation plots were derived 
from the formula 1 - [antibody formation (t)]. The log rank test (nonparametric) 
was used to compare antibody formation. The chi-square test was used to 
compare the incidence of antibodies in persons with different diseases. The 
Kruskal-Wallis test (nonparametric ANOVA) was used to compare medians. 
When multiple comparisons were performed, the Bonferroni test value was used 
to test for significant differences. In other cases, groups were assumed to differ 
significantly when the probability level was less than 0.05. 
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RESULTS 
Patient data are shown in Table 1. The median age at diagnosis was 69 years 
(range, 16-96), and the male-to-female ratio was 1.2.  
 
Table 1. Patient number and age (years) according to disease 
Patients Evaluable Median 
Disease 
Total Transfused Number Percentage age 
Range 
NHL 343 212 175 83 69 16-90 
MDS* 160 137 105 77 74 30-94 
AML 102 96 87 91 67 18-89 
Myeloma 117 94 86 86 70 34-91 
MYPRO 137 64 44 69 69 28-96 
CLL 115 43 31 72 71 41-85 
ALL 25 23 21 91 42 18-81 
Hodgkin lymphoma 67 28 15 54 38 20-80 
Total 1066 697 564 81 69 16-96 
*Myelodysplastic syndrome 
 
The 564 patients received 15,287 units of RBCs in 6182 transfusion episodes. 
The total number of units transfused per patient ranged from 1 to 338, with a 
median of 16 units. Men received a median of 19 units, and women received a 
median of 15 units (p>0.05). Gender and age had no influence on the rate of 
antibody formation. The median number of units transfused, the number of 
transfusion episodes, and the months of transfusion support are shown in Table 2. 
Patients with myeloproliferative diseases received almost three times as many 
units of blood (p<0.0001) in more than twice as many episodes (p<0.0001) over 
more than twice as long a period (p=0.0202) as patients with lymphoproliferative 
diseases. The median number of units transfused was 15 for the nonimmunized 
group and 47 for the immunized group (p<0.0001).  
Patient sera were screened for antibodies a median of 10 times (range, 2-93). The 
screening revealed that 1) Ten (1.8%) patients had a total of 12 RBC antibodies 
upon entering the study, and one of them formed additional antibodies. The latter 
antibodies were included in the study; 2) Seventeen antibodies against low-
frequency antigens were coincidentally found (9 anti-Wra, 5 anti-Lua, 2 anti-Cw, 
and 1 anti-Kpa); 3) There were 3 non-RBC-stimulated antibodies (2 anti-M and 1 
anti-Leb); and 4) There were 16 autoantibodies (13 aspecific autoantibodies and 3 
auto-anti-e). 
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Table 2. RBC transfusion data by disease 
Transfusion 
Number Episodes Months of support Disease 
Median Range Median Range Median Range 
AML 31 3-126 12 1-52 6 1-35 
MDS 30 2-229 12 1-89 13 1-94 
MYPRO 24 2-183 11 1-67 11 1-88 
Total* 30 2-229 12 1-89 9 1-94 
ALL 23 2-98 9 1-43 4 1-87 
Myeloma 15 2-66 7 1-30 7 1-60 
CLL 15 2-152 6 1-67 4 1-84 
NHL 8 1-338 4 1-84 3 1-116 
Hodgkin lymphoma 7 2-22 3 1-10 2 1-32 
Total† 11 1-338 5 1-81 4 1-116 
Overall total 16 1-338 7 1-89 5 1-116 
*All myeloprofiferative diseases 
† All lymphoproliferative diseases 
 
A total of 71 antibodies were formed by 51 patients (9.0% of the total group; 28 
men and 23 women). Fifty percent of the first antibodies were detected after 13 
units had been transfused (Fig. 1). Antibody formation first occurred after a 
median of 12 units had been transfused in six episodes. 
 
Table 3. Incidence and specificity of RBC antibodies 
Single 
antibody 
Number of 
patients 
Two 
antibodies 
Number of 
patients 
Multiple 
antibodies 
Number of 
patients 
D 3 D+E 1 E+c+AA* 1 
E 7 C+e 1 E+K+Fya 1 
c 1 C+E 1 E+c+K 1 
K 10 C+K 1   
Jka 1 E+c 5   
AA 12 E+K 1   
  E+Fya 1   
  E+AA 2   
  K+AA 1   
* Aspecific alloantibody  
 
The risk of alloimmunization, defined as the total number of alloantibodies 
divided by the total number of units transfused, was 0.5 percent. When related to 
the number of transfusion episodes, the risk was 1.15 percent. 
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Fig 1. Percentage of first antibodies formed in relation to the number of units transfused. 
          Fifty percent of antibodies were formed after 13 transfusions 
                   Units transfused 
 
Fig 2. Number of patients with antibodies in relation to hematologic disease 
⁪ 1 antibody, ⁪ 2 antibodies, ⁪ >2 antibodies 
 
The incidence of antibody formation and the antibody specificity are presented in 
Table 3. The distribution of alloantibody specificity did not differ significantly 
among patients with different diseases. Thirty-four patients formed one antibody, 
 
  
Percentage 
of first 
antibodies 
formed 
  MDS     NHL   MYPRO   AML  Myeloma  CLL     ALL  Hodgkin lymphoma    
Number of 
patients  
with 
antibodies 
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14 patients two antibodies, and 3 patients three antibodies. Figure 2 depicts the 
results by disease. 
These results indicate that, once a person is immunized, the risk of producing 
additional antibodies increases 3.3-fold.  
A total of 58 analyses of antibody specificity were documented: 46 for one 
antibody, 11 for two antibodies, and 1 for three. There was no difference between 
responders (those who formed 1 antibody) and “super-responders” (those who 
formed more than one antibody at one time) in terms of the number of units 
transfused before antibody formation occurred (median number of units, 15 and 
9, respectively; p>0.05). 
A Kaplan-Meier estimate of the cumulative probability function for all diseases 
illustrates the relationship between the first and additional antibody formation and 
the number of transfusions given (Fig. 3).  
 
Fig. 3. First versus additional antibody formation in relation to number of units 
           transfused.  
—, Transfusions before first antibody; - - - -, transfusions between first and additional antibodies. 
p>0.05. 
 
A logrank test revealed no significant difference (p>0.05) between the rates of 
antibody formation. Second antibody formation occurred after the transfusion of 
19 additional units (Table 4). 
Twenty-one patients received more than 100 units of blood; 14 did not become 
immunized - in one case, not even after receipt of 229 units. Investigation of 
alloantibody formation after the last transfusion was performed after a median of 
14 days (range, 4 days-9 years). No acute or delayed serologic transfusion 
Percentage 
of patients 
with 
antibodies 
Units transfused 
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reactions were reported. Febrile nonhemolytic reactions and allergic urticarial 
reactions were seen incidentally. 
 
Table 4. Number of RBC transfusions preceding first and second antibody formation 
episodes. 
 
Patients RBC number 
Transfusion 
episodes 
Disease Number Frequency Median Range Median Range 
Before first antibody        
MDS 15 14.3 12 4-60 5 2-24 
MYPRO 6 13.6 19 2-57 7 1-22 
ALL 2 9.5 43 41-44 20 19-21 
NHL 14 8.0 18 3-40 7 1-19 
Hodgkin lymphoma 1 6.7 10  5  
Myeloma 5 5.8 6 2-11 2 1-6 
AML 5 5.7 17 10-28 8 6-10 
CLL 1 3.2 53  21  
Total 49 3.2-14.3 12 2-60 6 1-24 
Before second antibody       
MDS 4 26.7 14 12-23 6 4-10 
MYPRO 1 16.7 32  9  
NHL 1 7.1 35  9  
Total 6 7.1-26.7 19 12-35 8 4-10 
 
 
Antibodies and platelet transfusions 
Three-hundred four patients received a total of 4263 platelet transfusions 
(median, 10; range, 1-80). Seventeen patients in this group formed a total of 21 
RBC alloantibodies. The risk of alloimmunization to RBC antigens was lower for 
patients who received platelet transfusions (0.21%) than for patients who did not 
(0.97%). Moreover, RBC alloantibody formation in patients who received platelet 
transfusions during the course of their disease was slower than that in patients 
who did not need platelet transfusions (Fig. 4, p<0.0001). 
Thirty-three patients received a total of 244 D-incompatible platelet transfusions 
(median, 4; range, 1-31). Three patients, two with AML with maturation (AML-
M2) and one with T-cell prolymphocytic leukemia, developed anti-D after 7, 7, 
and 11 D-incompatible platelet transfusions, respectively. 
Anti-E was detected after two platelet transfusions in a D-positive male patient 
with MDS-RA who had screened negative for antibodies on two previous 
occasions and had not received RBC transfusions. 
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Fig 4. RBC antibody formation in patients with and without platelet transfusions.        
—, Patients who received platelet transfusions; - - -, patients who did not receive platelet transfusions. 
P<0.0001 
 
Individual antibodies 
Anti-E was found in 20 patients after a median of 13 units had been transfused, 
anti-c in 8 patients after the transfusion of 6 units, and anti-K in 15 patients after 
the transfusion of 17 units. Antibodies from the RH and KEL systems together 
represented 73 percent of antibodies detected. The most frequently encountered 
combination was anti-E and anti-c (7 times). Anti-E occurred 14 times in various 
combinations. 
 
Persistence of antibodies 
We found that, in 26 cases (51%), 33 RBC antibodies (46%) did not always 
persist after recognition and were not detected on at least two consecutive 
occasions over time. The frequency of nondetection for each antibody is shown in 
Table 5. 
Units transfused 
Percentage 
of patients 
with 
antibodies 
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Table 5. Antibody detectability 
Time in months to become undetectable Antibody 
specificity <1 1-3 3-6 6-12 >12 
D      
E  5  2 2 
e  1    
C  1 1   
c  1 1 2 2 
K 4 2 1 1  
Jka     1 
AA* 1 2   1 
* Aspecific alloantibody 
 
Case reports with lymphoplasmacytoid B-cell NHL 
A patient (IgG immunocytoma) who received a total of 338 units of blood formed 
anti-C after receiving 24 units and anti-K after 60 units; no more antibodies were 
formed during the transfusion of the next 278 units of blood. The most prolific 
antibody responder, a patient with essential thrombocythemia complicated with 
an inexplicable anemia, produced four antibodies (anti-E, anti-c, anti-K, and anti-
Lua) after receiving only 3 transfusions; no further antibodies were formed during 
the next 53 transfusions. 
One patient, who entered the study with anti-Lua, formed anti-D and anti-E after 
an accidental transfusion of 4 units of D-incompatible white cell-reduced RBCs. 
A patient with therapy-resistant CLL complicated with pure RBC aplasia and an 
autoimmune hemolytic anemia (aspecific autoantibodies) formed anti-E after 53 
white cell-reduced RBC transfusions. 
 
 
DISCUSSION 
In several studies, the question has arisen as to whether patients who are 
transfusion dependent over a longer period, such as those with sickle cell disease 
or thalassemia, should receive blood transfusions that are matched for antigens 
other than ABO and D, in an attempt to prevent the formation of RBC 
alloantibodies1,4,6,10-14,17,22,23. Because of intensified treatment and improved 
survival, patients with hematologic malignancies are also in need of transfusion 
support over a period of several years; therefore, the same question could apply 
for that patient population. 
This retrospective study was designed to discover the prevalence of RBC 
alloimmunization due to transfusion in 564 patients with hematologic and 
oncologic malignancies. We found 71 RBC antibodies in 51 patients, for an 
Alloimmunization in hemato-oncology 
 81 
overall alloimmunization rate of 9.0 percent. Patients received a median of 16 
units of RBCs. Fifty percent of the antibodies occurred after 13 transfusions, 
which indicates that the majority of antibodies are formed early during the course 
of transfusions. Several authors2,4,12,17,18 reported comparable results for the risk 
and the number of transfusions. There are also studies that found higher1,6,11,22 and 
lower16,19,30,33-35 immunization rates. Factors such as the patient population under 
study, the transfusion policy, the time and frequency of testing, the sensitivity of 
the test methods, and the technical expertise of the transfusion laboratory staff 
play an important role in the difference in results obtained. Ramsey and 
coworkers20,21, who studied the persistence of RBC alloantibodies, reported that 
clinically significant alloantibodies may become undetectable in time; although 
this was not investigated systematically in the present study, our findings were 
similar. On the one hand, this may lead to underestimation of the number of 
antibodies formed; on the other hand, the consequence may be that the patient 
receives incompatible RBCs and experiences a secondary immune response, 
which compromises the benefit of the transfusion. This implies that information 
on previously detected RBC alloantibodies should always be available. 
Age and gender were of no influence on the rate of antibody formation. Seyfried 
and Walewska9 found that the probability of alloimmunization is a quadratic 
function of age. We could not reproduce these findings. The overall 
immunization risk was 0.5 percent per RBC unit transfused. Redman et al.18, who 
also performed serial posttransfusion testing for alloantibodies, obtained a much 
higher (5.9%) alloimmunization risk per unit transfused for a population of 452 
immunocompetent patients who had undergone elective surgery. They found 59 
RBC antibodies after the transfusion of 1002 units; the proportion of immunized 
patients (10.4%) did not differ significantly from the values in our and other 
2,3,7,9,13,17 studies. When we consider the fact that many antibodies are formed 
early during the course of transfusions, one would expect that, after the initial 
increase, the immunization risk per unit would eventually decrease as the number 
of units transfused increased. In our study, the immunization risk was 0.45 
percent after 2 units had been transfused; it increased to 0.65 percent after the 
transfusion of 11 units and stabilized at 0.46 percent after about 50 units had been 
transfused (Fig. 1). 
Seventeen patients formed more than one antibody. The risk of additional 
antibody formation therefore increased 3.3 times. Thus, we agree with 
others2,7,12,18, who found increased risk factors between 2.7 and 4.1. 
The most frequently encountered combination was anti-E and anti-c: 35 percent 
of the patients with anti-E also developed anti-c. Shirey et al.41 found that the 
overall rate of immunization against c in R1R1 patients with anti-E was 37 
percent. 
For 16 of 71 antibodies, the specificity could not be identified; this is in 
agreement with the study of  Redman et al.18, who found 9 antibodies of 
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unrecognized specificity in a total of 51 positive screening tests. In four cases, 
aspecific antibodies were found in combination with specific antibodies. 
We had one patient with CLL who presented with anti-E and aspecific antibodies 
after 53 transfusions. While several studies2,4,9,12 indicated that lymphocytic 
leukemia may be characterized by a lack of immunologic response, we were not 
able to demonstrate a significant difference between CLL patients and patients 
from other disease groups, as far as the risk of antibody formation is concerned. 
As in other studies12,13,18, antibodies against RH system antigens, especially -E 
and -c, and Kell system antibodies made up most of the antibodies found. On the 
basis of genetic frequency, 402 patients in our study were at risk of forming anti-
E, 105 patients anti-c, and 510 patients anti-K. When we consider the relative 
potency of the antigens - that is, the actual frequency with which alloantibodies 
are encountered - compared with the calculated frequency of the opportunity for 
immunization (E, 1.7%; c, 2.0%; and K, 5.0%)42 we can expect a median of 16 
transfusions to find 28 patients with anti-E, 23 patients with anti-c, and 35 
patients with anti-K. Anti-E was observed in 20 patients, anti-c in 8 patients, and 
anti-K in 15 patients, which suggests a relative potency of 1.2 percent, 0.7 
percent, and 2.1 percent, respectively. For anti-c and anti-K, these relative 
potencies are significantly lower (p = 0.007 and p = 0.004, respectively) than 
those found by Giblett42. 
Four patients formed RBC antibodies after transfusion of platelets: three formed 
anti-D and one formed anti-E once. Patients who received D-incompatible 
platelet transfusions were not treated with anti-D immunoglobulin. Because 
platelets do not bear RH system antigens52, immunization is enhanced through 
RBC contamination of the platelet components. Woodrow and Donahue53 found 
that as little as 0.1 mL of D-positive blood can immunize a D-negative recipient. 
In our study, only three patients formed anti-D after 244 incompatible platelet 
transfusions, which indicates that, for patients treated for hematologic and 
oncologic malignancies, the capacity to form anti-D after incompatible platelet 
transfusions is very low. Although the anti-E could have occurred naturally,37 that 
seems unlikely, because it was not detected on two previous occasions. 
Patients who received intensive chemotherapy and therefore required platelet 
transfusions produced antibodies against RBC antigens at a much lower rate than 
patients who did not need platelet support (Fig. 4). 
During the period under study, no (delayed) hemolytic transfusion reactions were 
reported. According to others16,25,28,43,44, we should have encountered three such 
reactions (range, 0.4-8.1). This difference might be explained by low awareness 
of this possibility, the fact that many reactions are clinically asymptomatic, or the 
possibility that the reaction was masked by the severity of the underlying disease. 
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Several authors found that patients with hematologic malignancies and those who 
undergo intensive chemotherapy have a low capacity for forming antibodies 
against foreign antigens9,19,24,26,27,30,43 and a lower frequency of transfusion 
reactions25,28 (most probably due to their altered immune status), which results in 
a tolerance for or an unresponsiveness to blood group antigens. Other authors45-49 
discovered that transfusion itself induces immunosuppression, although the 
mechanisms involved are not yet completely understood50,51. The low rate of 
response to foreign antigens seen in our study could be due to a combination of 
all three factors mentioned above. 
Except for the one patient with anti-e in combination with anti-C, we never had 
any difficulty finding compatible blood for our patients with antibodies. In the 
majority of cases (85%), the theoretical probability of finding compatible blood 
exceeded 20 percent. 
In patients with a hematologic and an oncologic malignancy, RBC antibody 
formation is comparable to that for other diseases requiring multiple transfusions. 
Patients with a hematologic malignancy who receive intensive treatment form 
RBC antibodies at a lower rate than those who are not treated intensively. 
In this cohort of patients, we encountered a low incidence of severe delayed 
hemolytic transfusion reactions and no real problems in finding compatible 
donors. Therefore, “prophylactic” matching for antigens other than ABO and D, 
as recommended by several authors, seems unnecessary in this clinical setting. In 
addition, extensive matching leads to increased costs at a time when we should 
seek ways to reduce operational costs while maintaining a high standard of 
patient care. 
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SUMMARY 
BACKGROUND: Red blood cell alloimmunization is common in transfused 
patients. Most studies report on the rate of alloimmunization in chronically 
transfused patients, which can be as high as 60%. Less is known on the incidence 
of clinically relevant antibodies in accidentally transfused patients. Because the 
probability of repeat transfusion increases with longer life expectancy, it was 
wondered to which extend non-chronically transfused alloimmunized patients are 
prone to form additional antibodies after repeat transfusion events 
STUDY DESIGN AND METHODS: A 20-year retrospective multicenter study 
analysing additional alloantibody formation, against the RH, KEL, FY, JK and 
MNS blood group systems. 
RESULTS: After additional transfusions, 21.4 percent of 653 patients produced 
additional antibodies, resulting in 157 new antibody specificities. At the end of 
the study 33.4 percent of patients had multiple antibodies. Eighty of 140 patients 
(57%) who formed additional antibodies did so after 1 transfusion episode of a 
median of 2 units RBCs. Based on the antigen profile of 316 patients, 83 percent 
of antibodies could have been prevented by extended matching for the C, E, c, K, 
Fya and Jka antigens. Considering the current available donors in our region, 1-
10% potential donors would be available for 39 percent of patients and greater 
than 10 percent of  potential donors for  61 percent of patients. 
CONCLUSION: It has been shown that nonhemato-oncologic alloimmunized 
patients are high antibody responders, with a more than 20 times increased risk to 
form antibodies compared to first-time alloimmunization risk. If extended 
matching for C, c, E, K, Fya and Jka antigens in the future is considered, this 
group should be taken into account. 
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INTRODUCTION 
Alloimmunization is common in transfused patients. The risk of immunization 
increases with the number of transfusion events, although in most polytransfused 
patients antibodies are formed early in the course of treatment1,2. Most studies 
have been performed in chronically transfused patients, for example, 
hemoglobinopathies3-10, hematologic malignancies1,2,11-14, organ transplant 
recipients15-17 and patients with renal failure11,18,19. Alloimmunization in these 
groups has a reported incidence up to 60 percent, with an up to fourfold increased 
risk of multiple antibodies compared to the risk of single antibodies1,2,15,21. In 
other transfused populations alloimmunization was described between less than 1 
and 10 percent, depending on the study design (e.g. retrospective resp. 
prospective)20, 21,30. 
Alloimmunization may cause several problems ranging from inconvenience due 
to delay in obtaining compatible blood to (delayed) hemolytic transfusion 
reactions. The development of alloantibodies was recently found to be associated 
with the development of RBC autoantibodies. Such autoantibodies can lead to 
shortened life span of the recipients own RBCs and may cause clinical 
hemolysis7, 22-25. 
Because of  longer life expectancy of the population and an increased probability 
of repeat surgery or diseases requiring blood transfusions, the clinical relevance 
of red blood cell antibodies in non-chronically transfused patients increases.  
We wondered to which extend non-chronically transfused patients who became 
alloimmunized are prone to form additional antibodies after one or more repeat 
transfusion events. To address this question, we retrospectively studied 
alloantibody formation over a 20-year period in a large non-hematological 
transfused alloimmunized patient cohort with special emphasis on additional 
antibody-forming episodes.  
 
 
MATERIALS AND METHODS 
We examined retrospectively all the records on warm-reacting RBC antibodies in 
the transfusion laboratory computer databases of HAGA Hospital, location 
Leyenburg (a 600-bed multidisciplinary teaching hospital in the Hague, the 
Netherlands) and Leiden University Medical Centre, (a 900 bed top-clinical care 
hospital, Leiden, the Netherlands) during a 20 year period, from 1983 through 
2002. We included only patients with antibodies against the RH, KEL, FY, JK 
and MNS blood group systems who experienced at least one subsequent 
transfusion event after alloimmunization. We excluded patients with a hemato-
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oncologic disease, patients with warm reacting autoantibodies,  patients with 
antibodies against low and high-frequency antigens and patients receiving 
preventive extended matched (e.g. c, E and K) RBC transfusions. Information 
collected was patient’s age; sex; RBC typing for C, E, c, e, K, Fya, Fyb, Jka, Jkb, 
M and S antigens; dates and results of RBC alloantibody screenings and 
transfusion history. The results of antibody investigation were valid for 72 hours 
(a transfusion episode). Detailed information on pregnancies, transfusions, and 
antibodies detected in other hospitals was not available. 
Primary antibodies were defined as the first time that antibodies were identified in 
patients in each hospital during the study period, and additional antibodies were 
defined as new antibody specificities detected after subsequent transfusions. After 
an antibody was identified, patients received RBC transfusions that were negative 
for the antigen corresponding to the implicated alloantibody, after complete 
cross-matching, including an indirect antiglobulin test. Preventive antigen-
matching (i.e. c, E and K) was not routinely performed in alloimmunized patients.  
 
Statistical analysis 
Statistical software packages (Excel 5.0, Microsoft , Redmond, WA; SPSS 11.0, 
SPSS 11.0, SPSS Inc., Chicago, IL) were used for data management and analysis 
respectively. The chi-square or Fisher exact test was used for comparisons of 
proportions in two groups. Student’s t test, Welch test, or Bonferroni test was 
used when (multiple) comparisons between groups were performed. After 
univariate analysis, multivariate analysis was used to determine factors that were 
independently associated with additional antibody production. 
The Kaplan-Meier product limit estimator was used to calculate the rate of 
additional antibody formation.   
Groups were assumed to differ significantly when the probability level was less 
than 0.05.   
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RESULTS 
Patient characteristics 
During the study period, 1043 patients belonging to the selected patients’ 
categories presented with irregular antibodies. Of these 653 patients returned for a 
subsequent transfusion request.  
Because statistical analysis revealed no differences in additional antibody 
formation regarding sex (female-to-male ratio 2.1 [1.8 if anti-D was excluded]; 
except for anti-D frequency at inclusion, which was higher in female compared to 
male patients, p<0.001) and hospitals, with respect to all tested parameters, data 
was not stratified for these factors during analyses. Patient age (median, 63 years; 
range, 1-96) was not associated with additional antibody formation.  
The median study period per patient, from inclusion to date of last antibody 
screening, was 22 months (range, 2 days to 20 years). Additional antibody 
screening tests after first antibodies were performed a median of three times 
(range, 1-37 times).  
 
Table 1. Transfusion characteristics in 653 alloimmunized patients  
 Patients presenting 
with alloantibodies 
Patients who developed 
new antibodies 
Number of patients 653 140 
Mean number of units transfused  
(total, median, range) 
9.0 
(5850, 5, 1-120) 
5.9 
(809, 4, 1-41) 
Mean number of transfusion episodes 
(total, median, range) 
2.8 
(1894, 2, 1-35) 
1.9 
(265, 1, 1-11) 
Number of transfusion episodes 
1 
2 
3 
4-6 
>6 
 
277 
110 
83 
116 
67 
 
80 
31 
17 
9 
3 
Mean number of transfusion months 
(median, range) 
10.3 
(0.3, 0.03-175) 
7.2 
(0.03, 0.03-118) 
 
Transfusion characteristics 
The 653 patients received a median of 5 units of RBC in a median of 2 
transfusion episodes over a period of a median of 10 months (transfusion 
months). Almost 60 percent of patients experienced less than three transfusion 
episodes (table 1). 
Eighty of the 140 patients (57%) who formed additional antibodies did so after 
one additional transfusion episode of a median of 2 units of RBC (range, 1-10 
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units), 31 patients (22%) developed additional antibodies after 2 additional 
transfusion episodes of a median of 5 units (range, 3-14 units), 17 patients (12%) 
did so after 3 episodes of a median 8 units (range, 6-18 units) and 12 patients 
(9%) after 4-11 transfusion episodes of a median of 19 units (range, 7-41 units; 
Table 1 and Fig. 1, Kaplan-Meier estimate).  
Multivariate analysis (variables; numbers of: RBC units transfused, transfusion 
episodes, transfusion months, and screening tests) revealed that additional 
antibody formation was independently associated with the number of transfusion 
episodes (inversely, p<0.001), indicating additional alloimmunization early 
during transfusion therapy, and the number of antibody investigations (p<0.001), 
reflecting longer patient follow-up.  
 
Fig. 1. Kaplan Meier estimate of the rate of additional antibody formation after transfusion 
in alloimmunized patients 
  
Red blood cell antibodies 
At presentation, 653 patients had antibodies against 772 RBC antigens, 555 
patients had an antibody against a single RBC antigen and 98 patients (15.0%) 
had multiple antibodies. After additional transfusion episodes, 140 patients 
(21.4%) developed additional antibodies, detected after a median interval of 12.5 
months (range, 3 days to 240 months), resulting in 157 new antibody specificities. 
Of these 140 patients, 79 patients received additional transfusions and 10 patients 
(12.7%) experienced a third antibody forming episode (140/653 vs 10/79, 
p=0.076) making 11 additional antibody specificities. The odds ratio (OR) for 
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additional antibody formation compared to primary antibody formation, which in 
a previous study was 0.9%31, is 29.1 (95% confidence interval [CI], 22.7-37.2; 
p<0.0001). 
 
Table 2. Number and antibody specificity in 653 alloimmunized patients  
Primary Antibodies Additional Antibodies Antibody 
Specificity Number Percent of total Number Percent of total
p Value* 
D 97 12.6 2 1.2 <0.0001 
C 51 6.6 16 9.5 0.19 
E 228 29.5 34 20.2 0.017 
c 38 4.9 27 16.1 <0.0001 
e 8 1.0 1 0.6 1.0 
K 178 23.1 39 23.2 1.0 
Fya 67 8.7 14 8.3 1.0 
Fyb 2 0.3 2 1.2 0.15 
Jka 46 6.0 12 7.1 0.6 
Jkb 16 2.1 7 4.2 0.16 
M 23 3.0 1 0.6 0.10 
S 17 2.2 11 6.5 0.009 
s 1 0.1 2 1.1 0.084 
Total 772  168   
* p Value primary antibody specificity versus additional antibody specificity as fraction of total first 
antibodies and additional antibodies 
 
The antibody specificity between first and additional antibodies differed with 
regard to anti-E, which was formed more often during the first antibody forming 
episode whereas anti-c and anti-S were more often formed after subsequent 
transfusion episodes (Table 2). The number and specificity of antibodies at 
presentation were not correlated with the incidence of additional antibody 
formation. D-negative patients with non-D antibodies formed additional non-RH 
antibodies as equally often as D-negative patients with anti-D. 
The red blood cell antigen profile was known in 316 patients (47.8%). In these 
patients, the number of antigens to which antibodies could be formed was not 
associated with the incidence of additional antibody formation or with the number 
of additional antibodies formed.  
We calculated the additional immunization risk per antigen per unit transfused in 
patients who lacked the corresponding antigen, based on the number of a specific 
additional antibody formed divided by the estimated number of antigen positive 
transfusions. The results showed that the immunization risk varied considerably 
for specific antigens (Table 3).  
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At the end of the study 33.8 percent of 653 patients had multiple antibodies. The 
most frequently encountered antibody combinations, with or without other 
antibody specificities, were DC (n=28), cE (n=22), EK (n=17) and KFya (n=11), 
representing 57 percent of all antibody combinations. 
 
Laboratory test problems associated with multiple alloantibodies 
A patient with multiple alloantibodies places the transfusion laboratory staff at 
great problems identifying the specificity of the individual antibodies and 
excluding the presence of other clinically significant antibodies. At presentation 
we found 31 different antibody combinations in 98 patients; at the end of follow-
up 64 different antibody combinations were present in 221 patients. With 
standard antibody specificity techniques (e.g., low-ionic-strenght saline enhanced 
and enzyme-test), a routine 3-cell screening test panel and a 11-cell identification 
test panel (DiaMed AG, Murten, Switserland), we calculated the number of 
antibodies that could not be excluded, based on the absence of a negative reaction 
with at least one test RBC with homozygous expression for the corresponding 
antigen. At presentation, identification of the alloantibodies and exclusion of 
possibly underlying antibodies was possible in 453 patients, but for 200 patients, 
one to six clinically relevant antibodies could not be excluded. At the end of the 
study, for 240 patients one to 8 antibodies could not be excluded.  
 
Preventive extensive antigen matching in alloimmunized patients 
For 316 patients the C, E, c, e, K, Fya, Fyb, Jka, Jkb, M and S phenotype was 
known. We performed the theoretical exercise for these patients regarding 
extended matching. To prevent additional antibodies (except for anti-e and anti-
M) for 95 percent of patients less than 1 percent (minimum, 0.22%) of potential 
Caucasian donors per RBC unit were to be expected for 15 percent of patients, 1 
to 10 percent of donors are expected to be compatible for 64 percent of patients 
and more than 10 percent compatible donors for 21 percent of patients. If 
extended antigen matching was limited to the C, E, c, K, Fya and Jka antigens, 
preventing 83 percent of additional antibodies, 1 to 10 percent of potential donors 
would be available for 39 percent of patients and more than 10 percent of donors 
for 61 percent of patients.    
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Table 3. Additional immunization risk per antigen per antigen-positive unit transfused in 
316 RBC antigen-phenotyped alloimmunized patients 
  Antigen 
Number of 
patients* 
Number of 
additional 
antibodies 
Number of 
RBC units 
transfused 
Number of 
antigen- positive 
RBC units † 
Immunization 
risk (%) ‡ 
K 211 19 2340 211 9.0 
C 80 7 762 192 3.6 
E 182 17 1952 566 3.0 
c 61 12 646 503 2.4 
e 4 1 55 53 1.9 
Jka 64 10 763 587 1.7 
Fya 89 10 1094 722 1.4 
Jkb 56 5 575 420 1.2 
S 156 6 1829 1006 0.6 
Fyb 56 2 710 589 0.3 
M 70 1 817 637 0.2 
* Number of patients with a specific RBC antigen to which an additional antibody could be formed.  
† The number of antigen-positive RBC units was calculated as total units transfused in patients with 
absent antigen multiplied by the change on specific mismatched RBC antigens. The chance of 
mismatched antigens was based on the antigen frequency in general Caucasian population (i.e., c = 
0.78, e = 0.96, K = 0.09, Fya = 0.66, Fyb = 0.83, Jka = 0.77, Jkb = 0.73, M = 0.78, S = 0.55; for C and 
E, the patient’s Rh(D) factor was taken into account DposCpos = 0.80, DnegCpos = 0.05, DposEpos = 0.33, 
DnegEpos = 0.06) 
‡ Immunization risk: number of additional antibodies per number of corresponding antigen positive 
units transfused. 
 
DISCUSSION 
 
In this 20-year retrospective study in two hospitals, we investigated the formation 
of additional RBC alloimmunization in 653 patients who initially presented with 
RBC antibodies and who had returned for a subsequent transfusion event. We 
found that 21.4 percent of patients formed additional antibodies after repeat 
transfusion episodes and 12.7 percent of these patients experienced a third 
antibody forming episode. Most additional antibodies were formed after one 
additional transfusion episode of a median of 2 units of RBCs. At the end of the 
study 33.8 percent of patients had multiple antibodies.   
In agreement with previous studies regarding primary antibody formation in 
multitransfused patients1,2, most additional antibodies in alloimmunized patients 
are also formed after a few additional transfusions. Fifteen patients experienced 
more than 11 transfusion episodes and none formed additional antibodies (Fig. 1).  
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Most studies report on the presence of multiple RBC antibodies in chronically 
transfused patients, with an up to fourfold increased risk of multiple antibodies 
compared to the general risk of antibody formation1,2,4,9,15,26-28.  
The calculations used are based on the formula: 
 
Number of patients with multiple antibodies / Number of patients with a single antibody 
Number of patients with antibodies / Number of transfused patients 
 
The results from these calculations do not give any indications regarding the risk 
of additional antibody forming episodes in alloimmunized patients after 
subsequent transfusion episodes. 
From a number of informative studies14,20,28,29, some including polytransfused 
patient groups, we could calculate that the incidence of additional antibodies after 
transfusion in alloimmunized patients is between 9 and 22 percent. Only few 
(7-14) alloimmunized patients in these studies, however, were retransfused.  
In retrospective studies, primary antibody formation in non-chronically transfused 
patients has a reported incidence of approximately 1 percent30. We previously 
analysed RBC alloimmunization in transfused patients during a 5-year period and 
found 0.9 percent alloimmunized patients, corresponding with an immunization 
risk of 0.2 percent per unit transfused31. The current study shows additional RBC 
immunization in 140 of 653 alloimmunized patients after subsequent transfusion 
(OR, 29.1; 95% CI, 22.7-37.2; p<0.0001). 
The formation of a first antibody apparently identifies high responders against 
subsequent alloantigenic challenges. The fact that the chance for subsequent 
antibody- forming episodes is so much higher than in hemato-oncologic 
patients1,2 may be explained by immunocompromised conditions in these patients.  
To our knowledge this is the first study calculating RBC alloimmunization risks 
for specific antigens in a RBC antigen-phenotyped population. Although factors 
influencing antibody specificity are not taken into account, such as time interval 
between transfusion and antibody screening, the results, in terms of antigen 
ranking, are in agreement with a previous study calculating antigenicity for the 
most important antigens31. Because antibody investigations in the present study 
were performed for a transfusion indication, the immunization risk per antigen 
may be even higher, considering that antibodies may have disappeared33,34. 
Although alloantibodies are considered not harmful, they place the patients at 
increased risk for complications such as transfusion delay, (delayed) hemolytic or 
serologic transfusion reactions, and even autoimmunization, compromising their 
clinical care. The last complication has recently been shown not to be restricted to 
chronically transfused patients25. 
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Extended antigen matching (e.g. c, E and K), preventing the formation of the 
majority of RBC antibodies in chronically transfused patients, has been advocated 
for selected patients populations. Some reports applying this policy showed a 
significant drop in alloimmunization rate and delayed hemolytic transfusion 
reactions7,34. Discussion remains, however, regarding to which patient 
populations this should be applied7,35.  
Such selection is of importance considering the high costs involved and donor 
feasibility. The costs are primarily based on extended donor and patient antigen 
typing. No data are available addressing costs involved with complex laboratory 
tests to identify antibody specificities in case of multiple antibodies and delayed 
and prolonged medical care, associated with transfusion delay, hemolytic 
transfusion reactions, additional transfusions, and autoimmunization.  
Donor genotyping for the most common clinically relevant blood group antigens, 
by means of automated DNA techniques, will soon be available. This will, most 
likely, reduce costs as well as workload involved in donor and patient antigen 
typing, compared to current phenotyping techniques and increase the opportunity 
for the use of extended phenotypically compatible transfusions.  
We calculated that donor feasibility could be problematic (<1% donors available) 
for the Blood bank in 15 percent of patients in case of extended matching 
included Jkb and S antigens. If antigen matching is restricted to antigens with the 
highest immunization risk (i.e. C, E, c, K, Fya and Jka), however, finding 
compatible donors should be no problem in the Netherlands with yearly 6.2x105 
blood donations from 4.5x105 donors.  
In summary, we showed that nonhematooncological patients who present with an 
alloantibody have a high probability of forming additional antibodies upon a 
subsequent transfusion indication. If extended matching for C, E, c, K, Fya and 
Jka antigens in the future is considered, this patient group should be taken into 
account.  
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ABSTRACT 
OBJECTIVE: Intra-uterine transfusion (IUT) is a life saving therapy for the 
severely anemic fetus with hemolytic disease. However, maternal additional 
antibody formation is a complication of the procedure. In this study, we 
determined antibody formation after introduction of preventive D-, C-, c-, E- and 
e- and K-antigen matching of IUT donors.  
STUDY DESIGN: A retrospective folluw-up study 
RESULTS: During an 11-year period, 686 RH and K matched IUTs were 
performed in 233 pregnancies and in 95% (652/686) post-transfusion antibody 
testing was performed after a median interval of 21 days. Twenty-five percent 
(53/212) of the women formed 64 new antibodies and, compared to our previous 
study, this incidence was not decreased by the use of RH and K matched donors. 
After delivery 72% (153/212) of the women had multiple RBC antibodies. 
Additional antibodies were in 48% (31/64) directed against RH and K antigens, 
induced by the fetus or as natural antibodies. In 52% (33/64) the antibodies were 
directed against non-RH and K antigens and in 65% (11/17) of eligible cases the 
IUT donor and not the fetus expressed the corresponding antigen(s). 
CONCLUSION: Despite RH and K matching, women treated with IUTs still 
show strikingly broad red cell alloimmunization. More extensive IUT donor red 
cell matching including FY, JK and S antigens to reduce the formation of new red 
cell antibodies should be explored.  
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INTRODUCTION 
In hemolytic disease of the fetus and newborn (HDFN), maternal IgG antibodies 
against fetal red cell blood antigens cross the placental barrier causing hemolysis, 
with the risk for severe fetal anemia, hydrops fetalis and intrauterine death. In 
severe HDFN, intra-uterine transfusions (IUTs) are administered to the fetus to 
prevent or reverse hydrops fetalis and to prevent fetal death1. IUT suppresses the 
fetal (compensatory) erythropoiesis, and after one or more IUTs most of the fetal 
blood is of donor origin2.  
Despite D immunization prevention programs, anti-D is still the major cause of 
severe HDFN3,4. Severe HDFN due to other blood group incompatibilities is less 
common and usually due to antibodies against c and K, or rarely to E, Kidd, 
Duffy, MS or private antigens2. Apart from K-immunization clinical presentation 
and management is similar to HDFN caused by anti-D5-10. Anti-K immunization 
may cause a different clinical picture and severe disease early in pregnancy due to 
the destruction of K-positive erythrocyte progenitor cells8,11-13.  
Intra-uterine transfusion with red cells lacking the offending antigen is a life-
saving procedure, however the treatment is not without risk. Fetal complications 
occur in 1 to 3% of the procedures3,14. Additional maternal red cell antibodies are 
often formed and can complicate subsequent pregnancies and future 
transfusions15-19. 
We previously analysed additional red cell immunization after IUTs in the period 
1987 through 199217. Since 1993, as for all high risk transfusion recipients, IUT 
donors were matched for the D-, C-, c-, E-, and e- and K-antigens.  
Here, we present the follow-up regarding formation of IUT induced irregular 
antibodies from September 1994 through September 2005. This study was 
undertaken to evaluate the aforementioned transfusion policy. 
 
 
METHODS 
Patients 
From the computer database of the Leiden Medical University Center (LUMC), 
we retrospectively analyzed the records of all women who had received IUTs, 
during an 11-year period since September 1994. The LUMC is the Dutch national 
reference center for intrauterine transfusion treatment.   
Maternal data collected from the computer database included RBC antigen 
profiles, RBC antibodies, antibody titers, previous transfusion history, ‘pregnancy 
number’, date and number of each IUT and the route of IUT administration 
(trans- vs, paraplacental). We excluded from the analysis women who were not 
available for subsequent antibody testing after receiving only one IUT and 
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women who could not form additional antibodies because their RBCs possessed 
the corresponding antigens.  
When available, the RBC antigen profiles of the fathers and IUT-donors were 
collected. 
Fetal data collected were limited RBC antigen profile, sex, gestational age at 
initial IUT, and presence of hydrops. 
 
Intra-uterine transfusions 
Ultrasound-guided fetal blood sampling, and in case of anemia followed by IUT, 
was performed as described previously3, whenever hydrops fetalis was present or 
fetal anemia was suspected on the basis of MCA Doppler (peak systolic velocity 
in the middle cerebral artery) and/or ultrasonographic findings (fetal liver length 
and spleen perimeter)20-22.  
Intra-uterine transfusions were prepared from fresh (<3 days old) leucodepleted 
(filtered pre-storage), irradiated (25 Gy) and CMV sero-negative RBCs. The 
supernatant was removed and adjusted to a hematocrit of 80% with 0.9% saline. 
The donors were D, C, c, E and e compatible with the mother, K-negative, and 
antigen-negative with maternal antibodies, including a complete crossmatch with 
maternal serum in the IAGT. 
 
Red cell serology 
Maternal, paternal and IUT donor RH, KEL, FY, JK and MSs antigen profiles 
were determined. 
Fetal RH, KEL and JK antigens were determined form a cord blood specimen 
prior to the first transfusion. Duffy and MSs antigens were not determined, due to 
the very limited volume of fetal cells and the necessity to elute the bound IgG 
antibodies before testing for these antigens using an indirect antiglobulin (IAGT) 
test. In case where both maternal and paternal antigens were known, the presence 
of FY and MSs antigens on fetal RBC were deduced. 
Maternal blood samples were tested against a screening panel one day prior to 
each (subsequent) IUT. In maternal sera we evaluated the development of 
additional clinically significant RBC antibodies e.g. anti-D, -C, -c, -E, -e, -K, -
Fya, -Fyb, -Jka, -Jkb, -M, -S and -s. 
 
 
Statistics 
Statitical software packages (Excel 5.0, Microsoft, Redmont CA; SPSS 11.0, 
SPSS inc. Chicago, Illinois) were used for data management and analysis. 
Students T-test and paired T-test (Wilcoxon signed rank test) were used when 
comparisons between groups were performed. The chi-square or Fisher exact test 
were used for comparisons of proportions in two groups. We evaluated risk 
factors for additional antibody formation by univariate analysis. Significant 
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factors in the univariate analysis as well as factors reported in the literature as risk 
factors were applied to a multivariate binary logistic regression analysis to 
determine the variables independently associated with additional antibody 
formation. Included in the analysis were: transplacental access, total number of 
IUTs administered, D immunization, number of antibodies at presentation, 
number of additional antibodies possible, gestational age at first IUT, previous 
transfusion history, presence of hydrops, maternal age, maternal antibody titer at 
presentation, fetal gender, and pregnancy number. 
Groups were assumed to differ significantly when the probability level was less 
than 0.05. 
 
 
RESULTS 
Patient characteristics 
From September 1994 through September 2005, 241 women were treated with 
IUTs. Excluded were, 12 women receiving only one IUT and not available for 
subsequent antibody testing and 17 women not at risk for additional RBC 
immunization because their RBCs possessed the corresponding antigens. 
Available for analysis were 212 women (median age, 33 years; range, 19-44 
years) who gave birth to 237 children (male to female ratio, 1.1) after 233 
pregnancies. There were 4 twin pregnancies and 17 women had successive (2-4) 
pregnancies. Twenty-nine women, involving 34 pregnancies, had a history of 
blood tranfusions. 
Eight women (3.8%) underwent IUT therapy during their first pregnancy. The 
antibodies involved were anti-D (n=3), anti-K (n-3) and anti-e and anti-c one 
each. More than 80% of IUT cases affected the second to fourth pregnancy. 
The 212 women possessed 412 antibodies at presentation (Table I). There was no 
association between pregnancy number and the number of antibodies at 
presentation. Multiple antibodies, mainly combinations of anti-CD, were present 
in 139 pregnancies (59%). 
 
Intra-uterine transfusions 
In the 233 pregnancies 686 IUTs (median 3; range 1-8 IUTs) were performed. 
First IUTs were performed at a median gestational age of 28 weeks (range, 17.6-
35.6 weeks). The median interval between first and second IUT was 15 days 
(range, 6-28 days) and the median interval between subsequent transfusions 28 
days (range, 5-38 days). 
In 135 pregnancies (58%) at least one IUT was administered through 
transplacental access. A transplacental route of IUT administration was associated 
with an increase in median D-antibody titer between first and second IUT (two-
Chapter7 
 
106
thousand respectively four-thousand; p<0.001, Wilcoxon signed rank test), while 
it did not rise when the paraplacental route was employed (p=0.48).  
 
Table I. Number of antibody specificities in 233 pregnancies with HDFN before the first, 
during and after the last IUT. 
Antibodies detectable 
before the first IUT 
Additional antibodies    
during IUT treatment1 
Antibody 
specificity Causal 
antibody of 
HDFN 
Additional 
antibodies 
Historical 
antibodies not 
detectable 
before the first 
IUT 
After 
IUT 1
After 
IUT 2
After  
IUT 3-6 
Antibodies 
detectable 
after IUTs 
D 191 0 1 (1)   192 
C 0 102 13 13 (2) 4 (2) 4 127 
E 1 21 6 6 (1) (1) 2 (1) 33 
c 8 0 0 1   9 
e 1 0 0    1 
K 32 4 2 1   37 
Fya 0 3 0 4  1 8 
Fyb 0 1 0 2 1  4 
Jka 0 9 3 9 3  21 
Jkb 0 0 0 3 2 1 6 
M 0 1 1 1 (1) 1 4 
S 0 8 2 1 (1) 1 2 (1) 14 
s 0 2 0 1   3 
Total 233 151 28 42 (5) 11 (4) 11 (2) 459 
1 Number of non-detectable historical antibodies that re-appeared during IUT treatment between 
brackets  
 
Additional antibodies during IUT treatment 
After 652 (95%) of 686 IUTs a serologic screening was performed. In the 
remaining 34 cases antibody follow-up was not performed after the last IUT. 
The median interval between two consecutive antibody tests was 20 days (range, 
2-49 days). The median interval was 15 days after the first IUT, 28 days after 
subsequent IUTs and 18 days after the last IUT.  
Twenty-eight women were known to have irregular antibodies in the past, but 
these were not detectable at presentation for the first IUT (historical antibodies). 
During IUT therapy, 11 of these 28 historical antibodies re-appeared. These were 
not classified as new antibodies (Table I). In 4 of 8 eligible cases the 
corresponding antigens were absent on the fetal RBCs. With regard to the 17 non-
emerged antibodies, the corresponding antigens were present on fetal RBCs in 7 
of 15 eligible cases. 
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Table II. Uni- and multivariate analysis of variables associated with the chance on 
additional antibody formation after IUTs 
Variables included in the analysis 
P-value 
univariate analysis 
P-value 
multivariate analysis 
Transplacental access <0.001 <0.001 
Total number of IUTs administered 0.003 0.015 
D immunization 0.051 0.0271 
Number of antibodies at presentation 0.065 0.34 
Number of additional antibodies possible2 0.35 0.036 
Gestational age at first IUT 0.30 0.38 
Previous transfusion history 0.39 0.60 
Presence of hydrops 0.38 0.34 
Maternal age 0.46 0.78 
Maternal antibody titer at presentation 0.67 0.97 
Fetal gender 0.76 0.22 
Pregnancy number 0.99 0.76 
1 Assuming that the formation of additional anti-C (n-21) was predominantly associated with D 
immunization as an independent variable for additional antibody formation, the analysis was also 
performed after the exclusion of C-antigen and C-antibodies. The results for D changed marginal, 
p=0.034.  
2 The number of additional antibodies possible for each pregnancy was calculated from the absence of 
corresponding RBC bloodgroup antigens on maternal RBCs. 
 
Fifty-three women (25%) formed new additional antibodies (Table I) during 54 
pregnancies. Five women formed additional antibodies on 2 separate occassions 
during IUT therapy. The mean immunization rate, expressed as new antibodies 
per IUT, was 18% after the first IUT and 5.5±1.2% after subsequent IUTs. 
The percentage of women with multiple antibodies increased from 59% at 
admission to 72% after delivery and the number of women with non-Rh/K 
antibodies increased from 25 (12%) to 52 (25%). 
Univariate analysis revealed that the chance of additional antibody formation 
after IUT was significantly associated with transplacental access (p<0.001) and 
the total number of IUTs (p<0.003), but not with other variables. When a 
multivariate analysis was employed, transplacental access (OR, 6.3; 95% CI, 2.5-
15.7), D immunization (OR, 2.8; 95% CI, 1.1-6.8), number of additional 
antibodies possible (OR 1.5; 95% CI, 1.03-2.25) and the total number of IUTs 
(OR 1.4; 95% CI, 1.07-1.87) were independently associated with additional 
antibody production (Table II). 
 
Etiology of new additional antibodies 
The mothers’ extended RBC antigen profile was known in all cases, the fathers’ 
profile in 36% of cases. The fetal RH-antigens were determined in 227 (98%), 
K-antigen in 218 (94%) and JK-antigens in 200 (86%) cases. RH and K antigens 
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of the IUT donors were known in all units and in 61% of units for FY, 63% for 
JK and in 43% for MSs bloodgroups. 
RH and K antibodies: In 95 pregnancies additional maternal antibodies could 
have been formed against 97 RH and 7 K incompatible antigens of the fetus. This 
actually occurred in 29 pregnancies (31%), with a total of 31 antibodies. In 27 of 
the 31 cases with additional RH and K system antibodies, the fetus possessed the 
antigen, but in 4 pregnancies, antibodies were formed although both the IUT 
donors and the children did not carry the corresponding antigens (Table III). 
Alternatively, 5 D-negative and 7 K-negative women did not form additional 
antibodies against the corresponding antigens, despite the antigens being present 
on the fetal cells. Two of these women responded with the formation of additional 
antibodies against other RBC antigens. 
 
Table III. Etiology of additional maternal antibodies after IUT 
Antibody 
specificity 
Antigen 
presence on 
donor RBCs 
Antigen 
presence on 
fetal RBCs 
Number of 
cases 
Causative RBCs 
C neg pos 21 Fetal 
E neg pos 5 Fetal 
 neg neg 3 None implicated 
c neg pos 1 Fetal 
K neg neg 1 None implicated 
Fya pos neg 2 Donor 
 pos n.d. 1 Donor possible 
 neg n.d. 1 Fetus probable 
 n.d. n.d. 1 Inconclusive 
Fyb pos neg 2 Donor 
 n.d. n.d. 1 Inconclusive 
Jka pos neg 4 Donor 
 pos pos 4 Both possible 
 pos n.d. 1 Donor possible 
 n.d. pos 3 Fetus possible 
Jkb pos neg 2 Donor 
 pos pos 2 Both possible 
 n.d. pos 2 Fetus possible 
M pos n.d. 1 Donor possible 
 n.d. n.d. 1 Inconclusive 
S pos neg 1 Donor 
 pos n.d. 1 Donor possible 
 n.d. n.d. 2 Inconclusive 
s n.d. n.d. 1 Inconclusive 
n.d., not determined 
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Non RH  and K antibodies: After IUT therapy 33 additional antibodies were 
formed. In 17 cases both the fetal and donor RBC antigen profiles were known; in 
11 of 17 cases (65%) the offending antigens were present in the donor and not in 
the fetus. The etiology could not be determined with certainty in 6 cases because 
both the donor and the fetus carried the antigens and in 16 cases because data 
regarding the corresponding antigens on fetal cells and/or donor cells were not 
available (Table III). In one of these cases, an additional anti-Fya was formed 
after the first IUT, despite the IUT donor lacked the Fya-antigen. 
 
 
COMMENT 
Since 1987 our hospital performs intra-uterine intravascular erythrocyte 
transfusions (IUT) for HDFN as the single national center in the Netherlands, 
with a population of 17 million and approximately 2x105 births annually. In our 
previous study, concerning 280 IUTs in 91 pregnancies in the period 1987-1992, 
we reported that the formation of additional antibodies following one or more 
IUTs was 26% 17. In 1993, we have adopted a new preventive program 
concerning RH and K antigen matching for recipients with a high risk for 
alloimmunization. In this retrospective study in patients receiving IUTs, we 
evaluated an 11-year period after introduction of this practice besides matching 
for the antigens involved in HDFN. Despite our new policy the percentage of new 
cases of alloimmunization remains 25% of women treated with IUT. RH and K 
matching of the IUT donor did not prevent the formation of antibodies against 
these antigens in 31% of pregnancies at risk. 
In 233 pregnancies with 686 IUTs, 53 of the 212 (25%) women formed new 
additional RBC antibodies. Of these additional antibodies, 48% were directed 
against RH and K antigens. The number of women with non-RH and -K 
antibodies increased from 25 (12%) to 52 (25%), predominantly due to Kidd 
antibodies. In 11 out of 17 (65%) informative cases, the IUT donor and not the 
fetus carried the immunizing antigens. 
After delivery, multiple antibodies were present in 72% of the women. However, 
since antibody screening after the last IUT was performed after a median of 18 
days and not at all in 34 (15%) cases, the real figure is likely higher, considering 
that from the second IUT onwards, the immunization rate did not decline between 
subsequent IUTs. 
Additional antibodies are formed by fetomaternal hemorrhage (FMH). FMH is 
common after transplacental puncture 23. Although in our previous study we 
could not find a significant difference in additional antibody formation among 
women who had undergone transplacental puncture and among those who had not 
17, the current study confirms the results from others that transplacental puncture 
is associated with enhanced antibody response 16,24.  
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Additional antibodies may have been induced by fetal or donor RBC antigens. 
The additional RH and K antibodies are obvious of fetal origin, or in incidental 
cases these antibodies occurred without an immunizing event as natural 
antibodies. The rise in anti-D titer, the re-appearance of historical antibodies as 
well as the formation of additional antibodies all occur predominantly after the 
first IUT, which has a three times higher immunization rate than subsequent IUTs 
(18.0 versus 5.5%). At one hand this can be explained by boostering of an 
immune response by fetal cells, and on the other hand by the fact that during the 
first IUT, there is actually exposure to RBCs from two donors, i.e. IUT and fetal 
RBCs. With subsequent IUTs fetal RBCs are virtually absent 2. Although very 
small amounts of (fetal) cells can boost antibodies, it is questionable whether 
these cells can induce primary immunization, because these small amounts of 
incompatible, IgG sensitized cells, will almost immediately be removed by 
splenic macrophages 25.  
Donor RBCs in this study were RH-compatible, K-negative and compatible with 
the maternal antibodies. These RBCs will survive normally and, despite the small 
dose, apparently are capable of initiating primary antibody production as was 
seen in 65% of eligible non-RH/K antibody cases. 
In pregnancy there exists a shift of the Th1/Th2 balance towards a T-helper cell 
type 2 (Th2) favouring humoral immunity 26.  This may not only explain the fast 
new antibody formation, upon small amounts of FMH, but also the boost of 
historical antibodies in the absence of the corresponding antigen, or of natural 
antibodies (bystander effect) as seen in 4 cases in our study. 
The development of additional antibodies potentially increases the risk for the 
mother and the current and future pregnancies and can complicate further 
transfusion therapy. Additionally, antibodies may become undetectable over time 
27, posing the mother at risk for delayed hemolytic transfusion reactions in case of 
transfusions later in life. 
Women who received IUTs represent the highest red cell multi-alloimmunized 
population, with at least 72% possessing antibodies against multiple red cell 
antigens. 
In conclusion, we found that additional antibody formation during IUT therapy is 
common, associated with transplacental puncture increasing FMH and not 
reduced, despite RH and K antigen matching of IUT donors. Although in 17 of 33 
immunizations against non-RH/K antigens the RBC antigen profiles of both 
donor and fetus were available, in 65% of FY, JK and S antibodies the fetus 
lacked the antigen. 
We presume that donor antigens may play a major role even if the antigens are 
also expressed on fetal RBCs, because fetal RBCs are promptly removed by 
maternal antibodies and the virtual absence of fetal red blood cell production after 
1-2 IUTs.  
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To reduce this high rate of alloimmunization, enhancing the risk for 
complications during pregnancies and maternal transfusions, we propose to study 
RBC immunization after IUTs, not only matched for RH and K, but also for JK, 
FY and S antigens, which are, following RH- and K-antigens, known to be the 
most immunogenic antigens. Prospective studies are needed to investigate the 
effects of employing this policy and will clarify the nature of additional RBC 
immunization during IUT treatment. 
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ABSTRACT 
BACKGROUND: A person exposed to foreign blood group antigens may 
produce antibodies. The persistence of antibodies varies among people and 
among antibodies. A study was performed to investigate the persistence of 
clinically significant RBC alloantibodies over a period of 20 years. 
STUDY DESIGN AND METHODS: A retrospective examination was 
performed of all records of RBC antibodies in the transfusion laboratory 
computer database from 1978 through 1997. Records of patients who underwent 
at least one antibody investigation after an antibody had been detected were 
studied. The study included all antibodies against the RH, KEL, FY, JK and MNS 
blood group systems. An antibody was regarded as not persistent if, after previous 
detection, the screening or panel studies became negative for the antibody under 
study. Anti-D due to RhIg administration was excluded. 
RESULTS: An analysis was performed of 480 records consisting of 593 
antibodies that fulfilled the criteria. Median antibody follow-up was 10 months 
(range, 1-240). In 137 patients, 153 (26%) antibodies became undetectable over 
the course of time. After initial negative screening investigations, 312 antibodies 
were formed. The antibodies that were still detectable had a median follow-up of 
7 months (range, 1-193). A patient's age, sex, and antibody specificity were of no 
influence on the length of time that antibodies were detectable. Antibodies 
detected with a more sensitive screening technique were less persistent 
(p=0.0002). For 28 patients, detection of antibodies was highly irregular. 
CONCLUSIONS: About 25 percent of all antibodies became undetectable over 
the course of time. The antibody screening technique used, rather than the 
antibody specificity, affected these results. To prevent delayed hemolytic 
transfusion reactions, precise antibody documentation is of great importance. 
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INTRODUCTION 
A person exposed to foreign blood group antigens through transfusion, 
pregnancy, or tissue transplantation may produce alloantibodies. Pretransfusion 
RBC compatibility testing, including the serologic history, is performed to detect 
clinically significant alloantibodies that are or were present in the serum of 
potential transfusion recipients. The persistence of antibodies at a serologically 
detectable level varies among people and among antibodies1-8. Antibody 
immunoglobin type and quantity, and sensitivity of the screening method are the 
major factors that determine pretransfusion detection. 
Once an antibody has been detected, good documentation and the patient's and 
doctor's awareness of the presence of the antibody are essential to avoid 
incompatible blood transfusions, especially when these patients are treated in 
various hospitals, as a result of hospital specialization. In the event of a 
previously identified clinically significant alloantibody, blood lacking the 
relevant antigens should be selected for transfusion. This should be done even if 
the current antibody detection test is negative, to avoid delayed hemolytic 
transfusion reactions (HTRs). 
The frequency of delayed HTR varies considerably, depending on the criteria of 
diagnosis. The impact of delayed HTR on morbidity and mortality is not well-
known and probably depends on the antibody involved. Because they are often 
mild, self-limiting reactions, many delayed HTRs resolve undetected; however 
some result in additional transfusions to alleviate anemia. 
We investigated retrospectively the persistence of clinically significant, RBC 
alloantibodies over a period of 20 years. 
  
 
MATERIALS AND METHODS 
We examined retrospectively records on warm-reacting RBC antibodies in the 
transfusion laboratory computer database of Leyenburg Hospital (a 600-bed, 
multidisciplin-ary teaching hospital in The Hague, the Netherlands) during a 
20-year period, from 1978 through 1997. Records of patients who underwent at 
least one antibody investigation after an initial antibody had been detected were 
studied. 
The study included all antibodies against the RH, KEL, FY, JK, and MNS blood 
group systems. When anti-D was discovered in women of child-bearing age, we 
asked the treating physician if RhIg had been administered recently. If so, we 
excluded the anti-D from our study. Information collected included the patient's 
age and sex and the dates and results of tests for RBC antibodies. No detailed 
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information on pregnancies and antibodies detected in other hospitals was 
available. An antibody was regarded as not persistent if, after previous detection, 
the screening or panel studies became negative for that antibody on one or more 
subsequent occasions. 
Blood samples from successive patients submitted to the blood transfusion 
laboratory from January 1978 through December 1997 were screened for RBC 
alloantibodies by use of a selected 2-cell (1978 through 1986) or 3-cell (1987 
through 1997) set of reagent RBCs for antibody detection. The first technique for 
antibody detection consisted of 100 μL of serum and 50 μL of 5-percent RBCs 
(serum: cell ratio, 40:1) to perform an indirect antiglobulin (IAT) tube test 
including readings at saline and albumin 37°C phases (1978 through 1990); later, 
25 μL of serum and 50 μL of 0.8-percent RBCs (serum: cell ratio, 63:1) were 
used in a LISS gel test (DiaMed AG, Bonaduz, Switzerland) (1991 through 
1997). 
New antibody identification or reconfirmation of previous antibodies was 
accomplished with commercial panels of RBCs obtained by means of similar 
methods or additional techniques (e.g., PEG, enzyme) when needed. If the 
specificity could not be determined clearly, the blood sample was sent to a 
reference laboratory for further analysis. Antibody titers were not investigated 
routinely. 
We evaluated the reactive antibody screening for each new sample for which 
antibody testing was requested. The results of both antibody screening and 
antibody identification were valid for 72 hours; in case of transfusion, a fresh 
blood sample was then tested. Data on antibody identification were kept on file in 
writing as well as in the computer database. 
Crossmatching, including an IAT, was performed routinely from 1978 to 1990; as 
of 1991, the type-and-screen policy was applied for all patients until antibody 
formation. After an antibody had been identified, RBC products that were 
negative for the corresponding antigen were transfused after complete 
crossmatching, including an IAT. Antibody survival studies were performed on 
antibodies that were formed after initial negative screening in our laboratory. 
 
Statistics 
Statistical software packages (Excel 5.0, Microsoft, Redmond, WA; NCSS 6.0, 
Jerry L. Hintze, PhD, Kaysville, UT) were used for data management and 
analysis, respectively. The Kaplan-Meier product limit estimator was used to 
calculate the rate at which antibodies became undetectable. We used Cox's 
proportional-hazard regression method to study the impact of factors on antibody 
detectability in time. The log rank test (nonparametric) was used to compare 
antibody persistence. The chi-square test was used to compare the incidence of 
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antibody undetectability between groups. Groups were assumed to differ 
significantly when the probability level was less than 0.05. 
  
RESULTS 
The records of 1291 patients with RBC antibodies were evaluated; 1066 records 
showed the patients had the antibodies listed above, and 480 of these records 
(female: male ratio, 2.7) fulfilled the criteria. Median patient age at the time of 
antibody detection was 66 years (mean, 62; range, 19-97). Patient sera were 
screened for antibodies a median of three times (mean, 3.9; range, 2-92). 
We identified 593 antibodies; 89 percent were detected in more than one sample. 
One hundred fifty-three antibodies (26%) in 137 patients (29%) became 
undetectable over the course of time (Table 1). Of these, 55 percent were 
undetectable in more than one consecutive specimen. In the period 1978 through 
1990, 23 percent of the antibodies became undetectable; in the period 1991 
through 1997, 36 percent became undetectable (p=0.012). This increase was not 
related to a specific antibody.  
 
Table 1. Antibody specificity and detectability over the course of time (all antibodies) 
Antibody 
specificity 
Absolute 
number 
Percentage of 
all antibodies 
Undetectable over the 
course ot time 
Percentage of 
this antibody 
K 166 28 48 29 
E 136 23 52 38 
D 118 20 15 13 
Fya 55 9 7 13 
C 49 8 9 18 
c 28 5 9 32 
Jka 17 3 6 35 
S 10 2 1 10 
Jkb 6 1 4 67 
e 5 1 1 20 
Fyb 2 <1 0 0 
s 1 <1 1 100 
 
Antibody follow-up from 1978 through 1990 lasted a median of 6 months (mean, 
24; range, 1-143), and that from 1991 through 1997 lasted a median of 5 months 
(mean, 13; range, 1-84). 
Three hundred twelve antibodies (53%) were formed after initial negative 
screening studies, whereas 281 antibodies were already present when the first 
screening was performed in our laboratory. Of the new antibodies, 108 (35%) 
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became undetectable. The antibodies that were still detectable had a median 
follow-up of 7 months (mean, 24; range, 1-193). The duration of detectability is 
presented according to antibody specificity in Table 2. 
 
Table 2. Detectability over the course of time of antibodies acquired during study 
Time (months) Antibody 
specificity 
Number 
Mean Median Range 
Percentage 
undetectable 
e 3 39 39 1-76 33 
D 17 58 34 1-193 47 
S 10 45 23 1-182 10 
c 22 13 8 1-60 32 
E 91 20 7 1-182 42 
K 108 25 6 1-188 34 
Fya 28 24 6 1-162 14 
C 16 18 6 1-73 25 
Jkb 5 9 3 1-26 30 
Jka 12 10 1 1-62 33 
 
A Kaplan-Meier estimate of the cumulative probability function for all RBC 
antibodies formed during the study illustrates the relationship between the type of 
antibody and the length of time it was detectable (Figs. 1 and 2). Cox's 
proportional-hazard regression function showed that age, sex, and antibody 
specificity had no influence on the length of time that antibodies were detectable. 
When the detectabilities of various antibody types were compared, the log rank 
test revealed no significant differences between the rates at which different 
antibodies became undetectable. 
fig. 1. Antibody persistence (all antibodies, n=312) 
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Fig. 2A [upper figure]) RH system antibody persistence: anti-D, n = 17; anti-C, n = 16; 
anti-E n = 91; anti-c, n = 22.  Fig. 2B [figure below]) Non-RH system antibody 
persistence: anti-K, n = 108; anti-S, n = 10; anti-Jka and Jkb*, n = 17; and anti-Fya, n= 28. 
*Because of small numbers of Jka and Jkb antibodies (table 2), they were lumped together. 
 
RBC antibodies detected by the tube albumin-IAT method persisted longer than 
those found by the column LISS-IAT technique (Fig. 3, p=0.0002). If we 
consider all D-antibodies (RhIg cases excluded), then those that were already 
present when the patients entered the study (n=101) seemed to persist longer than 
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newly formed ones (n=17) (Fig. 4, p=0.000036). This difference could not be 
demonstrated for other antibodies. 
 
 
Fig 3. Antibody persistence versus detection technique: albumin, tube test , —— 
(n = 127) ; and LISS, column test, - - - -  (n = 179). p=0.0002 
 
 
Fig. 4. D-antibody persistence: anti-D present at first examination, —— (n = 101); and 
anti-D developed during study, - - - - , (n = 17). 
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For 28 patients, antibody detection varied: 30 antibodies (14 anti-E, 11 anti-K, 2 
anti-D, and 1 each anti-C, -c, and -S) sometimes could not be detected, but at 
other times, they were detected. Two patients exhibited a highly variable antibody 
response (Table 3). Patient R, a male born in 1947, and his sister HR, born in 
1962, both had sickle cell anemia and had received numerous (exchange) 
transfusions from 1981 and 1982, respectively. 
 
Table 3. Two patients with sickle anemia  
Patient HR Patient R 
Period* Antibody Period Antibody 
02/81-09/83 None 08/82-08/89 None 
10/83-11/83 K 10/89 K 
12/83-04/84 None 12/89-08/93 None 
05/84-12/84 K 10/93-12/93 E 
09/85-12/92 None 02/94 None 
01/93 K 03/94 E 
02/93 None 05/94 None 
03/93 E 06/94 E 
05/93-07/93 None 07/94-08/94 None 
08/93-02/94 E 11/94-05/96 E 
04/94 None   
05/94-08/94 E   
09/94 None   
10/94-11/94 E   
01/95-07/95 K   
09/95-01/96 E + K   
02/96-04/96 None   
06/96 K   
07/96-01/97 None   
02/97 K   
03/97-04-98 None   
07/98 K   
                         * Month/Year 
 
 
DISCUSSION  
Because of hospital specialization, patients are not always treated in the same 
hospital. Awareness of existing antibodies may not be reported from one hospital 
to another; in addition, because RBC alloantibodies can become undetectable 
over time1-6, the risk of delayed HTRs due to the transfusion of incompatible 
blood increases. 
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This retrospective study was designed to discover the frequency and rate at which 
RBC alloantibodies become undetectable. We found that 26 percent of RBC 
alloantibodies were not discovered on one or more occasions after their first 
detection. New antibodies were still present after a median of 7 months. The data, 
although not statistically significant, varied considerably between antibodies. A 
patient's age, sex, and type of antibody had no impact on the rate at which 
antibodies became undetectable. Our results are comparable to those of others3-6 
as far as the overall undetectability of antibodies is concerned. There were 
differences in the nondetectability of anti-C (this study, 18%; Ramsey, 54%) and 
anti-Fya (this study, 13%; Rosse, 47%). 
Antibodies discovered by means of the tube albumin IAT were more persistent 
than those found with the column LISS IAT. It is known that antibody uptake by 
reagent RBCs is much faster at low ionic strength than at normal ionic strength9. 
Thus, antibodies at low titers can also be detected. From 1990 to 1991, the 
incidence of clinically significant antibodies increased 1.5-fold in our laboratory 
(unpublished observations). It is also conceivable that antibodies at low titers 
become undetectable sooner than high-titer antibodies. This could explain why 
antibodies discovered by a more sensitive technique disappeared earlier and more 
frequently. We found that Kidd antibodies are detectable for the shortest time. It 
is well known that the in vitro detection of Kidd antibodies is very difficult and 
that they frequently (30-60%) play a role in delayed HTRs10.  
When we compared the persistence of existing D antibodies, most probably made 
after pregnancy, to that of new D antibodies formed after incompatible RBC 
and/or platelet transfusions, we found a significant difference. This difference 
might be explained by the fact that in former years women were exposed through 
pregnancy to D-antigen for a long period (months) and repeatedly (multiple 
pregnancies, which enhance secondary immune responses), which resulted in 
very high titers of anti-D. In contrast, an incompatible transfusion is a short, one-
time event that may give rise to lower titer anti-D. On the other hand, because the 
women with anti-D (median age, 59 years) were many years past childbearing, it 
is possible that, in many women who had anti-D from pregnancy, the antibodies 
had become undetectable before the women's entry into our study. Only in those 
women who had a particularly high-titered anti-D did the antibody last until they 
entered the study population. 
For some patients, predominantly those with hematologic disorders, antibody 
detectability varied. Most of these patients suffered from dysfunctioning of the 
immune system due to chemotherapy, multiple blood transfusions, or the disease 
itself. Issitt and Anstee10 reported that patients with sickle cell anemia make an 
antibody that is detected for a short time, after which other antibodies are formed, 
each also detectable for a short time. In the study of Rubenstein et al.11, it was 
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shown that the titer of anti-D exhibits cyclical variations, with differences of up to 
30 percent. This could also be the case for other antibodies, and the lower levels 
could result in undetectability. 
In view of the observations reported in this and other studies10 of RBC antibody 
incidence and detectability, a large prospective study with sensitive screening 
methods and well-defined patient populations should be undertaken to interpret 
the differences found. The results of that study could have an impact on the 
immunogenicity of blood group antigens, as calculated by Giblett12. 
In this study, 18 to 30 percent of all antibodies became undetectable over the 
course of time, depending on the sensitivity of the antibody detection technique 
used rather than the antibody specificity. To prevent delayed HTRs due to the 
transfusion of incompatible blood, accurate blood bank records and precise 
patient files are of the utmost importance. 
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SUMMARY 
BACKGROUND: Alloimmunization after exposure to red cell (RBC) 
alloantigens depends on genetic and acquired patient-related factors, dose and 
route of administration and the immunogenicity of the antigen, but exact kinetics 
are still unknown. 
STUDY DESIGN AND METHODS: A 5-year retrospective multicenter study 
analyzing factors influencing the rate and specificity of RBC alloimmunization 
was performed, with special emphasis on the time interval between transfusion 
event and antibody detection. Included were clinically significant alloantibodies 
against the RH, KEL, FY, JK and MNS blood group systems.  
RESULTS: Multivariate analysis involving 1710 immunized patients revealed 
that time interval between transfusion and antibody tests was strongly associated 
with the antibody specificity. Anti-Jka and anti-Jkb were predominantly found in 
patients tested within 3 months, whereas anti-K and anti-Fya were the most 
encountered antibodies at more than 5 years after transfusion. Of all immunized 
patients, new antibodies were detected within 14 days after transfusion in 299 
patients (16.8%) and in 1479 patients (83.2%) after more than 14 days.  
Fifty percent of transfusion recipients were retested for alloimmunization because 
of a new transfusion indication. Eleven of 2932 patients (0.4%) retested up to 3 
days after transfusion had formed new antibodies. 
CONCLUSION: The time interval between transfusion and antibody test was 
associated with RBC antibody specificity. Because RBC antibody tests after 
transfusion are not routinely performed, many antibodies may (not) be detected at 
the time of a new transfusion event, posing the transfusion recipient at risk for 
transfusion delay or a (delayed) hemolytic transfusion reaction. Routine RBC 
antibody screening at set time intervals following transfusion would reduce these 
risks. 
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INTRODUCTION 
Individuals exposed to red blood cell (RBC) alloantigens through transfusion, 
pregnancy or transplantation may produce antibodies. Whether the recipient’s 
immune system will react depends on genetic or acquired patient-related factors, 
dose and route of administration and the immunogenicity of the antigen. 
Immunogenicity is defined as the ability of a given antigen to stimulate antibody 
production in a patient lacking the antigen. The D antigen is the most 
immunogenic. After transfusion in immunocompetent patients more than 80 
percent of the recipients will ultimately form anti-D, although this incidence is 
much lower in immunocomprimised patients1-3. Because it is common practice to 
prophylactically match RBC transfusions for the D-negative status, anti-D 
formation as a consequence of blood transfusion is rare. Such routine is not 
common to prevent other RBC alloimmunization, for which we rely on serologic 
screening before transfusion. The increasing number of multi-transfused patients 
raises the question whether this is a safe approach.  
For instance, delayed hemolytic transfusion reactions were reported in 72 patients 
over a 2-year period in the 2002 and 2003 annual Serious Hazards of Transfusion 
Reports (SHOT)4,5. The authors expressed their concern regarding 
underrecognition.  
The relative immunogenicity of blood group antigens is estimated from the 
antibody frequency. Giblett6 calculated the relative immunogenicity for a number 
of RBC antigens compared to the K antigen. She compared the frequencies in 
which particular antibodies are encountered with the calculated probability of 
exposure. Based on her calculations, the relative likelihoods of non-D blood 
group antibody formation are K (0.05) > c (0.0205) > E (0.0169) > Fya (0.0023) > 
Jka (0.0007). 
We recently performed a large retrospective multicenter study in order to 
compare alloimmunization against clinically significant alloantigens before and 
after universal leucodepletion, which turned out not to be different7. Here we 
report our investigation in this cohort on factors relevant for immunization and 
specificities of antibodies, with special emphasis on the time interval between 
transfusion event and antibody testing. 
 
 
MATERIALS AND METHODS 
We examined retrospectively the records of all patients with newly detected RBC 
antibodies by searching the computer databases from 19 hospitals within the 
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Dutch Sanquin Bloodbank Southwest region during a 5-year period from 1999 
through 2003. The study included all clinically significant alloantibodies against 
the RH, KEL, FY, JK and MNS blood group systems. Autoantibodies, D 
antibodies and antibodies to low- and high-frequency antigens were excluded. 
Only patients of whom the transfusion history was known were included in the 
study. Data collected included age, sex, transfusion history, and the interval 
between transfusion and antibody screening. The clinical indications for the 
immunizing transfusions were not available.  
The hospital laboratories used a poluethylene glycol enhancement tube test or a 
low-ionic-strenght saline enhancement column technique, both of comparable 
sensitivity for antibody detection and cross-matching.  
The relative potency of antigens, compared to K-antigen, was determined with 
Gibletts equation: 
 
 Number of antibodies of interest        Probability of exposure to K-antigen 
                                                          X 
     Number of K-antibodies                   Probability of exposure to antigen of interest 
 
Antibody investigation was performed in case a patient was referred for a 
transfusion indication. The routine pre-transfusion antibody screening practice 
was studied by investigating the interval between transfusion and antibody 
screening tests in all transfused patients during the period 1999 through 2003 in 
one of the two University Hospitals in our region.  
 
Statistical analysis 
Statistical software packages (Excel and Access, Microsoft, Redmond, WA; 
SPSS 11.0, SPSS Inc. Chicago, IL) were used for data management and analysis, 
respectively. The chi-square or Fisher exact test was used for comparisons of 
proportions in two groups. Multivariate analysis was used to determine factors 
that were independently associated with antibody specificity. 
Groups were assumed to differ significantly when the probability level was less 
than 0.05.   
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RESULTS 
Patient characteristics 
New antibody specificities (n=2177, Table 1) were found in 1778 patients 
(female-to-male ratio 2.2; mean age 64 years; range, 1-101 years), including 83 
patients (4.7%) with antibodies before entering the study. Multiple new antibody 
specificities (2-5) were seen in 284 patients (16.0%).  
Patients had received 12,379 RBC units (mean 7 units; median 4 units; range, 1-
116 units) transfused in 4,050 transfusion events (mean, 2.3 transfusion events; 
median, 1 transfusion event; range, 1-50 transfusion events). Patients with 
multiple antibodies had received slightly more transfusions than patients with one 
antibody specificity (mean, 8.0 units vs. 6.7 units; p=0.018).  
 
Table 1. Antibody specificity and frequency in 1778 alloimmunized patients 
Frequency Antibody 
specificity Number % of total 
E* 740 34.0 
K 541 24.9 
Fya 195 9.0 
c 186 8.5 
Jka 173 7.9 
C* 138 6.3 
Jkb 54 2.5 
S 50 2.3 
M 45 2.1 
e 28 1.3 
Fyb 19 0.9 
s 7 0.3 
k 1 0.05 
Total 2177  
* anti-E including anti-DE (n=14) and anti-C including anti CD (n=52). 
 
Factors associated with antibody specificity 
Multivariate analysis (Table 2) revealed that anti-C presence was higher in 
patients with older age, but when anti-CD was excluded this relation disappeared. 
Anti-M and anti-S were identified more frequently in younger patients. Anti-Jka 
was seen predominantly in male patients and after a few units transfused, while 
anti-K was more frequent in multi-transfused patients. 
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Table 2. Multivariate analysis of factors independently associated with antibody 
              specificity 
P-value of factors included in the multivariate logistic analysis Antibody 
specificity Sex Age (years) Interval (months)* Units transfused 
C (+CD) n.s. 0.035 n.s. n.s. 
C (minus CD)      n.s. n.s. 0.095 n.s. 
E n.s. n.s. <0.001 n.s. 
c n.s. n.s. 0.017 n.s. 
e n.s. n.s. 0.086 n.s. 
K n.s. n.s. <0.001 0.019 
Fya n.s. n.s. <0.001 n.s. 
Jka 0.022 n.s. <0.001 0.026 
Jkb 0.077 n.s. 0.037 n.s. 
M 0.087 0.029 n.s. n.s. 
S n.s. 0.009 n.s. n.s. 
n.s.: non significant p>0.1; * time interval between transfusion and antibody test;  Not included in the 
table are antibodies with p>0.1 for all factors included in the multivariate analysis (anti-k, anti-Fyb 
and anti-s). 
 
Interestingly, the interval between transfusion and antibody  tests was associated 
with particular antibody specificities. Anti-E was the most encountered antibody 
up to 5 year following transfusion, but from 12 months onward declined from 45 
to 20 percent of encountered antibodies persisting after more than 5 years. Anti-c 
presented 10 to 15 percent of antibodies found up to 5 years after transfusion, 
after which period it decreased to less than 3 percent. Anti-K showed a gradual 
increase from 20 percent after 1 month to 45 percent after more than 5 years after 
transfusion. Anti-Fya rapidly increased from less than 10 percent after 1 year to 
27 percent of antibodies found after more than 5 years. Anti-Jka and anti-Jkb were 
predominantly found in patients tested during the first 3 months after transfusion; 
thereafter they decreased from, respectively, 18 and 5 percent to, respectively, 3 
and less than 2 percent (Fig. 1).  
The type of RBC bloodproduct transfused (leucoreduction by buffycoat depletion 
vs. prestorage filtration) did not influence the results regarding antibody 
incidence and specificity, neither was there a relation of the function of interval 
between transfusion and specific antibody detection. 
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Fig. 1  Antibody number and specificity in relation to the time interval between 
           transfusion and antibody testing. 
d = days; m = months; y = years 
           Anti-Jkb              Anti-Jka          Anti-Fya            Anti-K            Anti-c         Anti-E 
 
Because most E, c, K, Fya and Jka antibodies (n=936) are formed within 6 months 
after transfusion, we calculated after this period the immunogenicity relative to 
the K antigen. This revealed that the K antigen was 1.3 times more immunogenic 
than the E antigen, 3.5 times more than the Jka antigen, 4.9 times more than the c 
antigen and 11.6 times more immunogenic than the Fya antigen. When these 
antibodies are taken into account when detection tests were performed after a 
longer period than 6 months (n=787), anti-K was 2.5 times more immunogenic 
than E antigen, 22.4 times more than Jka antigen, 6.5 times more than c antigen, 
and 5.8 times more immunogenic than Fya antigen. Figure 2 depicts the 
immunogenicity results, showing a considerable variation with time interval. 
 
RBC alloimmunization suggesting a secondary immune respons 
Of all patients who developed alloantibodies, 299 patients (16.8%) did so within 
14 days after transfusion. The blood group specificities involved were RH 
(n=180; predominantly anti-E, n=128), JK (n=80), K (n=60), MSs (n=21) and FY 
(n=16). Forty-six antibodies, predominantly anti-E and anti-K (n=21 and n=14, 
respectively), were found within 3 days post-transfusion in 41 patients (2.3% of 
all immunized patients). 
Comparison of antibody frequency within 14 days versus more than 14 days after 
transfusion, showed that anti-Jka and anti-Jkb were more often involved within the 
short interval after transfusion (p<0.0001 and p=0.016, respectively), while anti-
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K and anti-Fya were present more often after more than 14 days (p=0.0003 and 
p=0.0007, respectively).  
 
Fig. 2. Relative potency of E, c, Fya and Jka antigens to K antigen as a function of time 
           interval between transfusion and antibody test. 
 
Anti-E                    anti-c             anti-K                    anti-Fya                     anti-Jka 
* Overall immunogenicity relative to K-antigen (= 0.05): E-antigen = 0.0275; c-antigen = 0.0093; 
 Fya-antigen = 0.0066 and Jka-antigen = 0.0073 
 
 
Routine antibody screening practice  
Routine antibody screening practice was studied in one of the two participating 
university hospitals. The interval between transfusion and antibody screening 
tests in all transfused patients during a 5-year period form 1999 through 2003 was 
investigated.  
During this period, 16,126 patients received transfusions. Antibody screens were 
performed 1 to 2 days before scheduled transfusion in 20 percent and on the day 
of transfusion in 80 percent. Almost 50 percent of patients (n=8004) were retested 
for alloimmunization because of a new transfusion indication, resulting in 165 
new antibodies in 150 patients. Twelve new antibodies (6x anti-E, 5x anti-K, 1x 
anti-Jka) were found in 11 of 2,932 patients (0.4%) who were retested up to 3 
days after transfusion and 7 antibodies (4x anti-E, 2x anti-K and 1x anti-Jka) in 7 
of 2,386 patients (0.3%) if testing was performed up to 2 days after transfusion. 
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DISCUSSION 
In this large multicenter retrospective study we investigated factors that could 
influence antibody specificity and found that age, gender, number of transfusions 
and as most important factor the time interval between transfusion and 
performance of antibody detection test were independent significant factors for 
antibody specificity. We did not include genetic or acquired patient related factors 
in our analysis; therefore our reported associations may also be due to other 
variables. It has been published that disease and/or treatment are important factors 
with respect to RBC antibody responses2,11-14,21,23,28. The role of the time interval 
after transfusion before specific antibody detection was never addressed before 
and only one study reports on the association of disease and antibody specificity8.   
To our knowledge, this is the first study investigating factors in a multivariate 
analysis. Most studies performed univariate analysis of alloantibody formation, 
regardless of antibody specificity. Discordant results regarding the influence of 
age, gender and number of transfusions or transfusion events have been reported9-
14. In our analysis, gender was correlated with anti-Jka, age with anti-M and anti-
S, and the number of transfusions with anti-K and anti-Jka. Previous studies also 
showed the higher prevalence of anti-M in younger patients9,15.  
We could not confirm the observations by Winters and coworkers9 regarding 
older age with the presence of anti-K and anti-Fya, but results concerning 
increasing age with anti-C (including anti-D) were in agreement. The latter 
probably reflects CD immunization through pregnancy and the close pair 
clustering of anti-D and anti-C9. The differences found are probably explained by 
the study design. Except for differences in the study population and in the number 
of the same antibodies studied (806 vs. 2177 in our series), Winters performed an 
univariate analysis on RBC antibodies during a 20-year period without 
information on transfusion history, while we multivariately analyzed RBC 
alloimmunized patients, including the transfusion history.  
The relation between higher number of units transfused and anti-K development 
can be explained by the chance of K alloantigenic exposure. After 4 units of 
RBCs were transfused (median number in our study), K-antigen exposure was 
much less compared to the exposure of all other relevant antigens (K 0.31 vs. 
0.74 for E and >0.96 for other RH, FY, JK and MS). The chance of exposure 
(Exp) per antigen was calculated using the formula:  
 
Exp = 1-[chance of matched RBC exposure]median number of units transfused. 
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Relatively little is known about the kinetics of red cell alloimmunization within 
the first months after transfusion. Some information comes from studies that 
address (delayed) hemolytic transfusion reactions16-19, but most studies report on 
antibodies found after a longer period of time20-23 after transfusion or even 
regardless the transfusion history9,24. 
RBC alloimmunization investigations are in most cases only performed before a 
new transfusion event and not after a fixed time following antigenic challenge. 
Consequently, many antibodies may not be discovered, either because there is no 
new transfusion indication or because antibodies have disappeared. In one of the 
two university hospitals in our study, not necessarily representative for all 
hospitals, owing to the relative predominance of complicated patients 
experiencing multiple transfusion episodes, 50 percent of patients were retested 
for alloimmunization because of a new transfusion indication within 5 years.  
When patients were retested within one month after transfusion, Kidd antibodies 
represented more than 20 percent of the antibodies and are more frequent than 
anti-K, whereas anti-Kidd frequency declined to a relative proportion of 3 to 6 
percent when retesting was performed after more than 3 months. It is recognized 
that Kidd antibodies are frequently involved in delayed hemolytic transfusion 
reactions16,17,25, in which a booster respons is held responsible. Although we 
could not distinguish a primary from a booster reaction, the high frequency in our 
study, shortly after transfusion, suggests a rapid primary immune response. 
Heddle and coworkers18, prospectively studied alloimmunization after transfusion 
in 2082 patients and found 32 new RH, K, FY, JK or MSs antibody specificities, 
of which 9 (28%) were anti-Jka, detected after a median of 4 days (range, 1-94 
days) after transfusion. A positive direct antiglobulin test was found in 31 percent 
of the new alloimmunized patients. Only 3 patients showed hemolysis, of which 1 
was an anti-Jka case. In a number of other reports, rapid primary immune 
responses with or without delayed hemolytic transfusion reactions are described 
2,26-31. 
Duffy antibodies are seen infrequently (5-8%) in the cases tested the first 6 
months after transfusion in our study, but they represent up to 27 percent of 
antibodies after 6 months and become even more frequent than anti-E after 5 
years after transfusion. Slow anti-Fya evolving after transfusion as well as 
disappearance of other antibodies over time could explain the frequency 
difference. In previous studies 13 to 17 percent of Fya antibodies in contrast to 29 
to 50 percent of E, K and Jka antibodies became undetectable over time32,33. 
Overall, our results regarding relative immunogenicity are similar to those 
previously reported9,20,22. Compared to the original results of Giblett, however, we 
observed a significant increase (p<0.0001) in relative immunogenicity of Fya and 
Jka antigens compared to K antigen, probably reflecting the use of more sensitive 
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antibody screening tests for these antibodies over the years and a decrease in 
relative immunogenicity of the c antigen (p<0.0001). The reason for the decrease 
in c antigen immunogenicity is not apparent.  
Our results illustrate that relative immunogenicity is dependent on the interval of 
testing after transfusion and calculations can best be performed after 3 to 6 
months after transfusion when most antibodies have developed and are still 
detectable. Such information regarding relative immunogenicity of antigens can 
support transfusion policy decisions.  
According to the Blood Transfusion Guidelines from the Dutch Quality Institute 
for Healhtcare, CBO, published in 2004, pretransfusion antibody tests are allowed 
to be performed up to 3 days before scheduled transfusion34. This practice 
implicates a small risk for hemolytic transfusion reactions as we found in our 
study that 0.3 to 0.4 percent of transfused patients had developed antibodies 
within 3 days after transfusion. 
Other issues concern prevention of hemolytic transfusion reactions. A nationwide 
database is being developed in the Netherlands, registering patient RBC 
alloantibody information, to reduce the risk of transfusion reactions and delay of 
transfusion for patients shifting between hospitals. Such prevention improves 
when antibody investigations are performed at the appropriate intervals after 
transfusion.  
In the ideal situation, RBC antibody tests after transfusion should be performed 
twice, the first time shortly after transfusion, to detect boostering of existing 
antibodies or fast appearing new antibodies (i.e. anti-Jka and anti-E), and a second 
time after a longer period of time, to detect slower developed antibody 
specificities Our study design does not allow to be more specific on the time 
points. More prospective investigations are needed to recommend on timing of 
optimal posttransfusion antibody testing. Finally, because automated medium and 
high-throughput DNA techniques will soon be available for large-scale donor and 
patient blood group genotyping, extended matching for the most clinically 
relevant red blood cell antigens (i.e. RH, K, FY, JK and S) to prevent 
alloimmunization will become a topic of discussion. The benefits of such a 
policy, in terms of immunization prevention and costs can only be based on 
reliable figures of alloimmunization, incidence of repeated transfusions and costs 
of current policy.  
In conclusion, the time interval between transfusion and antibody test is strongly 
associated with the identified RBC antibody specificity. RBC antibody tests 
following transfusion are not routinely performed and in case the antibodies are 
detected for the first time at the time of a new transfusion indication, or have 
become undetectable, they are posing the transfusion recipient at risk for 
transfusion delay or a (delayed) hemolytic transfusion reaction. To anticipate 
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future developments, such as large-scale extended phenotyping of donors, the 
kinetics and frequency of RBC alloimmunization need to be more precisely 
determined through prospective studies in which antibody detection tests are 
performed at set time intervals after transfusion.  
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Due to the several hundreds polymorphic blood group epitopes, a red blood cell 
transfusion is inevitable incompatible. The formation of antibodies against 
foreign red blood cell antigens is a common side effect of transfusion. Over the 
years, techniques with increasing sensitivity to detect RBC antibodies during pre-
transfusion testing have been implemented in the hospital transfusion 
laboratories. Low-ionic strenght enhanced column-agglutination techniques or 
polyethyleneglycol enhanced tube tests, both of comparable sensitivity, together 
with commercial available test-erythrocytes are nowadays routinely used in most 
Dutch laboratories. The specificity of these techniques to detect only the 
clinically relevant RBC antibodies, however, still needs improvement. Panel cells 
still are dependent on the variability of donor cells. A recent development, using 
recombinant fusion proteins containing the Fya and Fyb extracellular antigen 
domain produced by E. coli transformed with Duffy expression plasmids, shows 
promising results1. In addition, DNA can be transfected into cells and grown in 
tissue culture. Kell and Duffy proteins have been expressed in mouse 
erythroleukemic (MEL) cells or 293T cells and detected by human antibodies2. 
Theoretically, it is possible to produce a panel of cell lines expressing the 
individual clinically relevant blood group proteins allowing simultaneous single 
step detection and identification of (multiple) blood group antibodies. 
 
In chronically transfused hemoglobinopathy patients the incidence of RBC 
antibodies is high, but for other patient populations it is largely unknown. 
Chronically transfused patients are frequently tested for the presence of red cell 
antibodies and therefore, despite retrospectively studied, data on 
alloimmunization risk and the antibody specificities involved are most likely 
accurate. The vast majority of studies on RBC alloimmunization in non-
chronically transfused patients are retrospective or observational cohort studies, 
in which data are obtained from a single or a few antibody tests per patient. The 
results from these studies, which show <1-3 percent immunization risks, are 
hampered by the fact that patients are routinely only tested for RBC antibodies 
before a new transfusion event and antibodies that may have formed after the last 
transfusion may have become undetectable before the next transfusion. In chapter 
8 we report our results on the persistence of 593 antibodies with various 
specificities. Overall, 26 percent of antibodies become undetectable. Five years 
after the initial identification more than 50% of antibodies are no longer 
detectable and this increases to 70% after more than 10 years. Besides, 
detectablity varied considerably for the various antibody specificities, although 
not statistically significant. Especially Kidd antibodies are detectable for the 
shortest period of time, which is consistent with the fact that they are often 
involved in delayed transfusion reactions. Due to this disappearance of antibodies 
the frequency of RBC alloimmunization in non-prospective studies is most likely 
underestimated, both in general and for certain antibody specificities. This is 
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confirmed by the few studies that adress alloimmunization in non-chronically 
transfused patients, prospectively. Hewitt and Heddle both studied the incidence 
of new antibodies formed within 1 week after a mean of 4.5 units transfused, in 
cardiac surgery, respectively random patient, populations3,4. New antibody 
formation occurred in 2-2.8% of patients. Most of these patients had a history of 
transfusion and/or pregnancy and therefore a booster response is most likely. In 
chapter 9 we report that at least 16.8% of 1778 patients who had formed RBC 
antibodies did so within 14 days after transfusion and 2.3% already within 3 days. 
For transfused patients who were retested for antibodies within 7 days after the 
previous transfusion we found new antibodies in 0.9% (unpublished data), which 
is not at variance with the results from Hewitt (1,7%) and Heddle (1.5%) when 
only the clinically important antibodies in these studies are considered. 
Redman and colleques performed serial RBC antibody testing during a 9 month 
period following transfusion in a cohort of 452 elective surgery patients5. New 
antibodies with clear specificity were detected in 8.4% of patients between 2-24 
weeks after a mean of 3 RBC units transfused. Van de Watering found new RBC 
antibodies, after a maximum follow-up of 50 days, in 5.3% of 374 cardiac surgery 
patients, who had received a mean of 4.8 RBC transfusions6.  
However, all of the aforementioned studies considered all transfused patients in 
stead of only those who are actually at risk for RBC antibody formation, e.g. 
patients lacking specific RBC antigens and transfused with units containing these 
foreign antigens. This discrimination may result in higher individual patient 
alloimmunization risk and more accurate data on the immunogenicity of the 
various RBC antigens.   
 
Contrary to the ‘disappearance’ of antibodies, some antibodies may persist for 
decades after the immunizing event. In chapter 8 we report that D-antibodies that 
are formed after pregnancy may persist for longer periods of time than those that 
are formed after transfusion. Although this observation needs further 
investigation, one could speculate on the mechanism(s) involved in long-term 
antibody persistence. One possible explanation may be related to persistent 
antigen exposure as the result of the long-term survival of allogeneic blood cells 
in the recipient, e.g. microchimerism. Microchimerism is often the byproduct of 
organ transplantation, pregnancy or transfusion. Cell traffic between mother and 
fetus during pregnancy has been found to result in frequent and long-term 
persistence of fetal cells in the mother and maternal cells in her progeny7-9 Long-
term microchimerism after transfusion has been reported especially in trauma 
patients and in children that had received intra-uterine transfusions10-14. It is 
conceivable that differentiation of chimeric hematopietic stem cells towards the 
erytropoietic cell line may result in a continuous production of foreign 
erythrocytes maintaining antibody production by the host. On the other hand, 
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maternal or donor hematopoietic progenitor cell chimerism after transfusion early 
in life may induce tolerance against foreign RBC antigens introduced later in life. 
 
The factors that regulate whether an individual will mount an immune response to 
transfused RBCs remain largely undetermined. The probably most important is 
the degree of genetic disparity between the donor and the recipient. Some 
diseases, restricted to certain ethnic groups, e.g sickle cell disease, exhibit high 
immunisation risks, especially when the patients are transfused in countries where 
the ethnic group is underrepresented in the donor population. Prophylactic 
matching for the most important antigens (RH and K) has reduced RBC antibody 
formation in these patients substantially and is standard practice in the 
Netherlands15. However, no randomized controlled studies have been performed 
yet to evaluate this policy. 
Immunogenetic factors, such as MHC-type, CD4+ T-cell, B-cell and cytokine 
polymorphisms can all contribute to the presentation and recognition of foreign 
antigen and maturation of the immune response resulting in antibody production. 
Differential immunogenicity of mismatched antigens is, besides non-antigen 
specific co-stimulatory help, largely dependent on MHC-restricted activation of 
T-cells. Alarif and colleques showed that HLA-B35 positive sickle cell patients 
are six times more likely to form RBC alloantibodies with various specificities 
after transfusion than those lacking that antigen16. Recent studies have identified 
possible relationships between the HLA-DRB-restriction sites and the immune 
response to a number of RBC antigens. The HLA-DRB1*1501 allele is 
significantly overrepresented in D-negative donors who have produced D-
antibodies in response to D-positive cells compared to non-responders17. 
Jka-immunization has been found associated with the HLA-DRB1*0101, HLA-
DRB1*0102 and HLA-DRB1*1001 alleles, which share a common gene sequence 
in the P4 pocket of the peptide binding site, which is the major determinant of T 
cell antigen recognition18,19. Also for K and Fya immunized persons associations 
with HLA-DRB1 polymorphisms have recently been described (table 1)20,21. 
However, HLA associations alone can not explain the incidence of specific 
antibodies. From mouse models, there is evidence that genetically determined 
immunomodulatory genes outside MHC are also involved in the regulation of the 
extent of an immune response against sheep red blood cells22-26. Recently a 
transfusion model using donor transgenic mice, expressing Fyb antigen, and Fya 
positive mice as recipient was developed to study anti-Fyb alloimmunization after 
intravenous RBC transfusion27. This model may serve to further study the 
immune mechanisms involved in antibody formation. 
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Table 1. HLA-DRB1 restriction sites and immunization to RBC antigens 
Frequency (%) 
RBC 
antibody 
HLA-
restriction 
site 
P4 pocket 
sequence Immunized 
persons 
Controls
Odds Ratio 
(95% CI, p-value) 
Jka 
DRB1*0101
DRB1*0102
DRB1*1001
F13/R71/A74 65 19.5 
7.7 
(2.9-20.5, <0.05) 
K 
DRB1*11 
DRB1*13 
S13/D70/A74 83 52 
4.5 
(2.1-9.7, <0.001) 
Fya DRB1*04 - 100 19 
12.9  
(8.0-20.7, <0.0001) 
 
Patient related clinical factors will influence the possibility of a patient to 
respond. A suppressed  immune system as a result of either the disease’s 
pathophysiology or severe immunosuppressive therapy may result in a reduced 
immune response, while on the other hand a normal or enhanced immune status, 
again related to the disease’s pathophysiology or, for instance, the presence of 
inflammation (danger signal)28, may result in (enhanced) antibody production. 
Other, yet unknown, clinical factors may play a role in distinquishing patients that 
will or will not form antibodies after transfusion.  
A higher number of transfusions will increase the possibility of encountering a 
foreign antigen. Obviously, this is the case for some antigens such as K-antigen 
and low-frequency antigens. For other common antigens (e.g. non-D RH, FY, JK, 
S) the theoretical chance of encounter is already more than 90 percent after 
transfusion of 3-4 RBC units. For anti-D, a single transfusion of D-positive RBCs 
will mount an immune response with detecable anti-D within a few weeks after 
the transfusion in most immunocompetent persons, but for other blood groups the 
number of transfusions to mount an immune response as well as the kinetics 
involved are largely unknown. 
 
Although RBC antibodies by themselves are not considered harmfull, its presence 
can evoke serious problems.  
Fetal and neonatal hemolytic disease originates from maternal RBC 
alloimmunization. D-antibodies are the result of a previous pregnancy, but 
approximately 50 percent (range 10-83%, depending on the antibody specificity) 
of other blood group antibodies during pregnancy are caused by previous 
transfusions29. Therefore, K-antigen compatible transfusions are given to females 
of (pre)child bearing age to prevent K-antibody formation15. For c and E antigens, 
these preventive measures are still a matter of debate.  
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Many blood groups are exposed on tissues other than blood, and corresponding 
antibodies can facilitate immune damage to transplanted tissues, which may lead 
to allograft rejection or even poor patient survival20-32. As a consequence, the 
presence of pre-transplant antibodies can complicate allograft selection.  
Alloantibody formation can be associated with temporary pan-reactive 
autoantibody formation triggering a phenomenon known as ‘bystander immune 
cytolysis’, where the autologous red cells of the recipients are destroyed and 
which can result in life-treatening anemia. This phenomenon is estimated to occur 
in 4-11% of sickle cell patients33,34, but has recently been described in other 
patients35,36 and is probably the result of an antibody booster reponse.  
Hemolytic transfusion reactions, after an incompatible transfusion in an 
immunized patient, can result in serious morbidity and mortality37-40. Delayed 
transfusion reactions (DTR) occur after transfusion of seemingly compatible RBC 
in previously alloimmunized patients in whom the antibody titers have fallen 
below serological detectable levels or rarely after an early primary antibody 
response. In the majority of cases, which are termed ‘delayed serological 
transfusion reactions’ (DSTR), the serologic findings are consistent with DHTR 
but there is no clinical evidence of hemolysis. Delayed serologic reactions appear 
to occur almost four times more frequent than DHTR, which has a frequency of 
one per 5400-6700 transfusions41-43. According to the 2004 and 2005 annual 
reports from the UK and Dutch hemovigilance organizations clinically relevant 
DHTR occur once per 46.000 units transfused37,38,45,46. This lower rate compared 
to previous studies may be explained by factors such as, improved pre-transfusion 
antibody screening, shortened hospital stay resulting in underrecognition, and a 
more restrictive transfusion policy. A wide variety of blood group antibodies are 
involved in DTR, but antibodies against E and Jka antigens are involved in more 
than 50% of cases and compared to other antibody specificities, anti-Jka is most 
frequent present in the hemolytic type. Recently, a nation-wide antibody 
registration system (TRIX) has been installed and is expected to be implemented 
for all Dutch hospitals in 2007. The aim of this registration is to provide 
transfusion laboratories with information regarding (historical) RBC antibodies in 
patients to prevent transfusion delay and to prevent hemolytic transfusion 
reactions. Studies given insight into the incidence of antibody based transfusion 
delay and transfusion reactions are needed to evaluate the efficacy of this 
registration. 
At last, in patients with multiple antibodies or antibodies against high-frequency 
antigens obtaining compatible blood for future transfusions can be complicated 
and may result in transfusion delay. 
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The age of genomics has enabled the application of DNA-based molecular 
methods to transfusion medicine. Isolation of the molecules that carry blood 
group antigens, followed by cloning of the genes and the development of DNA 
sequencing and PCR, have made application of genetic information to blood 
transfusion possible. Although assays for blood group antigens encoded by single 
SNPs are highly reproducible and correlate well with RBC genotype, genotyping 
for ABO and RH systems are still challenging because of the many mutations 
responsible for A and B subgroups and numerous variant and hybrid RH genes.  
The development of high-throughput genotyping platforms that utilize micro-
array and chip technologies will offer the opportunity to perform large scale 
testing on numerous antigens simultaneous and this will decrease costs compared 
to labor-intensive serologic techniques. Centralized data systems containing the 
complete molecular profile of all donors will give blood banks instant access to 
many different typed donors allowing an accurate selection of donor units to 
facilitate matching of donor RBCs to the recipient’s blood type. This will create 
the opportunity to extend routine antigen matching between donor and recipient 
to prevent alloimmunization to RBC antigens. Matching for C, E, c, e and K 
antigens will theoretically reduce clinically important antibody formation by 
70%, adding Fya, Jka and S antigens will increase this to almost 90%. Preventive 
extended matching is currently only applied for females of (pre)child bearing age 
(K blood group) to prevent hemolytic disease of the fetus and newborne and for 
patients who suffer from hemoglobinopathies or hemolytic anemias (RH and K 
blood groups) who are known to ultimately develop antibodies. However, patients 
with myelodysplastic and myeloproliferative syndromes have shown to also 
exhibit a high antibody response after transfusion (chapter 5). In addition, patients 
who have already made RBC antibodies are also high responders towards other 
blood group antigens after repeat transfusion (chapters 6 and 7). Therefore 
extended antigen matching for these patients may be considered.  
Although RBC antibodies are in most cases only of interest in case of repeat 
transfusion, longer life expectancy of the population and an increased probability 
of repeat surgery or diseases requiring blood transfusion increas the clinical 
relevance in non-chronically transfused patients as well. 
The introduction of extending current preventive measures should be preceded by 
studying its feasibility and cost-effectiveness.  
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Summary 
Chapter 1 
In this chapter blood group alloimmunization after transfusion is outlined in short, 
followed by a description of the aim and design of the studies of the thesis. 
 
Chapter 2 
Chapter 2 contains a review of the literature on red cell immunization after blood 
transfusion covering the developments in this field in the past century. The 
discovery of the ABO-blood group system, the alloimmune origin of hemolytic 
disease of the fetus and newborne and the antiglobulin test by Coombs are the 
most important developments. Transfusion safety increased tremendously with 
the routine introduction of sensitive pretransfusion compatibility testing and 
current protocols primarily focus on potential clinical significant antibodies that 
only react in the indirect antiglobulin phase.  
After the development of DNA sequenching and amplification techniques the 
genes encoding almost all blood group antigens were characterized on the 
molecular level, elucidating that many blood groups arise from single nucleotide 
polymorphisms. In clinical transfusion practice, genomic typing assays are 
increasingly being used for donor and patient blood group typing. Studies on the 
functional aspects of the molecules that express RBC antigens, showed their 
possible significance in pathophysiology, e.g. red cell abormalities and organ 
dysfunction.   
The evolving field of immunology unravelled processes, immune cells and 
molecules involved in the alloimmune response against foreign antigens. Antigen 
presenting cells, T- and B-cells regulated by (co-)stimulatory factors are 
responsible for the formation of antibodies, whereas inhibitory signals control 
homeostasis of the immune response. Besides genetic recipient factors, e.g. MHC 
polymorphisms, several unknown or ill-defined factors may influence the 
immune response towards red blood cell transfusions and need elucidation in the 
coming years.  
The incidence of RBC alloimmunization after transfusion varies between less 
than 1% up to over 70%, depending on the population studied. From all studies, it 
appeared that E and K blood group antigens are the most immunogenic non-D 
antigens and are responsible for the majority of antibodies found. The high 
immunization rate in patients with sickle cell disease and thalassemia has led to 
the policy to prophylactically match donor RBCs for RH and K antigens.     
 
 
 
 
Red blood cell alloimmunization after blood transfusion 
 
 156
Chapter 3 
Chapter 3 describes the results of a retrospective multicenter study, performed on 
a large non-selected patient cohort in the Sanquin Southwest region, with the aim 
to establish whether prestorage leucodepletion alters the development of 
clinically relevant red blood cell antibodies after transfusion. Two periods were 
investigated, 2 years before and 2 years after the introduction of universal 
leucodepletion. We compared new antibodies that were detected in patients 
transfused during the study intervals (antibody incidence) with antibodies in 
patients admitted to the hospitals in the same period but who had not received 
transfusions during the study periods (antibody prevalence). A total of 4148 
patients possessed 4770 RBC antibodies.  
No differences in antibody incidence or prevalence as well as antibody 
specificities, multiple antibodies, historical antibodies and additional antibodies 
between the two study periods were found. Similarly, patient cohorts were 
comparable with regard to age, sex, number of units transfused, transfusion 
events, interval from transfusion to antibody detection and alloimmunization rate 
(0.13%, expressed as the number of immunized patients per RBC unit 
transfused).      
From this pre- and post intervention study we concluded that RBC 
alloimmunization in non-selected random transfused patients was not favourably 
affected by universal leucodepletion compared to buffy-coat leucoreduced RBC 
transfusions. 
 
Chapter 4 
In chapter 4 we present a study on the frequency of coincidentally discovered 
antibodies against low incidence antigens in a RBC alloimmunized patient 
population during a 23 year period. The aim of the study was to investigate 
whether the type and screen policy, without performing a complete crossmatch 
before transfusion in non-immunized patients, is a safe procedure, with regard to 
the risk on transfusion reactions due to antibodies against low incidence antigens. 
In addition the presence of anti-Wra was studied in random hospital patients with 
and without RBC antibodies, in pregnant women and in blood donors.  
Antibodies to low incidence antigens were detected in 50 patients who did not 
possess other RBC antibodies and in 39 patients together with other RBC 
antibodies (2.2% of patients with RBC antibodies). Fourteen antibodies to low 
incidence antigens were found for the first time during 117,000 complete 
crossmatch tests (0.01%). During the study period, no transfusion reactions were 
reported due to antibodies against low incidence antigens. 
The prospective study on the presence of anti-Wra revealed that 4.3% of blood 
donors, 5.8% of random non-immunizd hospital patients, 10.2% of pregnant 
women and almost 20% of patients with other antibody specificities possessed 
this antibody.  
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From this study we concluded that antibodies to low incidence antigens are often 
present in patients as well as in healthy persons, but that the risk of a transfusion 
reaction due to these antibodies is very low and therefore that transfusion without 
complete crossmatch is a safe procedure. 
 
Chapter 5 
In this chapter, red blood cell antibodies found after transfusion in various 
malignant myelo- and lymphoproliferative diseases are described from a 10-year 
retrospective study. The 564 evaluable patients received a total of 15,287 RBC 
units in 6182 transfusion episodes. Patients with myeloproliferative diseases 
required transfusion support for a twice as longer period resulting in almost 3 
times more RBC units transfused compared to patients with lymphoproliferative 
diseases. A total of 71 allo-antibodies, predominantly anti-E and -K, were found 
in 51 patients. Multiple antibody specificities were present in 33% of immunized 
patients. Fifty percent of antibodies were already formed after 13 RBC 
transfusions, indicating that the majority of antibodies are formed early during the 
course of transfusions. The alloimmunization rate was 0.5% per RBC unit 
transfused. Patients who received intensive chemotherapy produced RBC 
antibodies at a much lower rate than those who are not treated intensively. This 
was further confirmed by the fact that only three patients formed anti-D after 244 
D-incompatible platelet transfusions. 
From this study, we concluded that antibody formation in patients with malignant 
hematologic diseases is comparable to that for other diseases requiring multiple 
transfusions. Therefore prophylactic antigen matching to prevent antibody 
formation seems unnecessary in this clinical setting. 
 
Chapter 6 
The aim of the 20-year retrospective multicenter study described in this chapter 
was to explore to what extend non-chronically transfused allo-immunized patients 
are prone to form additional clinically significant RBC antibodies upon repeat 
transfusions. A total of 653 patients who presented with 772 RBC antibodies 
received a median of five additional RBC transfusions during median two 
transfusion episodes. A total of 140 patients formed 157 additional antibodies and 
57% did so after a single additional transfusion episode. At the end of the study 
almost 34% of patients had multiple antibodies. The odds ratio for additional 
antibody formation compared to primary antibody formation (see chapter 3) was 
29 (95% CI, 22.7-37.2). The calculated risk on additional immunization per unit 
transfused, for 316 patients from whom the RBC antigen profile was known, 
showed considerable variation between specific RBC antigens; K-antigen exhibit 
the highest immunization risk of 9%, RH-antigens between 1.9 and 3.6% and 
other antigens between 0.2 and 1.7%.  
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The theoretical exercise regarding extended matching, in patients with RBC 
antibodies, showed that donor feasibility should be no problem in the Netherlands 
if matching is restricted to the most immunogenic antigens (RH, K, Fya and Jka).  
This study showed that non-chronically transfused patients who formed RBC 
antibodies after a previous transfusion are high-antibody responders to 
subsequent alloantigenic challenges. Extended antigen matching seems feasible 
and should be considered for subsequent transfusions in this patient group. 
 
Chapter 7 
This chapter describes the results of a study, performed at Leiden Medical 
University Center, the Dutch national reference center for intrauterine transfusion 
(IUT) treatment, with the aim to evaluate maternal additional clinically 
significant antibody formation after introduction of preventive D, C, c, E, e and K 
matching of IUT donors. During an 11-year period 686 IUTs were performed 
during 233 pregnancies in 212 women. Before IUT treatment the women 
possessed 242 antibodies and multiple antibodies, mainly anti-CD, were present 
in 59% of pregnancies. After IUT treatment fifty-three women (25%) had formed 
64 new additional antibodies and in 11 women historical antibodies that were no 
longer detectable before IUT treatment had reappeared. The percentage of women 
with multiple antibodies increased from 59% at admission to 72% after delivery 
and non-RH/non-K antibodies increased from 12% to 25%. The mean 
immunization rate (new antibodies per IUT) was 18% after the first IUT and 
declined to about 5.5% after subsequent IUTs. 
Multivariate analysis revealed that additional antibody formation was 
predominantly associated with transplacental puncture to administer the 
transfusion. 
Rh- and K-matching of the IUT donor did not prevent the formation of RH and K 
antibodies in 31% of pregnancies at risk, because the fetal RBCs carried the 
antigens. In 11 of 17 (65%) evaluable cases the additional non-RH/non-K 
antibodies were induced by the donor and not by fetal RBC antigens. 
We concluded from this study that additional antibody formation during IUT 
therapy is common, associated with transplacental puncture and not reduced, 
despite RH- and K-matching of the IUT donors. To reduce the high rate of 
alloimmunization in these patients we propose to extend matching of IUT donors 
also for JK, FY and S antigens. 
 
Chapter 8 
The purpose of the study, of which the results are described in chapter 8, was to 
investigate the persistence of clinically significant RBC alloantibodies during a 
20-year period. We identified 593 antibodies in 480 patients whose sera were 
screened multiple times for antibodies after first antibody detection. Overall, 153 
antibodies (26%) became undetectable over time. Four years after the first 
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detection of newly formed antibodies 50% had become undetectable and this 
increased to more than 70% after 16 years. Although there were no statistically 
significant differences in the rates with which the various antibody specificities 
became undetectable, Kidd antibodies were detectable for the shortest period of 
time, which may explain their frequent cause of delayed hemolytic transfusion 
reactions. 
We concluded from this study that it is common for RBC alloantibodies to 
become undetectable over time and that accurate blood bank records and precise 
patient files are of importance to prevent (delayed) hemolytic transfusion 
reactions due to the transfusion of incompatible blood.  
 
Chapter 9 
Chapter 9 describes the results of a 5-year retrospective multicenter study on 
factors relevant for immunization and specificities of clinically significant 
alloantibodies, with special emphasis on the time interval between transfusion 
event and antibody testing. Two thousand one-hundred and seventy-seven new 
antibody specificities were found in 1778 patients in the years 1999 through 
2003. Patients had received 12,379 RBC units in 4,050 transfusion events.  
Male gender was correleated with anti-Jka, younger age with anti-M and anti-S 
and the number of RBC transfusions with anti-K and anti-Jka. The most important 
independent factor associated with particular antibody specificities was the time 
interval between transfusion and antibody tests. Anti-E was the most encountered 
antibody up to 5 year following transfusion, but from 12 months onward declined 
from 45 to 20 percent of encountered antibodies persisting after more than 5 
years. Anti-c presented 10 to 15 percent of antibodies found up to 5 years after 
transfusion, after which period it decreased to less than 3 percent. Anti-K showed 
a gradual increase from 20 percent after 1 month to 45 percent after more than 5 
years after transfusion. Anti-Fya rapidly increased from less than 10 percent after 
1 year to 27 percent of antibodies found after more than 5 years. Anti-Jka and 
anti-Jkb were predominantly found during the first 3 months after transfusion; 
thereafter they decreased from, respectively, 18 and 5 percent to, respectively, 3 
and less than 2 percent.  
In 299 patients alloantibodies were detected within 14 days after transfusion, 
either due to a secondary or to a rapid primary immune response.  
We concluded that the time interval between transfusion and antibody tests is 
strongly associated with the number and RBC antibody specificity. Because RBC 
antibody tests are not routinely perfomed after transfusion, many antibodies may 
(not) be detected at the time of a new transfusion event, posing the recipient at 
risk for transfusion delay or a hemolytic transfusion reaction. The frequency and 
kinetics of RBC alloimmunization need further study, to determine the optimal 
moment for antibody testing and to anticipate on possible future developments 
regarding extended donor RBC matching. 
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Chapter 10 
This chapter contains a discussion on the significance of the results of the studies 
included in the thesis and directions for future research in the field of RBC 
alloimmunization after transfusion. 
From our studies, we conclude that certain patients groups are at increased risk 
for RBC alloimmunization, and should be considered for extended donor RBC 
antigen matching. For other transfusion populations the risk is still largely 
unknown, but most probably underestimated. The main reason for discripancies 
found are related to the study designs, which are hampered by the fact that not all 
patients are routinely tested after a transfusion event and antibodies may have 
become undetectable before the next transfusion. Prospective studies should 
ideally focus on patients actually at risk for antibody formation, e.g. patients who 
have received RBC transfusions containing foreign antigens. 
Contrary to the disappearance of antibodies, some antibodies persist for decades. 
The mechanisms involved are yet largely unknown, but persistent 
microchimerism of donor cells may be one explanation.  
The immune mechanisms and patient related clinical factors involved in RBC 
alloimmunization will be the subject of studies in the coming years and may 
define patients at increased risk for antibody formation after transfusion.  
Finally, the development of high-throughput genotyping platforms will offer the 
opportunity to perform large scale testing on numerous antigens simultaneously, 
and will create the possibility to extend routine donor antigen matching for 
patients at risk for alloimmunization. 
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Samenvatting 
Hoofdstuk 1 
Dit hoofdstuk bevat een korte beschrijving van alloimmunisatie na bloed 
transfusie, gevolgd door een beschrijving van opzet en doel van de studies van dit 
proefschrift.  
 
Hoofdstuk 2 
Hoofdstuk 2 bevat een samenvatting van de literatuur betreffende rode bloedcel 
immunisatie na bloed transfusie, met inbegrip van de ontwikkelingen op dit 
gebied in de afgelopen eeuw. De ontdekking van het ABO bloedgroep systeem, 
de alloimmuun oorzaak van hemolytische ziekte van de foetus en pasgeborene en 
de antiglobuline test van Coombs zijn de belangrijkste mijlpalen geweest. De 
veiligheid van transfusies verbeterde enorm na de routinematige toepassing van 
de indirecte antiglobuline in pretransfusie compatibiliteit onderzoek, en de 
huidige protocollen zijn primair gericht op de detectie van klinisch belangrijke 
alloantistoffen in de indirecte antiglobuline fase.  
Na de ontwikkeling van DNA sequentie en amplificatie technieken werden de 
genen coderend voor bloedgroep antigenen op moleculair niveau gekarakteriseerd 
en bleek dat veel bloedgroepen het gevolg zijn van enkelvoudige nucleotide 
polymorfismen. In de klinische transfusie geneeskunde wordt genotypering in 
toenemende mate gebruikt voor bloedgroep bepaling van donor en patiënt. Uit 
studies naar de functie van bloedgroep moleculen is gebleken dat zij een rol 
spelen in de pathofysiologie, zoals erytrocyten afwijkingen en orgaan dysfuncties. 
Ontwikkelingen in de immunologie hebben inzicht gegeven in de processen, de 
immuuncellen en de moleculen die betrokken zijn bij de alloimmuun respons 
tegen lichaamsvreemde antigenen. Antigeen presenterende cellen, T- en B-cellen 
gereguleerd door (co)stimulatoire signalen zijn verantwoordelijk voor de vorming 
van antistoffen, terwijl inhiberende factoren de homeostase van het 
immuunsysteem controleren. 
Naast genetische factoren bij de ontvanger, zoals MCH-polymorfismen, spelen 
nog andere (onbekende) factoren een rol bij de immuunrespons tegen rode bloed 
cel transfusies. Toekomstig onderzoek zal de rol van deze factoren ophelderen.  
De incidentie van RBC alloimmunisatie na transfusie ligt tussen minder dan 1% 
en meer dan 70% en is afhankelijk van de onderzochte populatie. Uit alle studies 
blijkt dat, van de non-D antigenen, de E en K bloedgroep antigenen het meest 
immunogeen zijn en verantwoordelijk zijn voor het merendeel van de gevonden 
antistoffen. Het hoge immunisatie risico bij patiënten met sikkelcel ziekte en 
thalassemien heeft ertoe geleid dat bloedtransfusies bij deze patiënten preventief 
gematcht worden voor de RH en K antigenen. 
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Hoofdstuk 3 
Hoofdstuk 3 beschrijft de resultaten van een retrospectieve multicentrum studie, 
uitgevoerd in een groot ongeselecteerd patiënten cohort in de Sanquin Zuidwest 
regio, met als doel vast te stellen of algehele leucodepletie van RBC producten 
invloed heeft op de vorming van klinisch relevante RBC antistoffen na transfusie. 
Er werden 2 perioden onderzocht, 2 jaar voor en 2 jaar na de implementatie van 
algehele leucodepletie. We hebben het aantal nieuw gevormde antistoffen die 
gevormd waren door patiënten die in de studieperiode getransfundeerd zijn 
(antistof incidentie) vergeleken met antistoffen die gevormd waren gedurende 
dezelfde periode bij patiënten die niet getransfundeerd waren in het betreffende 
ziekenhuis (antistof prevalentie). In totaal werden 4770 RBC antistoffen 
aangetoond bij 4148 patienten. 
Er werden geen verschillen aangetoond tussen de twee studie perioden met 
betrekking tot antistof incidentie, antistof prevalentie, antistof specificiteiten, 
historische antistoffen en additionele antistoffen. 
De patiënten cohorts waren vergelijkbaar voor leeftijd, geslacht, aantal 
transfusies, aantal transfusie episoden, interval tussen transfusie en antistof 
detectie en het alloimmunisatie risico (0.13%, weergegeven als het aantal 
patiënten met antistoffen per getransfundeerde RBC eenheid). 
Op grond van deze pre- en post interventie studie kan worden geconcludeerd dat 
RBC alloimmunisatie in een ongeselecteerde transfusie populatie niet gunstig 
beïnvloed word na universele leucodepletie van RBC producten in vergelijking 
met buffy-coat gedepleteerde RBC producten.  
 
Hoofdstuk 4 
In hoofdstuk 4 presenteren we een studie naar de frequentie van bij toeval 
gevonden antistoffen gericht tegen laag frequente RBC antigenen in een RBC 
geïmmuniseerde patientenpopulatie, gedurende een periode van 23 jaar. Het doel 
van de studie was te onderzoeken of het type en screen beleid, waarbij geen 
complete kruisproef wordt uitgevoerd voor transfusie bij patiënten zonder RBC 
alloantistoffen, veilig is met betrekking tot het risico op een transfusiereactie ten 
gevolge van antistoffen tegen laag frequente antigenen. Tevens werd de 
frequentie van Wra antistoffen onderzocht in niet-geselecteerde ziekenhuis 
patiënten met en zonder RBC antistoffen, in zwangere vrouwen en in bloed 
donoren.   
Atistoffen tegen laag frequente antigenen werden gevonden in 50 patienten 
zonder andere RBC antistoffen en in 39 patienten waarbij ook andere RBC 
antistoffen werden aangetoond (2.2% van de patiënten met RBC antistoffen). 
Tijdens 117.000 kruisproeven uitgevoerd in de indirecte antiglobuline test werden 
14 antistoffen tegen laag frequente antigenen gevonden (0.01%). Gedurende de 
studie periode werden geen transfusiereacties gemeld ten gevolge van antistoffen 
tegen laag frequente antigenen.  
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In het prospectieve onderzoek werden Wra antistoffen aangetoond bij 4,3% van 
de bloed donoren, bij 5,8% van de patiënten zonder andere RBC antistoffen, bij 
10,2% van de zwangere vrouwen en bij bijna 20% van de patiënten waarbij ook 
andere RBC antistoffen waren aangetoond.  
Op basis van de resultaten van dit onderzoek is geconcludeerd dat antistoffen 
tegen laag frequente RBC antigenen vaak voorkomen in patiënten en in gezonde 
personen, maar dat het risico op een transfusiereactie ten gevolge van deze 
antistoffen zeer laag is en dat daarom transfusie zonder een kruisproef in de 
indirecte antiglobuline test veilig is.  
 
Hoofdstuk 5 
In dit hoofdstuk worden de RBC antistofvorming na transfusie beschreven in 
patiënten met maligne myelo- en lymfoproliferatieve ziekten. Gedurende een 
periode van 10 jaar hadden 564 evalueerbare patiënten in totaal 15.287 RBC 
transfusies ontvangen in 6182 transfusie-episoden. Patiënten met 
myeloproliferatieve ziekten hadden 2 keer langer transfusie ondersteuning nodig, 
resulterend in bijna 3 keer meer RBC transfusies dan patiënten met 
lymfoproliferatieve ziekten. In totaal werden 71 alloantistoffen, voornamelijk 
anti-E en anti-K, aangetoond in 51 patienten. Bij 33% van de RBC 
geïmmuniseerde patiënten werden meerdere antistoffen gevonden. Vijftig procent 
van de antistoffen waren al gevormd na 13 RBC transfusies, hetgeen aangeeft dat 
het merendeel van de antistoffen al gevormd worden in het begin van de 
transfusie therapie. Het immunisatie risico was 0,5% per getransfundeerde 
eenheid voor de totale bestudeerde populatie. Patiënten die intensief met 
chemotherapie werden behandeld vormden minder RBC antistoffen dan patiënten 
die niet intensief chemotherapeutisch werden behandeld. Dit verlaagde 
immunisatie risico werd bevestigd doordat maar 3 patienten anti-D vormden na 
244 D-incompatibele trombocyten transfusies. 
De resultaten van deze studie laten zien dat antistofvorming door patiënten met 
maligne hematologische ziekten vergelijkbaar is met andere ziekten waarbij de 
patiënten frequent getransfundeerd worden. Er is in deze populatie vooralsnog 
geen reden om antistof vorming te voorkomen door preventief donor antigeen 
matchen.  
 
Hoofdstuk 6 
Het doel van deze multicenter retrospective studie was te onderzoeken in 
hoeverre niet-chronisch getransfundeerde patiënten met RBC antistoffen 
additionele klinisch belangrijke antistoffen maken nadat zij opnieuw transfusies 
hebben ontvangen. In een periode van 20 jaar werden 653 patienten met 772 
eerste antistoffen getransfundeerd met mediaan 5 RBC eenheden in mediaan 2 
transfusie-episoden. Additionele antistoffen met 157 specificiteiten werden 
gevormd door 140 patienten en bij 57% van de patiënten werden deze antistoffen 
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gevormd na één transfusie episode. Aan het einde van de studie hadden 34% van 
de patiënten multiple antistoffen. Het risico op additionele antistofvorming is, 
vergeleken met primiare antistofvorming (hoofdstuk 3) een factor 29 hoger (95% 
BI, 22,7-37,2). Het berekende risico op additionele antistofvorming, in 316 
patienten waarvan het antigeenprofiel bekend was, liet behoorlijke verschillen 
zien tussen specifieke RBC antigenen; het K-antigeen heeft het hoogste 
immunisatie risico van 9%, RH-antigenen tussen 1,9% en 3,6% en de andere 
antigenen tussen 0,2% en 1,7%. 
Een theoretische exercitie naar de beschikbaarheid van getypeerde donoren voor 
uitgebreid matchen voor deze patiënten, liet zien dat dit in Nederland geen 
probleem is als matchen beperkt wordt tot de meest immunogene antigenen (RH, 
K, Fya en Jka). 
In deze studie werd duidelijk dat patiënten die na voorgaande transfisies 
antistoffen hebben gevormd ‘high-responders’ zijn na een nieuwe antigeen 
expositie. Uitgebreid matchen voor deze patiënten lijkt mogelijk en zou 
overwogen moeten worden. 
 
Hoofdstuk 7 
Dit hoofdstuk beschrijft de resultaten van een studie verricht in het Leids 
Universitair Medisch Centrum, het nationale behandelcentrum voor intrauteriene 
transfusies. Het doel van het onderzoek was het effect van preventief D, C, c, E, e 
en K matchen van de IUT donors en moeders, met betrekking tot maternale 
additionele antistofvorming, te evalueren. Gedurende een periode van 11 jaar 
werden in 233 zwangerschappen bij 212 vrouwen 686 IUTs gegeven. Voor IUT 
behandeling hadden de vrouwen 242 antistoffen en multiple antistoffen, 
voornamelijk anti-CD, bij 59% van de vrouwen. Na de behandeling hadden 53 
vrouwen (25%) 64 nieuwe antistoffen gevormd en bij 11 vrouwen werden 
historische antistoffen die voor de eerste IUT niet meer aantoonbaar waren, weer 
aangetoond. Het percentage vrouwen met multiple antistoffen nam toe van 59% 
tot 72% na de bevalling en non-RH/non-K antistoffen van 12% naar 25%. Het 
gemiddelde immunisatie risico (aantal nieuwe antistoffen per IUT) was 18% na 
de eerste IUT en daalde naar ongeveer 5,5% na volgende IUTs. 
Multivariaat analyse toonde aan dat additionele antistofvorming voornamelijk 
geassocieerd was met de transplacentale transfusieroute. 
Matchen voor de RH en K antigenen voorkwam niet dat RH en K antistoffen 
gevormd werden in 31% van de zwangerschappen waarbij deze antigenen 
voorkwamen op de foetale erytrocyten. In 11 van de 17 evalueerbare (65%) 
patiënten waren additionele non-RH/non-K antistoffen het gevolg van donor en 
niet van foetale antigenen.  
De conclusies van deze studie zijn dat additionele antsitofvorming tijdens IUT 
behandeling frequent voorkomt, geassocieerd is met transplacentair puncteren en 
niet verminderd is ondanks RH en K matchen van de IUT donors. Om het hoge 
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risico op alloimmunisatie in deze patiënten te verminderen, wordt voorgesteld om 
de IUT donors ook te matchen voor JK, FY en S antigenen. 
 
Hoofdstuk 8 
Het doel van deze studie, waarvan de resulaten beschreven zijn in hoofdstuk 8, 
was de persistentie van klinisch belangrijke RBC alloantistoffen geduirende een 
periode van 20 jaar te onderzoeken. We identificeerden 593 antistoffen in 480 
patienten waarvan het bloed, na de eerste antistof detectie, meerdere keren was 
onderzocht op antistoffen. In totaal waren 153 antistoffen (26%) na verloop van 
tijd niet meer aantoonbaar. Vier jaar na de eerste detectie van nieuw gevormde 
antistoffen was 50% niet meer aantoonbaar en dit steeg tot meer dan 70% na een 
periode van 16 jaar. Ondanks dat er geen significante verschillen konden worden 
aangetoond in de snelheid waarmee de verschillende antistof specificiteiten 
onaantoonbaar werden, waren Kidd antistoffen maar zeer kort aantoonbaar. Dit 
kan verklaren waarom deze antistoffen zeer frequent betrokken zijn bij 
uitgestelde hemolytische transfusiereacties.  
We concludeerden dat het RBC alloantistoffen frequent onaantoonbaar worden na 
verloop van tijd en dat accurate registratie van antistoffen in bloedbank en 
patienten dossiers van het grootste belang om (uitgestelde) hemolytische 
transfusiereacties, ten gevolge van transfusie met incompatibel bloed, te 
voorkomen.   
 
Hoofdstuk 9 
In hoofdstuk 9 beschrijven we de resultaten van een 5 jaars retrospectieve studie 
naar relevante factoren voor immunisatie en specifiteiten van klinisch relevante 
alloantistoffen, met speciale nadruk op het tijdsinterval tussen transfusie en 
antistofscreening. In de periode 1999 t/m 2003 werden 2177 nieuwe antistoffen 
gevonden bij 1778 patienten na een totaal van 12379 RBC transfusies in 4050 
transfusie episoden.  
Mannelijk geslacht was gecorreleerd met anti-Jka, lagere leeftijd met anti-M en 
anti-S en het aantal RBC transfusies met anti-K en anti-Jka. De belangrijkste 
onafhankelijke factor geassocieerd met bepaalde antistofspecificiteit was het 
interval tussen transfusie en daaropvolgende antistofscreening. Anti-E was de 
meest frequent voorkomende antistof tot 5 jaar na transfusie, maar nam vanaf 12 
maanden na transfusie af van 45% tot 20% van het totaal aantal gevonden 
antistoffen dat aanwezig was tot 5 jaar na transfusie. Anti-c betrof 10-15 procent 
van de antistoffen tot 5 jaar na transfusie, en daalde daarna tot minder dan 3 
procent. Anti-K toonde een geleidelijke toename van 20 procent na 1 maand tot 
meer dan 45% van alle antistoffen na meer van 5 jaar na transfusie. Anti-Fya 
steeg snel van minder dan 10 procent na 1 jaar tot 27 procent van alle antistoffen 
na 5 jaar. Anti-Jka en anti-Jkb werden voornamelijk aangetoond in de eerste 3 
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maanden na transfusie; daarna nam hun aantal af van, respectievelijk 18 en 5 
procent naar resp. 3 en minder dan 2 procent. 
Bij 299 patienten werden antistoffen aangetoond binnen 14 dagen na transfusie, 
ten gevolge van een secundaire of een snelle primaire immuun respons. 
De conclusie van dit onderzoek is dat het tijdsinterval tussen transfusie en 
antistofonderzoek sterk geassocieerd is met het aantal en de specificiteit van RBC 
antistoffen. Omdat RBC antistofonderzoek niet routinematig gedaan wordt na een 
transfusie, is het mogelijk dat antistoffen (niet) gevonden worden voor een 
volgende transfusie. Hierdoor loopt de patient het risico op enerzijds transfusie 
uitstel of anderzijds op een hemolytische transfusiereactie. De frequentie en de 
kinetiek van RBC alloimmunisatie dient verder onderzocht te worden, om zo het 
optimale moment voor antistofscreening te bepalen en te anticiperen op 
toekomstige ontwikkelingen met betrekking tot preventief donor matchen. 
 
Hoofdstuk 10 
Dit hoofdstuk bevat naast een algemene discussie over de betekenis van de 
resultaten van de studies in dit proefschrift ook aanbevelingen voor toekomstig 
onderzoek op het gebied van RBC alloimmunisatie na bloed transfusie. 
De conclusie van onze studies is dat sommige patiënten een verhoogd risico 
hebben op RBC antistofvorming en dat overwogen kan worden om transfusies 
uitgebreid te matchen tussen patient en donor. Voor andere populaties is het 
immunisatie risico nagenoeg onbekend, maar waarschijnlijk onderschat. De 
voornaamste reden voor de gevonden discrepanties is gerelateerd aan het feit dat 
niet alle patiënten routinematig getest worden op antistofvorming na transfusie en 
antistoffen alweer onaantoonbaar kunnen zijn voor de volgende transfusie. 
Prospectief onderzoek zou idealiter gericht moeten zijn op de patiënten die ‘at 
risk’ zijn voor antistofvorming, t.w. patiënten die transfusies hebben ontvangen 
met een alloantigeen. 
In tegenstelling tot het verdwijnen van antistoffen persisteren sommige 
antistoffen tientallen jaren na het ontstaan. De mechanismen die hierbij een rol 
spelen zijn nog grotendeels onbekend, maar persisterend microchimerisme van 
donor cellen zou één van de verklaringen kunnen zijn. 
De immunologische mechanismen en patient gerelateerde factoren betrokken bij 
RBC alloimmunisatie zullen onderwerp van studies zijn in de komende jaren en 
mogelijk dat hierdoor patienten met een verhoogd risico op antistovorming 
geïdentificeerd kunnen worden. 
De ontwikkeling van ‘high-throughput’ genotyperings systemen zullen het 
mogelijk maken om vele antigenen tegelijkertijd te typeren bij zowel donoren als 
patiënten, waardoor routinematig uitgebreid matchen tussen donor en patiënten 
met risico op antistofvorming mogelijk wordt. 
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